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Preterm birth (PTB), birth prior to 37 weeks of gestational age, is a major cause of early 
childhood mortality and morbidity in the United States. 17alpha-hydroxyprogesterone caproate 
(17-OHPC) has recently been documented to reduce the incidence of preterm birth. A complete 
understanding of the pharmacokinetics of 17-OHPC will help in improving clinical outcome.  
The goal of this dissertation research was to evaluate the preclinical and clinical 
pharmacology of 17-OHPC in order to optimize the use of this drug in preventing preterm birth. 
Studies in human liver microsomes and human hepatocytes indicate that 17-OHPC is 
metabolized by CYP3A. Significant transplacental transfer of 17-OHPC (cord blood to maternal 
plasma ratio of 0.3) has been observed in pregnant subjects. Studies were performed in fetal 
hepatocytes to evaluate the metabolism of 17-OHPC. Fetal hepatocytes demonstrate the ability 
of human fetal liver to metabolize 17-OHPC to fetal specific metabolites, with oxidation being 
the major metabolic pathway. Further, 17-OHPC and/or its metabolites inhibit bile salt transport 
in both adult and fetal hepatocytes.  
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17alpha-Hydroxyprogesterone Caproate (17-OHPC): 
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To understand the clinical pharmacology of 17-OHPC, pregnant women who received 
17-OHPC for clinical reasons were studied and blood samples collected periodically. Wide-
interindividual variation was observed in the pharmacokinetics of 17-OHPC in pregnant subjects. 
The half life of 17-OHPC was 9 days and plasma concentrations of 17-OHPC did not achieve 
steady state. The race and body mass index of the pregnant subjects affect the plasma levels of 
17-OHPC.  
In conclusion, since CYP3A is involved in the oxidative metabolism of numerous 
commonly used drugs; 17-OHPC may be involved in clinically relevant metabolic drug 
interactions with co-administered CYP3A inhibitors or inducers. Since 17-OHPC crosses the 
placental barrier and reaches the fetus, use of higher doses of 17-OHPC should be approached 
with caution. The clinical effectiveness of 17-OHPC in preventing preterm birth has been 
observed in only 33% of the patients. Given the wide interindividual variability, modification of 
the starting dose based on BMI and race alongwith monitoring of plasma levels and adjustment 
of subsequent doses accordingly may be needed to improve therapeutic outcomes in the 
treatment of preterm birth with 17-OHPC. 
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1.0  Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 Preterm birth and its significance 
Preterm birth (PTB) as the name suggests is birth before term i.e. 37 weeks of gestation.  
The gestational length of a normal pregnancy is around 40 weeks and the babies born between 
37-42 weeks of gestation are termed full term.  In Europe and other industrialized nations the 
rate of pre-term birth has been reported to be between 5 and 9% (Slattery and Morrison, 2002; 
Hamilton et al., 2006). In the United States, about 12.8 % or a little more than half a million of 
all births are premature.  The rate of preterm birth in the U.S. has increased by ~30% since the 
early 1980s i.e. from 9.5% (% of all births) in 1981 to 12.8% in 2006 (Goldenberg et al., 2008; 
Martin et al., 2008).  This increase in the rate of PTB (32-36 weeks) has been largely associated 
with an increase in the age at which women become pregnant (>35 yrs) and the use of assisted 
reproductive technologies (Martin et al., 2008; Sunderam et al., 2009).  
Preterm birth is a serious health problem as it is reported to be one of the major causes of 
neonatal mortality and early childhood morbidity in the United States (McCormick, 1985).  The 
perinatal mortality rate has been shown to be associated with the gestational age at birth.  In 
developed countries, perinatal survival ranges from <5% at 22 weeks to almost 100% above 31 
weeks gestation and can be attributed to the recent advances in neonatal medicine (Slattery and 
Morrison, 2002).  Babies born premature are at an increased risk for a number of health problems 
like low birth weight, respiratory and breathing difficulties, cerebral palsy, vision and hearing 
loss, underdeveloped organs/organ systems and even death.  Most prematurely born infants 
require admission to intensive care units equipped with specialized medical staff and equipment 
trained to deal with the issues related to PTB.  Recent reports in literature have indicated an 
increased risk of autism (Limperopoulos et al., 2008; Schendel and Bhasin, 2008) alongwith 
certain adult health problems, such as diabetes (Hovi et al., 2007), and heart disease 
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(http://www.nichd.nih.gov/womenshealth/research/pregbirth/preterm.cfm) in individuals who 
were born premature.  Preterm birth has an impact on the long term health of the infants 
including mental or physical disability in 1 out of 4 babies born at less than 25 weeks’ gestation 
(Wood et al., 2000).  Further, higher healthcare costs are incurred due to longer hospital stays as 
babies born at less than 28 weeks spend 85 times longer in hospital as compared to term babies 
in the first five years of life (Petrou et al., 2003). In premature babies, even if the gestational age 
at birth is >32 weeks, educational and behavioural problems occur in 1 in 3 children at the age of 
7 and these children require support from non-teaching assistants at school (Huddy et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Increase in preterm births (% of all births) in the USA (1981-2006) 
Reference: (Goldenberg et al., 2008; Martin et al., 2008) 
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1.2 Epidemiology of preterm birth 
Preterm birth can be divided into two categories (based on the nature of obstetric 
precursors leading to labour), namely, indicated and spontaneous.  Preterm birth is classified as 
indicated when labour is induced or the infant delivered via caesarean section for maternal and 
fetal indications.  Preterm births that occur when labour occurs spontaneously, irrespective of 
whether the method of delivery is vaginal or caesarean section, is termed as spontaneous PTB 
(Tucker et al., 1991). Indicated PTB can result due to medical conditions that put the mother 
(maternal sepsis or hypoxia), fetus (maternal diabetes or intrauterine growth restriction) or both 
(maternal hypertension, placenta previa, or abruption) at risk should the pregnancy continue its 
normal course.  About 30-35% of all preterm births are indicated. The most common 
pathological conditions that led to indicated preterm births in one study reported by Meis et al. 
were preeclampsia (~40%), fetal distress (25%), intrauterine growth restriction (10%), placental 
abruption (7%), and fetal demise (7%) (Meis et al., 1998). Other risk factors for indicated 
preterm birth include maternal proteinuria, chronic hypertension, Mullerian duct fusion, age over 
30 years, nulliparity, maternal pulmonary disease, drug (cocaine) use and maternal asthma 
(Cherukuri et al., 1988; Meis et al., 1998; Dombrowski, 2006).   
Spontaneous PTB can be further divided into two categories - spontaneous preterm 
labour with intact membranes and preterm premature rupture of membranes (PPROM).  About 
40-45% of all preterm births follow spontaneous preterm labour and 25-30% follow PPROM 
(remaining 30-35% being indicated PTB).  Preterm premature rupture of membranes is defined 
as the rupture of the amniotic membranes with release of the amniotic fluid more than 1 hour 
prior to the onset of labour (Simhan and Canavan, 2005).  Spontaneous PTB has been reported to 
follow two different patterns which can be distinguished on the basis of the gestational age at 
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delivery and the likelihood of repeated preterm birth in future pregnancies (Goldenberg et al., 
1998).  Preterm births that occur before 32 weeks of gestation, also known as early PTB, are 
more likely to be associated with infection. This type of PTB is observed more commonly in 
African- Americans and Caribbean Hispanic women and less so in African, non-Caribbean 
Hispanic and Caucasian women.  Early preterm births have been reported to be associated with 
long-term morbidity in infants and also is associated with a greater likelihood of recurrence in 
subsequent pregnancies.  However, births that happen after 32 weeks of gestation are less likely 
to be associated with clinical or sub-clinical intra-amniotic infection, are less likely to be 
followed by long-term morbidity in infants and are associated with a lower risk of recurrence in 
subsequent pregnancies.  This type of PTB is often associated with increased uterine contraction 
frequency, increased uterine volume caused by hydramnios or multiple gestation (Iams, 2003). 
Preterm birth has been classified as a syndrome since it is initiated by multiple 
mechanisms which include, infection, inflammation, uteroplacental ischaemia or hemorrhage, 
uterine overdistension, stress and other immunologically mediated processes (Romero et al., 
2006).  Since an exact explanation of the mechanism behind PTB has not been established to 
date, factors that put the pregnant women at an increased risk for the occurrence of PTB have 
been sought to explain its pathophysiology.  Identifying risk factors can help in 1) determining 
when to initiate risk-specific treatments, 2) defining a population that can be used to study the 
specific treatment options and 3) explaining the mechanisms leading to PTB.  A number of risk 
factors have been reported which include – 
Obstetric history: A history of PTB has been associated with an increased risk of early preterm 
early in subsequent pregnancies.  Risk factors differ among women with recurrent versus 
nonrecurrent PTBs.  For nonrecurrent PTBs the risk factors include second trimester bleeding, 
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abnormal amniotic fluid volume, multiple gestation, substance abuse and trauma.  For recurrent 
PTBs the risk factors include genitourinary infection, maternal ethnicity, and the gestational age 
of prior PTB (Mercer et al., 1999).   
Cervical length: Before 16 weeks, the relationship between cervical length, as measured by 
transvaginal ultrasonography and PTB is not evident. Between 18 and 32 weeks the risk of PTB 
increases with decrease in the cervical length (Urbaniak et al., 2005).  Iams et al. (Iams et al., 
1996) have reported that the relative risks of preterm delivery in women with shorter cervixes (as 
measured at 24 weeks) were as follows: 1.98 for cervical lengths at or below the 75th percentile 
(40 mm), 2.35 for lengths at or below the 50th percentile (35 mm), 3.79 for lengths at or below 
the 25th percentile (30 mm), 6.19 for lengths at or below the 10th percentile (26 mm), 9.49 for 
lengths at or below the 5th percentile (22 mm), and 13.99 for lengths at or below the 1st 
percentile (13 mm).  For the lengths measured at 28 weeks, the corresponding relative risks were 
2.80, 3.52, 5.39, 9.57, 13.88, and 24.94. 
Infection: Substantial evidence exists in the literature showing the association of PTB with 
infection caused mainly by bacteria of vaginal origin which reside in the uterus (Hillier et al., 
1988; Romero et al., 1989b; Andrews et al., 2000).  These include: Ureaplasma urealyticum, 
Mycoplasma hominis, Gardnerella vaginalis, peptostreptococci, and bacteroides species. Micro-
organisms such as Chlamydia trachomatis, trichomonas, Escherichia coli, and group B 
streptococcus, are less commonly recovered. Bacterial vaginosis, a pathological conditon caused 
mainly by gram negative bacteria (Gardnerella vaginalis, Bacteroides, Prevotella, Mobiluncus, 
and Mycoplasma species), has been shown to be associated with more than two fold increased 
risk of spontaneous PTB (Meis et al., 1995).  Infections outside the genital tract have also been 
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reported to be associated with PTB and include urinary tract infections, pyelonephritis and 
appendicitis (Romero et al., 1989a). 
Maternal Race: The rate of PTB before 37 weeks in African-American women is twice that in 
women of other races and for delivery before 32 weeks the rate is three times higher than in 
white women (Iams, 2003).  However, it is interesting to note that the black women born outside 
the United States have a lower risk of preterm delivery than those in the US (Martin et al., 2002). 
Bleeding: Vaginal bleeding during the second trimester due to placenta previa or placental 
abruption has been reported to be associated with PTB with a relative risk of 15.1 (Ekwo et al., 
1992). 
Uterine Anomalies: Preterm births have been reported to occur in 25-50% of women diagnosed 
with uterine abnormalities like Mullerian fusion anomalies, implantation of the placenta on the 
uterine septum or a T-shaped uterus (Raga et al., 1997; Kaufman et al., 2000). 
Uterine contractions: An increased frequency of uterine contractions has been linked to preterm 
delivery before 35 weeks with a relative risk (RR) of 1.62 (Mercer et al., 1996). 
Multiple pregnancies: A strong association exists between the multiple gestation and PTB with 
the rate approaching almost 100% for quadruplets. The increased rate is caused in part because 
of overdistension of the uterus. As the incidence of multiple gestation has increased in recent 
years because of assisted reproductive technologies (ART), so has the rate of PTB (MMWR, 
2000). 
Behavioural factors: Sexual practices (Moore et al., 1994), maternal stress, maternal cigarette 
smoking (Savitz et al., 2001; Kyrklund-Blomberg et al., 2005) and the duration and intensity of 
work (Mamelle et al., 1984) has also been linked to the incidence of preterm birth. 
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The abovementioned epidemiologic characteristics of pregnant women who deliver their infants 
before term provide us with clues as to the cause of this most important obstetric problem. 
1.3 Mechanisms of preterm birth 
A number of mechanisms are responsible for preterm birth due to the initiation of preterm 
labor.  
Infection and Inflammation: Studies have shown that infection accounts for 25-40% of all 
preterm births (Romero et al., 1992).  Microbial infection in the amniotic fluid is associated with 
inflammation as evidenced by the high concentration of IL-6, a marker for intra-amniotic 
inflammation (Wenstrom et al., 1998).  Further, a significantly higher concentration of other 
markers including, matrix metalloproteinase (MMPs) 8 (Yoon et al., 2001), tumor necrosis 
factor-α (Heyborne et al., 1992), and angiogenin (Spong et al., 1997) has also been reported in 
women who deliver prior to term.  However, the concentration of IL-6 in the maternal serum was 
not associated with the incidence of preterm birth (Wenstrom et al., 1996).   
A gene-environment interaction has also been reported for the occurrence of preterm 
birth. The genotype of interest was TNF-alpha allele 2. The host factor which constituted the 
environmental aspect of the interaction was the presence of bacterial vaginosis in the pregnant 
subject. The presence of this gene leads to hyperresponsiveness of the individual to genital tract 
infection, thus, promoting preterm premature rupture of the fetal membranes and subsequent 
preterm delivery (Roberts et al., 1999). 
Microbial infections can produce an inflammatory response primarily through the 
recognition of bacterial toxins (lipopolysaccharide, peptidoglycans and lipoglycans) by pattern 
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recognition receptors including, C-reactive protein (CRP) and Toll-like receptors (TLRs).  Using 
a TLR knockout mouse model, Wang et al (Wang and Hirsch, 2003) have shown that the 
likelihood of preterm delivery due to lipopolysaccharide administration is significantly reduced 
in comparison to the wild type thus confirming the role of TLRs in preterm birth.   
Uteroplacental ischaemia: Maternal vascular lesions in the placenta including, atherosis 
and thrombosis of the spiral arteries can lead to uteroplacental ischaemia.  Uteroplacental 
ischaemia leads to the generation of thrombin which stimulates the generation of MMP-1, 
urokinase type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA). These 
products can cause the degradation of collagen and fibronectin which are important constituents 
of the extracellular matrix in the chorioamniotic membranes (Aplin et al., 1985) thus causing 
preterm delivery. 
Uterine overdistension: Intra-amniotic pressure remains relatively constant throughout 
pregnancy. This is due to the progressive relaxation (stretching) of the myometrium by 
progesterone or nitric oxide.  However, rapid stretching can induce increased myometrial 
contractility (Kloeck and Jung, 1973), prostaglandin release (Laudanski and Rocki, 1975), 
expression of gap junction protein (Sladek et al., 1999) or connexin (Ou et al., 1997), and 
increased oxytocin receptor which can lead to preterm delivery. 
Immunological phenomena: Some studies support the hypothesis that suppression of 
immune response occurs during pregnancy which enables the body to treat the feto-placental unit 
as an allograft. Recognition of the fetus as a foreign antigen by the immune system of the mother 
causes production of mediators like natural killer cells and macrophages leading to preterm birth 
(Aksel, 1992) . There is also evidence suggesting the involvement of an allergic phenomenon in 
preterm birth. The human fetus is exposed to common allergens like house dust mite and this 
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compound has been detected in both amniotic fluid and fetal blood. The uterus is a rich source of 
mast cells—the effector cells of allergic-like immunological reactions. Upon coming in contact 
with the allergen, mast cell degranulation occurs, the products of which have been reported to 
induce myometrial and cervical contractility (Padilla et al., 1990). Thus, this type of allergic 
response can be implicated as one of the mechanisms causing preterm labour and preterm birth. 
The current scientific literature considers preterm birth as a syndrome. Multiple 
pathological processes (indicated above) may lead to myometrial contractions, 
membrane/decidual activation, cervical ripening and hence preterm birth. Since, preterm birth is 
caused by multiple etiologies; the treatment should be aimed at ameliorating the symptoms 
associated with the multiple mechanisms mentioned above.   
1.4 Interventions for the prevention of preterm birth 
Interventions to reduce the incidence of preterm labour can be classified, based on the 
goals of the therapy, into primary (initiated before or during pregnancy in all women to prevent 
or reduce risk), secondary (only in women known to have the risk factors associated with PTB) 
and tertiary (initiated once the labour has started to prolong the delivery or improve the neonatal 
outcome).  
Primary Intervention: Primary prevention strategies have shown success in the treatment 
of cancer (cervical cancer) and vascular disease and thus form a desirable strategy in the 
treatment of PTB (Iams et al., 2008). These strategies include: 
Public educational interventions – involving educating the public about potentially avoidable risk 
factors (mentioned previously). For example, awareness of the association between repeated 
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uterine trauma due to curettage/ endometrial biopsy or use of assisted reproductive technologies 
resulting in singleton or multiple gestations and PTB.    
Public and professional policies – to improve work related conditions like providing minimum 
maternity leave of 14 weeks, time off for prenatal visits and protection from workplace hazards 
(working in a standing position or lifting objects). 
Nutritional Supplements – multivitamins (Vahratian et al., 2004) especially vitamins C 
(Rumbold et al., 2006) and E (Rumbold and Crowther, 2005) and calcium (Crowther et al., 1999) 
supplementation has been recommended both prior to and during pregnancy. However, the 
effectiveness of nutritional supplementation in reducing the rate of PTB or improving the 
neonatal outcome for infants born premature is not clear. 
Prenatal care – with the objective to prevent prematurity within prenatal care has shown promise 
in Europe but has received little attention in USA. In France, prenatal care has been shown to be 
associated with reduced PTB rates over time (Papiernik et al., 1985). 
Periodontal care – has been suggested in pregnancy as it has been demonstrated that maternal 
periodontal disease may increase the relative risk for preterm or spontaneous preterm births 
(Offenbacher et al., 2006). However, the association between periodontal care and PTB needs to 
be confirmed in larger clinical trials. 
Screening of low-risk women – for signs of infections (bactriuria, bacterial vaginosis), routine 
cervical examination and testing for fetal fibronectin can help in identifying these subjects and 
help reduce the risk of PTB (Goldenberg et al., 1998). 
 Secondary Intervention: The efforts under this strategy are directed at women who are at 
risk of PTB as indicated by their obstetric history (previous PTB or uterine anomaly) or present 
pregnancy risk factors.  The interventions include both preconception and postconception 
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strategies.  Under the preconception interventions, control of risk factors like presence of 
diabetes, seizures, asthma and hypertension identified based on careful evaluation of patient 
history, correction of uterine anomalies, and antibiotic treatment can reduce the risk of PTB.  
Postconceptional interventions include control of risk factors like pre-eclampsia with low dose 
aspirin (Sibai et al., 1993). Treatment options for pre-eclampsia including multivitamins (Poston 
et al., 2006), antioxidants (Rumbold et al., 2008), fish oil (Olsen et al., 1992), calcium, omega-3 
polyunsaturated fatty acids (Olsen et al., 1992) have been shown to be either marginally effective 
or ineffective. Other prevention strategies include modification of maternal activity (bed rest, 
sexual activity) (Goldenberg et al., 1994; Sosa et al., 2004), improved prenatal care (social 
support, home visits, education) (Bryce et al., 1991; Kitzman et al., 1997), antibiotic treatment 
(clindamycin or metronidazole for bacterial vaginosis) (Lamont, 2005), progesterone 
supplementation (modulation of inflammation or cervical ripening) (Keirse, 1990; da Fonseca et 
al., 2003), and cervical cerclage (in women with short cervix) (Berghella et al., 2005; Mancuso 
and Owen, 2009). 
 Tertiary Intervention: The main goal here is to improve the outcome for women (and the 
infant) in whom symptoms of preterm birth are detected proximate to delivery.  The treatment 
options include antibiotics (ampicillin or amoxicillin/clavulanic acid plus erythromycin) to 
reduce  neonatal morbidity (Kenyon et al., 2001b; Kenyon et al., 2001a; Schrag et al., 2002; Law 
et al., 2005) and corticosteroids (to reduce neonatal morbidity or mortality from respiratory 
distress, hemorrhage, necrotizing enterocolitis and patent ductus arteriosus) (Roberts and Dalziel, 
2006; Wapner et al., 2006). Further, tocolytic drugs i.e. drugs that prolong the delivery long 
enough to enable to transfer of the pregnant subject to a specialist care facility, are also used. 
These include calcium channel blockers (nifedipine, nicardipine), beta agonists (ritodrine, 
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terbutaline) (Anotayanonth et al., 2004) and prostaglandin inhibitors (Indomethacin) (Niebyl, 
1981).  
 Most interventions intended to reduce preterm birth do not show consistent results when 
tested in randomized trials, which, in turn can mostly be attributed to the insufficient data 
available at the time of their design. However, prophylactic treatment with progestogens (e.g. 
progesterone, 17-OHPC, etc.) is one of the options that has shown promise in preventing PTB 
associated morbidity and cost.        
1.5 Progesterone and preterm birth 
Progesterone is essential in maintaining pregnancy.  Progesterone has been reported to 
promote myometrial quiescence, down-regulate gap junction formation, inhibit cervical ripening, 
and decrease the production of chemokines (i.e. IL-8) by the chorioamniotic membranes 
(Gorodeski et al., 1987; Chwalisz, 1994; Stjernholm et al., 1996; Mesiano, 2001; Brown et al., 
2004). Further, administration of progesterone receptor antagonists (Mifepristone) to pregnant 
women has been shown to induce labour (Bygdeman et al., 1994). In many species (rats, mice, 
rabbits, goats and pigs) a fall in circulating levels of progesterone occurs prior to parturition; 
however, a similar decline has not been reported in humans. Thus, the concept of “functional 
withdrawl” of progesterone has been suggested to explain the role of progesterone in human 
pregnancy or lack thereof in causing preterm birth. This concept explains the loss or decline in 
sensitivity to progesterone prior to parturition at term or preterm on the basis of: 1) reduced 
bioavailability of progesterone by binding to a high affinity protein; 2) increased cortisol 
concentration in late pregnancy that may compete with progesterone for binding to the 
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glucocorticoid receptor (GR) which results in suppression of the immunosuppressive activity 
associated with progestins; 3) conversion of progesterone to an inactive form within the target 
cell by 5alpha-reductase and 20alpha-hydroxysteroid dehydrogenase; 4) quantitative and 
qualitative changes in progesterone receptor isoforms (PR-A, PR-B, PR-C) with an increase in 
PR-A/PR-B ratio being associated with reduced mymetrial response to progeserone; 5) changes 
in progesterone receptor co-regulators (Steroid hormone Receptor Coactivator, SRC-1,2,3) ; and 
6) a functional progesterone withdrawal through NF-kB wherein the latter, generated as a result 
of inflammation, interacts directly with progesterone receptor and reduces its transcriptional 
activity (Brown et al., 2004). Based on this concept of functional withdrawal and to remedy the 
situation, progestational agents (17alpha-hydroxyprogesterone caproate, medroxyprogesterone 
acetate) have been used in the prophylactic treatment of preterm birth, although with varying 
rates of success. 
1.6 17α-hydroxyprogesterone caproate: Clinical history & Effectiveness 
The Food and Drug Administration (FDA) approved the use of 17α-hydroxyprogesterone 
caproate (17-OHPC; Fig 3A) in pregnancy in 1956 (Delalutin®). It was indicated for the 
treatment of habitual and recurrent abortion, threatened abortion, and post-partum “after pains.” 
This approval was based largely on safety consideration in that it occurred prior to the FDA Drug 
Amendment of 1962, which required drug manufacturers to provide proof of the effectiveness 
and safety of their drugs before approval. In 2000, the FDA withdrew approval for Delalutin® at 
the request of the holder of the New Drug Application (NDA), Bristol-Myers Squibb Co, 
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because the company was no longer marketing the drug. The action was not taken because of 
safety concerns.  
The published literature includes several studies evaluating the efficacy of 17-OHPC in 
preventing preterm birth (Table 1). 
 
Table 1. Studies of the Efficacy and Safety of 17-OHPC in Preventing Preterm Birth 
Investigator  Drug:Dose  Inclusion 
Criteria  
Study 
Design 
Subjects  Start Stop  Outcome 
% PTB#  
No. of 
SAB+  
(Levine, 
1964) 
17OHPC: 
500 mg 
weekly vs. 
Placebo 
3 SABs 
RCT, 
DBC 
Placeb
o 1:1 
17OHPC
: 15 
Placebo: 
15 
< 16 
wks 
36 
wks 
17OHPC: 
7/15 (46%) 
Placebo: 
10/15 
(66%) 
17OHPC
: 3/15 
Placebo: 
7/15 
(Papiernik-
Berkhauer, 
1971) 
17OHPC: 
250 mg q 3 
days vs. 
Placebo 
High risk 
of preterm 
birth 
RCT 
Placeb
o 1:1 
17OHPC
: 50 
Placebo: 
49 
28 – 
30 
wks 
8 
doses 
17OHPC: 
(4%) 
Placebo: 
(19%) 
 
(Johnson et 
al., 1979) 
17OHPC: 
250 mg 
weekly vs. 
Placebo 
2 SABs or 
1PTB + 1 
SAB or hx 
2 PTBs 
RCT, 
DBC 
Placeb
o 1:1 
17OHPC
: 18 (4 
cerclage) 
Placebo:  
22 (3 
cerclage) 
< 24 
wks 
37 
wks 
17OHPC: 
0/18 (0%) 
Placebo: 
9/22 (41%) 
17OHPC
: 3/23 
Placebo: 
0/27 
(Hartikainen
-Sorri et al., 
1980) 
17OHPC: 
250 mg 
weekly vs. 
Placebo 
Twin 
gestation 
 
RCT, 
DBC 
Placeb
o 
77 
subjects 
28-
33 
wks 
37 
wks 
17OHPC: 
31% 
Placebo: 
24% 
 
(Yemini et 
al., 1985) 
17OHPC: 
250 mg 
weekly + 
cerclage vs. 
Placebo 
2 SABs or 
2 PTBs 
RCT, 
DBC 
Placeb
o 1:1 
17OHPC
: 39 (39 
cerclage) 
Placebo: 
40 (40 
cerclage) 
12 
wks 
37 
wks 
17OHPC: 
5/31 (16%) 
Placebo: 
14/37 
(38%) 
17OHPC
: 8/39 
Placebo: 
3/40 
(Suvonnakot
e, 1986) 
17OHPC: 
250 mg 
weekly vs. 
no 
treatment 
1 PTB or 2 
late SABs 
Non-
random
ized 
17OHPC
: 36 No 
Rx: 39 
16 – 
20 
wks 
37 
wks 
17OHPC: 
5/35 (14%) 
No Rx: 
19/39 
(49%) 
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Investigator  Drug:Dose  Entry 
Criteria  
Design Subjects  Start Stop  Outcome 
% PTB#  
No. of 
SAB+  
(Hauth et al., 
1983) 
17OHPC: 
1000 mg 
weekly vs. 
Placebo  
Military  RCT, 
DBC 
17OHPC
: 80 
Placebo: 
88  
16 – 
20 
wks  
36 
wks  
17OHPC: 
(6.3%) 
Placebo: 
(5.7%) 
 
(Meis et al., 
2003) 
 
17OHPC: 
250 mg 
weekly vs. 
Placebo 
1 PTB RCT, 
DBC 
17OHPC
: 310 
Placebo: 
153 
16 – 
20 
wks 
36 
wks 
17OHPC: 
(36%) 
Placebo: 
(55%) 
 
(Rouse et 
al., 2007) 
17OHPC: 
250 mg 
weekly vs. 
Placebo 
Twin 
gestation 
RCT, 
DBC 
17OHPC
: 325 
Placebo: 
330 
16 – 
20 
wks 
36 
wks 
17OHPC: 
(42%) 
Placebo: 
(38%) 
 
(Caritis et 
al., 2009) 
17OHPC: 
250 mg 
weekly vs. 
Placebo 
Triplet 
gestation 
RCT, 
DBC 
17OHPC
: 71 
Placebo: 
63 
16 – 
20 
wks 
35 
wks 
17OHPC:  
(83.0 %) 
Placebo: 
(84.0 %) 
 
# PTB=Preterm Births 
+ SABs=Spontaneous Abortions 
RCT, DBC=Randomized Controlled Trial, Double Blind 
At present, the body of evidence available in the literature on the efficacy of 17-OHPC in 
preventing preterm birth in women at high risk has shown the drug to be effective in singleton 
gestation, but ineffective in multiple gestation. No other progestational drugs have shown 
efficacy in randomized trials and insufficient data exists for these other compounds such as 
Medroxyprogesterone Acetate. The dose of 17-OHPC used in most of the reported trials has 
been 250 mg/week. Little data exists from pharmacokinetic or pharmacotherapeutic studies to 
argue for or against this dose. Doses of 1000 mg/wk and upto 2000 mg of 17-OHPC have been 
used but no adverse effect has been reported thus deeming this drug to be safe. However, there is 
a signal for embryo–fetal toxicity associated with 17-OHPC in the largest clinical trial (Meis et 
al., 2003) conducted to date and there is also a signal for embryo–fetal toxicity with 17-OHPC in 
rhesus monkeys (Hendrickx et al., 1987). The relationship between these signals is unclear given 
the absence of state-of-the-art reproductive toxicology studies and human pharmacokinetic 
studies. Treatment of preterm birth with 17-OHPC has also been reported to be associated with 
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significant medical cost savings. It has been estimated that treatment of eligible women could 
result in direct medical cost reductions (exclusive of 17P treatment costs) per treated individual 
of between $1000 and $3800 in initial neonatal hospital care, $7500 in medical care through age 
15 years, and $15,900 in medical care through age 75 years. Overall, treatment of all eligible 
women with 17-OHPC would achieve $2 billion in annual direct medical cost reductions 
(Armstrong, 2007). Thus, understanding the pharmacokinetics of 17-OHPC in humans is 
essential 1) to optimize the current fixed dosing regimen for maximum therapeutic effectiveness, 
2) to reduce the medical cost associated with management of preterm birth, and 3) to elucidate 
the mechanism of action of 17-OHPC in preventing preterm birth and any associated risk of 
adverse event. Understanding the pharmacokinetics of 17-OHPC (a steroid analog), or any other 
compound for that matter, involves elucidating the metabolic pathways (mediated mainly by 
Phase I and II enzymes) and transport processes (Phase III) involved in its disposition. 
1.7 Drug metabolism pathways 
The major organ responsible for metabolism of drugs in humans is the liver although 
some metabolism also occurs in the gut wall, lungs and kidneys.  Hepatocytes, one of the 
primary functional cells of the liver, contain the enzymes necessary for the metabolism of 
xenobiotics and endogenous compounds. The xenobiotic-metabolizing enzymes convert drugs 
and xenobiotics into hydrophilic derivatives that are more easily eliminated through excretion 
into the aqueous compartments of the tissues (bile and urine). Thus, the process of drug 
metabolism that facilitates elimination of compounds plays a major role in determining the 
biological activity of a drug (Woolf, 1999). Historically, xenobiotic metabolizing enzymes have 
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been grouped into the phase 1 and phase 2 enzymes.  Phase 1 enzymes catalyze reactions which 
include primarily, oxidation, reduction, and hydrolytic reactions, whereas phase 2 enzymes 
catalyzed reactions, in which a conjugate of the substrate (drug or its phase 1 product) is formed.   
The phase 1 enzymes lead to the introduction of functional groups (-OH, -SH, -NH2 or –
COOH) making the metabolite more polar than the parent compound (Gibson and Skett, 2001).  
The addition of functional groups may not increase the water solubility of the drug significantly, 
but can dramatically alter its biological properties. Phase 1 reactions, also classified as the 
functionalization phase of drug metabolism, can not only lead to the inactivation of an active 
drug but in certain instances, can also cause bioactivation of a drug (e.g. cyclophosphamide).  
Phase 1 enzymes include cytochrome P450s (CYP), flavin-containing monooxygenases (FMO), 
and epoxide hydrolases (EH). The CYPs are the most important phase I enzymes and are 
essentially a superfamily of heme containing enzymes. Some CYPs (CYP11A1, CYP11B1, 
CYP11B2, CYP24, CYP27A1, CYP27B1, and CYP27C1) expressed mainly in the adrenal are 
found in the mitochondrial inner membrane and are responsible for steroid biosynthesis and 
Vitamin D metabolism). However, the greatest amount of CYPs (CYP1A, CYP2A, 2B, 2C, 2D, 
2E and CYP3A) are expressed in the liver and the intestine. In liver and most other tissues, they 
are present mainly in the membranes of the smooth endoplasmic reticulum (ER), which 
constitute part of the microsomal fraction when tissue is subjected to subcellular fractionation. 
These CYPs are responsible for the metabolism of a variety of xenobiotics and endobiotics 
(Woolf, 1999).  Human CYP isoforms involved in the metabolism of xenobiotics include 
CYP1A1/2, CYP2B6, CYP2C8/9/19, CYP2D6, CYP2E1 and CYP3A4/5, of which CYP3A is 
the most abundant isoform (30 % of the hepatic CYPs) in human livers (Shimada et al., 1994; 
Eagling et al., 1998; Woolf, 1999). Functionally, CYP3A is responsible for the metabolism of 
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about 53% of commonly prescribed drugs, followed by CYP2D6, CYP2C, CYP1A2 and 
CYP2E1 accounting for 25%, 18%, 3% and 1% of drug metabolism, respectively (Shimada et 
al., 1994; Woolf, 1999). The subfamily of CYP3A includes CYP3A4, CYP3A5 and CYP3A7. 
CYP3A4 and CYP3A5 are expressed in adult livers, while CYP3A7 is expressed mainly in fetal 
liver (Venkatakrishnan et al., 2000).    
Phase 2 enzymes are responsible for the elimination of drugs and the inactivation of 
electrophilic and potentially toxic metabolites produced by phase 1 pathway like oxidation. 
Unlike phase 1 reactions, phase 2 reactions produce a metabolite with significantly improved 
water solubility and increased molecular weight, which helps in the elimination of the drug from 
the tissue (urine or bile).  Phase 2 enzymes include glutathione-S-transferases (GST), UDP-
glucuronosyltransferases (UGT), sulfotransferases (SULT), N-acetyltransferases (NAT), and 
methyltransferases (MT).  These conjugation reactions usually require the substrate to have 
oxygen (hydroxyl or epoxide groups), nitrogen, and sulfur atoms that serve as acceptor sites for a 
hydrophilic moiety, such as glutathione, glucuronic acid, sulfate, or an acetyl group, that is 
covalently conjugated to an acceptor site on the molecule.  Uridine diphosphate 
glucuronosyltransferases (UGTs) are the important phase II enzymes located in the membrane of 
endoplasmic reticulum.  They are responsible for the glucuronidation of endogenous and 
exogenous compounds, wherein glucuronic acid is delivered to the functional group, forming a 
glucuronide metabolite that is now more water soluble with a higher molecular weight that is 
targeted for excretion either in the urine or bile (Mackenzie et al., 2003).  Sixteen different UGT 
isoforms have so far been identified in humans and have been classified into 1A or 2B 
subfamilies (Tukey and Strassburg, 2000).  Among the UGT1A family, UGT1A1 is the most 
important isoform involved in the glucuronidation of endogenous compounds like bilirubin, 
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estradiol as well as xenobiotics like acetaminophen and irinotecan (Cheng et al., 1998; Court et 
al., 2001; Tukey et al., 2002).  UGT1A6 and UGT1A9 are other isoforms involved in the 
metabolism of catechols, acetaminophen and 4-methylumbelliferone (Court et al., 2001).  Table 
2 lists selected drug metabolizing enzymes along with their respective substrates, inducers and 
inhibitors (Bowen et al., 2000; Sueyoshi and Negishi, 2001; Asghar et al., 2002; Kostrubsky et 
al., 2003; Chandra and Brouwer, 2004). 
Table 2. Selected substrates, inducers and inhibitors for drug metabolizing enzymes and 
drug transporter. 
CYP3A4/5 BSEP
SUBSTRATES
Testosterone Taurocholate 
Midazolam  
Erythromycin  
FK506  
Cyclosporine  
Amlodipine  
Cisapride  
INDUCERS
Rifampin CDCA 
Hyperforin  
Phenobarbital  
Carbamazepine  
Troglitazone  
INHIBITORS
Ketoconazole Cyclosporin 
Ritonavir Troglitazone 
Itraconazole Rifampin 
Verapamil Glyburide 
Source: FDA Document on Drug Development and Drug Interactions: Table of 
Substrates, Inhibitors and Inducers. 
 
Steroids are lipophilic, low-molecular weight compounds derived from cholesterol that 
play a number of important physiological roles. Steroids are known to occur in several 
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biologically active forms. This is not only due to the large range being synthesized by the body 
but also because of their extensive metabolism in the liver and in their target tissues, where 
conversion to an active form is sometimes required before they can elicit their biological 
responses. Most of the peripheral metabolism occurs in the liver and to some extent in the 
kidneys, which are the major sites of hormone inactivation and elimination, or catabolism. For 
certain classes of hormones and particular target tissues, steroids (progestins and androgens) 
must be converted in situ to an active form (metabolic activation) before they can interact with 
their specific receptor(s). For example unlike its parent compound, the progesterone metabolite 
5α-dihydroprogesterone has no effect on the uterus, but is more effective than progesterone itself 
in the facilitation and/or inhibition of GnRH-induced LH release in vitro (Gower, 1979). It also 
has a barbiturate-like action on brain GABAA receptors, as the other metabolite pregnanolone 
(5β-pregnane-3β-ol-20-one).  
Inactivation can occur at various stages of hormone action. Peripheral inactivation, which 
is the metabolic conversion of a biologically active compound into an inactive one, is required to 
ensure steady-state levels of plasma hormones as steroids are more or less continuously secreted 
into the bloodstream. The main site of peripheral steroid inactivation and catabolism is the liver, 
but some catabolic activity also occurs in the kidneys. Usually, steroids are eliminated once they 
have been inactivated. This elimination (e.g. as a urinary excretion products) requires conversion 
to hydrophilic compounds in order to ensure their solubility in biological fluids at rather high 
concentrations. Depending on the structure of the starting steroid, the following reactions may be 
involved (Karavolas, 1990): 1) Reduction of a double bond at C-4 and reduction of an oxo(keto) 
group at C-3 to a secondary alcoholic group, 2) Reduction of an oxo group at C-20 to a 
secondary alcoholic group, 3) Oxidation of a 17β-hydroxyl group, 4) Further hydroxylations at 
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various positions of the steroid nucleus (e.g. 7-hydroxylation of 5α-reduced androgens), and 5) 
Conjugation (sulphate and/or glucuronide derivatives). 
A number of studies have shown that CYP3A4 is one of the major P450 enzymes 
involved in the oxidation of steroid hormones in human liver microsomes. The substrates that are 
catalyzed by CYP3A4 included testosterone (6β-, 15β -, and 2β-hydroxylations), progesterone 
(6β- and 16α-hydroxylations), 17β-estradiol (2- and 4-hydroxylations), 17α-ethinylestradiol (2-
hydroxylation), and dehydroepiandrosterone 3-sulfate (16α-hydroxylation) (Guengerich, 1988; 
Brian et al., 1990; Guengerich, 1995; Yamazaki and Shimada, 1997). In human liver 
microsomes, metabolism of progesterone generates six metabolites including, 6β-
hydroxyprogesterone (-OHP) which was the predominant metabolite, followed by 16α- and 21-
OHP (Swinney, 1990). Similarly, studies by Kobayashi et al. (Kobayashi et al., 2000) in human 
liver microsomes and expressed enzymes demonstrated CYP3A4 as the major enzyme involved 
in the metabolism of Medroxyprogesterone Acetate (MPA), a progesterone analog, used in the 
treatment of breast and endometrial cancer. The major metabolites generated were identified to 
be hydroxylated-MPA with preferred sites of hydroxylation at 2-, 6-, and 21-positions (Zhang et 
al., 2008a; Chen et al., 2009). Thus, it is likely that 17alpha-hydroxyprogesterone caproate, a 
progesterone analog, will be metabolized in the human liver with CYP3A4 being the major 
enzyme involved and that hydroxylation will be the main reaction involved in 17-OHPC 
metabolism. Further, we predict that metabolism of 17-OHPC will lead to the cleavage of the 
caproate side chain and production of 17-OHP which is hypothesized to be responsible for the 
prolonged and more potent action of 17-OHPC over progesterone. In addition to metabolism, 
various organs also take advantage of the presence of transporters to move chemicals in and out 
of tissues. Liver in addition to its metabolic capability is also rich in several transporters.     
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1.8 Hepatic transport systems 
Transport of endogenous compounds and xenobiotics across hepatocyte plasma 
membranes serves a vital role in their hepatic clearance and usually occurs through different 
carrier-mediated systems.  The transport process also known as hepatobiliary transport involves 
uptake of compounds by passive diffusion or membrane transporters, conversion to a 
pharmacologically inactive, active or sometimes toxic metabolite(s) and finally efflux via plasma 
membrane transporters.  Hepatobiliary transport and bile flow play numerous vital roles 
including maintenance of cholesterol and lipid homeostasis, the removal of endogenous and 
exogenous substances from the body, and adequate bile salt flow and recycling (Faber et al., 
2003).  
The membrane transporters involved in the uptake of the chemicals are expressed on the 
sinusoidal (basal) membrane of the hepatocyte and include Na+-dependent (driven by the 
transmembrane Na+ gradient, unidirectional) or Na+-independent (mediated by facilitated 
exchange with intracellular anions such as glutathione) anionic and some cationic transporters 
(Kullak-Ublick et al., 2000b; Lecureur et al., 2000). These transporters (e.g. NTCP, OATP, 
OCT1, OAT2) are involved in the transfer of amphipathic and polar organic compounds, as well 
as some lipophilic molecules from the sinusoidal plasma to hepatic cytosol.  The membrane 
transporters (efflux transporters) that are involved in the transfer of chemicals from the hepatic 
cytosol to the biliary space and subsequently into bile are expressed on the apical side of the 
hepatocyte (Muller and Jansen, 1997).  These transporters are members of the ‘ATP binding 
cassette’ (ABC) family, characterized by the presence of an ATP-binding site and require ATP 
hydrolysis for their transport function e.g. MDR1, BSEP, MRP2.  Figure 2 shows a schematic 
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diagram of the uptake and efflux transporters in human liver and their localization in human 
hepatocytes. Table 2 lists selected drug transporters, their substrates, inducers and inhibitors.   
Basal Membrane Uptake Transporters: 
NTCP (Na+-taurocholate co-transporting polypeptide): belongs to the solute carrier 
family (SLC) and is also known as SLC10A1 (Hagenbuch et al., 1991; Kullak-Ublick et al., 
2000a).  NTCP is primarily involved in the Na+-dependent transport of conjugated bile salts 
(TC, tauroursodeoxycholate, taurochenodeoxycholate), although it also transports unconjugated 
bile salts (cholate) to a lesser extent (Karpen et al., 1996; Kouzuki et al., 2000; Chandra and 
Brouwer, 2004). Dehydroepiandrosterone sulfate (DHEAS) (Meier et al., 1997), 3, 3’, 5-triiodo-
L-thyronine (T3), thyroxine (T4) (Friesema et al., 1999), bromosulfophthalein (BSP), and 
estrone-3-sulfate are non-bile salt substrates for this protein (Meier et al., 1997). 
OATPs (organic anion transporting polypeptides): are sodium-independent, bi-directional 
transporters involved in the hepatic uptake of substrates driven by countertransport of reduced 
glutathione present within the hepatocyte (Kullak-Ublick et al., 2000b).  The major transporters 
that form a part of this family include: OATP1A2 (SLCO1A2), OATP1B1 (SLCO1B1), 
OATP1B3 (SLCO1B3), and OATP2B1 (SLCO2B1) (Li et al., 1998).  OATP1B1 is the primary 
Na+-independent bile salt uptake system in human liver, with OATP1A2 and OATP1B3 playing 
a less extensive role (Kullak-Ublick et al., 2001). However, OATP2B1 does not transport bile 
salts. OATPs have been reported to transport various other substrates including 
bromosulphophthalein, glycocholate, prostaglandin E2, organic anions like estradiol-17β (β-D-
glucuronide) and anionic peptides ([D-penicillamine2,5]-enkephalin (DPDPE) and BQ-123 
(Meier et al., 1997; Tamai et al., 2000).  
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Apical Membrane Efflux Transporters:   
MDR1 (P-gp, ABCB1):  The multidrug resistance transport protein is the most widely 
recognized member of the ABC family of proteins and plays a major role in the hepatic excretion 
of a vast number of endogenous and exogenous compounds, including many drugs and 
metabolites.  Development of resistance to chemotherapeutic agents by cancer cells has been 
attributed to the over expression of this transporter (Pastan and Gottesman, 1987). MDR1 is 
primarily involved in the transport of compounds with following physicochemical characteristics 
- hydrophobic, molecular weight >400 (Schmid et al., 1999), and a log partition coefficient >2 
(Oude Elferink et al., 1995). 17-OHPC is a hydrophobic molecule having a molecular weight of 
428.7, a LogP value of 5.63 with no apparent charges on the molecule.  
Thus, it is likely that 17-OHPC will be a P-gp substrate. Further, steroids have been 
reported to behave both as inhibitors (Progesterone, Dehydroepiandrosterone) and substrates 
(Hydrocortisone, Flunisolide) of P-gp. 
BSEP (bile salt export pump, ABCB11): is a unidirectional, ATP-dependent transport 
protein expressed on the canalicular membrane responsible for the excretion of conjugated and 
unconjugated bile salts into the canalicular space (Hyde et al., 1990; Gerloff et al., 1998).  
Though this protein does not appear to play a key role in hepatic excretion of xenobiotics, drug 
interactions leading to clinical hepatotoxicity have been reported (Kostrubsky et al., 2006).      
MRPs (multidrug resistance–associated protein): consists of at least 6 members, known 
as MRP1-6.  MRP2 is the most studied member of this family and is involved in the biliary 
transport of organic anions including LTC4, divalent bile salts, and glutathione, glucuronide, and 
sulfate conjugates (Konig et al., 1999a).  Deficiency in the expression of MRP2 has been known 
to cause Dubin-Johnson syndrome in humans (Konig et al., 1999b).  Further, it has also been 
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implicated in the producing resistance to chemotherapy (anthracyclines, vinca alcaloids, 
methotrexate, SN38, SN38-glucuronide and cisplatin) by cancer cells (Chu et al., 1997; Masuda 
et al., 1997; Cui et al., 1999).   
BCRP (Breast cancer resistance protein, ABCG2): is a transmembrane half-transporter, 
overexpression of which confers multidrug resistance (MDR) to tumor cells and often limits the 
efficacy of chemotherapy (mitoxantrone, doxorubicin, daunorubicin, and sulfated conjugates). 
BCRP has been reported to play an important role in the biliary excretion of the sulfated 
conjugates of steroids and xenobiotics (Doyle et al., 1998; Suzuki et al., 2003).   
Alterations in hepatic transporters, through inhibition or induction, can affect the 
intracellular concentration of xenobiotics, resulting in altered pharmacokinetic and 
pharmacodynamic profiles, or of endogenous substances, altering normal physiological 
processes in the liver. 
The compound under investigation, 17-OHPC, is a highly lipophillic molecule with low 
solubility. The highly hydrophobic nature makes this compound highly permeable to lipid 
membranes. Based on these properties it can be classified under BCS Class II (Wu and Benet, 
2005). For BCS class II compounds being administered orally, as stated by Wu et al., efflux 
transporter effects are important clinically because they affect the oral bioavailability and the rate 
of absorption.  
In the case of intramuscular administration, low concentrations are expected at the 
hepatocyte-blood interface due to the diluting effect of volume of distribution and thus, 
saturation of hepatic transporters (uptake and efflux) is unlikely. Thus, with the intramuscular 
route of administration (assuming no transporter is involved in the absorption of 17-OHPC at the 
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depot-plasma interface), both uptake and efflux transporters can be important in determining the 
overall disposition of 17-OHPC. 
In this dissertation, we will evaluate the metabolic pathways and transport processes 
involved in the disposition of 17-OHPC using human liver microsomes and primary hepatocyte 
culture system.  
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Figure 2. Hepatic uptake and efflux transporters in human liver 
Source: (Faber et al., 2003; Chandra and Brouwer, 2004) 
1.9 Use of human hepatocytes to study drug metabolism and drug transport 
Hepatic drug metabolism and transport has been studied in a variety of in vitro or in vivo animal 
or human systems (Table 3).  The similarity to the in vivo situation increases as the complexity of 
the model increases e.g. from immortalized cell lines to animals.  Studies performed in humans 
are believed to be a more accurate indicator of a drug’s pharmacokinetics, as they comprise all of 
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the biological process that will interact with a compound in one contained system.  However, due 
to ethical considerations it is not practical to carry out studies in-humans routinely.  In-vivo 
animal studies are also considered as a reasonable alternative for the prediction of a drug’s 
pharmacokinetics, but have the limitation of ethical issues, cost involved and extrapolation to 
humans. Liver slices and whole perfused livers have the advantages of maintaining the in vivo 
liver architecture but have the disadvantage of being viable for only 4-6 hours and thus show 
poor reproducibility. Human liver microsomes, a subcellular preparation made from endoplasmic 
reticulum membranes, are one of the most widely models to evaluate drug metabolism. The main 
advantage is their long storage life (in years at -80ºC) without loss of enzyme activity. However, 
the disadvantages include: inapplicability for studying the effect of inducers, role of transporters 
and enzyme-transporter interplay, and problems with extrapolation to the in-vivo situation due to 
variables like preparation process, cofactors and substrate concentrations, and incubation 
conditions.         
Recombinant enzyme systems (expressed enzymes) are genetically transformed insect cells 
expressing a specific human metabolizing enzyme. They are widely used to answer questions 
regarding specific enzyme(s) and metabolic pathway(s) involved in the metabolism of a 
molecule. The disadvantages of this system are similar to human liver microsomes. 
Human hepatocytes, the functional units of liver, form the next best model systems for studying 
drug metabolism and transport.  Hepatocytes provide a physiological environment that contains 
normal concentrations of enzymes and cofactors, as well as the cellular machinery necessary to 
regulate the synthesis of new proteins.  Further, similar to the in-vivo situation, xenobiotics must 
cross a biological membrane, interact with cellular organelles and receptors, and compete with 
endogenous substrates for biotransformation.  Thus, hepatocytes provide a system which 
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replicate the in-vivo conditions more closely than isolated enzymes, subcellular fractions or 
homogenates, and liver slices.    
Primary cultures of human hepatocytes (PCHH) are viable for up to 2 weeks, or one 
month if placed in a three-dimensional culture, and express the majority of drug metabolizing 
phase 1 and 2 enzymes as well as several active transport mechanisms (uptake and efflux), thus, 
making them a versatile in vitro system to study induction and inhibition of drug metabolism and 
transport (Gebhardt et al., 2003).  Hepatocytes have been used to study various aspects of drug 
metabolism including, metabolic profiling (formation of metabolites for identification purposes), 
biotransformation pathways, and inter-species comparisons of metabolism to determine which 
animal species best represents the metabolism in humans. Further, they have also been used to 
elucidate the physiological response of cofactors, regulatory biomolecules, or xenobiotics on 
hepatocyte function. Hepatocytes have been widely used by the pharmaceutical industry for 
studying the detoxification or toxification of xenobiotics derived through metabolism. 
As the use of PCHH has advanced, modified culturing techniques have enabled the 
examination of other processes involved in drug metabolism, namely the uptake and efflux of 
drugs and their metabolites by hepatic drug transporters. The loss of tight junctions secondary to 
the hepatocyte isolation procedure results in a loss of cellular polarity, or depolarization, and 
results in changes in hepatically expressed genes. Normal monolayered PCHH show reduced 
albumin secretion over time, increased levels of alpha-fetoprotein, a protein that is associated 
with depolarization and dedifferentiation of hepatocytes, dephosphorylation of cell surface 
receptors responsive to growth factors and, in the case of rat hepatocytes, a rapid loss of drug 
metabolizing activity and MDR1 expression (Luttringer et al., 2002; Richert et al., 2002; Boess 
et al., 2003). 
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Table 3. Systems to study hepatic drug metabolism 
System Complexity Ease of use 
Subcellular fractions 
Supersomes 
Microsomes 
Cytosol 
Expressed Enzyme Systems 
Human hepatocyte cultures 
Suspended cultures 
Tumor derived cell lines 
Cryopreserved hepatocytes 
Primary hepatocytes 
3D cultures 
Liver slices 
Whole Liver perfusion 
In vivo animal model 
Human 
 
 
Source: Adapted from Brandon et al. (2003). Tox App Pharmacol 199:233-246.   
The application of extracellular 3D matrix prevents the loss in albumin synthesis, leads to 
the phosphorylation of hepatocyte growth factor receptors and results in cuboidal, polar 
hepatocyte structure. This has been shown to result in relocalization of MDR1 in hepatic 
canalicular membrane (Sidhu and Omiecinski, 1995; Kudryavtseva and Engelhardt, 2003; Engl 
et al., 2004). Hepatocytes in 3D culture have been utilized to document the effects of a variety of 
compounds on MDR1, NTCP, MRP2 and BSEP expression and activity (Liu et al., 1999a; 
Luttringer et al., 2002; Kostrubsky et al., 2003; Hoffmaster et al., 2004). Thus, primary 
hepatocytes (in culture or suspension) are an excellent in-vitro tool for not only evaluating the 
role of metabolic pathways and transporters in the disposition of a compound and any interplay 
between metabolizing enzymes (Phase 1 and 2) and transporters (uptake and efflux) but also 
provide data that can predict the in-vivo situation with better accuracy. 
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1.10 Summary and introduction to dissertation 
Preterm birth (PTB), birth prior to 37 weeks of gestational age, is the leading cause of neonatal 
mortality (infant death <28 days of life) and is a major cause of early childhood mortality and 
morbidity in the United States.   
17alpha-hydroxyprogesterone caproate (17-OHPC) has recently been documented to 
reduce the incidence of preterm birth.  17-OHPC is administered intramuscularly once a week at 
a fixed dose of 250 mg.  Currently very limited documentation is available on the 
pharmacokinetics of 17-OHPC in humans or animals. The purpose of this dissertation work is to 
elucidate the pharmacokinetics of 17-OHPC in both in-vitro (preclinical) and in-vivo (clinical) 
conditions in order to optimize the dosing regimen of this agent for preventing preterm birth.    
The progestational effect of 17-OHPC is expected to be related to its concentration in the 
pregnant subjects.  In earlier clinical studies 17-OHPC was demonstrated to be effective in only 
about 33% of patients.  It is possible that this variability in clinical response may be related to the 
concentration of 17-OHPC.  Inter-individual variability in the metabolism is an important factor 
contributing to the variability in the pharmacokinetics of several drugs. The metabolic fate of 17-
OHPC is not completely understood. The metabolism of 17-OHPC in human has not been 
characterized. The role of the metabolites of 17-OHPC on the progestational effects of 17-OHPC 
or in mediating any side effects of 17-OHPC is also not known.  A complete understanding of 
the pharmacokinetics of 17-OHPC will help in designing an optimal dosing regimen for this 
agent and improve therapeutic outcomes.   
The following research will evaluate the preclinical and clinical pharmacology of 17-
OHPC.  We hypothesize based on the structural similarity between Medroxyprogesterone 
Acetate (MPA), a CYP3A4 substrate, and 17-OHPC (a progesterone analog) that CYP3A4 will 
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be the major enzyme involved in the metabolism of 17-OHPC by adult human liver.  Further, 
given the substrate overlap between CYP3A4, CYP3A5 and CYP3A7, we hypothesize that fetal 
liver will metabolize 17-OHPC with CYP3A7 being the major isoform involved in the 
metabolism.  Additionally, we hypothesize that metabolism of 17-OHPC will lead to the 
cleavage of the caproate side chain and production of 17-OHP which is responsible for the 
prolonged and more potent action of 17-OHPC over progesterone. We also hypothesize based on 
the fact that progesterone and its metabolites interfere with bile salt transport via inhibition of 
bile salt export pump (BSEP) that 17-OHPC, a structural analog of progesterone, will also inhibit 
bile salt transporter (BSEP) in adult and fetal human hepatocytes.  Finally, since 17-OHPC is 
administered as a fixed dosing regimen consisting of 250mg weekly injection and a high inter-
individual variability has been reported in CYP3A4 expression, we hypothesize that a large 
variability will be observed in the exposure of 17-OHPC in pregnant subjects.  
Full descriptions of the methods used in this research project are outlined in Chapter 2.  The 
aim of Chapter 3 was to investigate the metabolizing enzymes and metabolic pathways involved in 
the disposition of 17-OHPC in adult human liver using human liver microsomes and adult human 
hepatocyte primary cultures.  The purpose of Chapter 4 was to elucidate the metabolizing enzymes 
and metabolic pathways involved in the disposition of 17-OHPC by fetal human liver. Primary 
cultures of fetal hepatocytes were used as the model system to study the metabolism and enzyme 
kinetics.  The goal of Chapter 5 was to evaluate the role of transporters in the disposition of 17-
OHPC and the effect of 17-OHPC on bile salt transport.  Primary cultures of human fetal 
hepatocyte overlaid with Matrigel® were used for this study.  The purpose of Chapter 6 was to 
evaluate the pharmacokinetics of 17-OHPC in human pregnant subjects with multiple gestation. 
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2.0  Material & Methods 
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2.1 Chemicals  
17α-hydroxyprogesterone caproate (17-OHPC, Mol. Wt. 428.6) was a gift from Diosynth Inc, 
Chicago. The radioactive isotope of 17α-hydroxy [1, 2, 6, 7-3H]-progesterone [1-14C] caproate was 
custom synthesized by RTI International (Research Triangle Park, NC).  Quinidine, sulfaphenazole, 
coumarin, ketoconazole, methimazole, α-naphthoflavone, testosterone, 6-β-hydroxytestosterone, 
medroxyprogesterone acetate, rifampin, phenobarbital, cyclosporine and NADPH were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).  Methanol and HPLC grade water were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA).  Microsomes derived from baculovirus-infected insect cells 
expressing human CYP isoforms (CYP3A4, 3A5 and 3A7) were purchased from BD-Gentest 
(Woburn, MA, USA).  EMEM (Eagle’s Minimum Essential Medium), HBSS (Hank's balanced salt 
solution), HMM (Hepatocyte. Maintenance Medium), DMEM (Dulbecco’s Modified Eagle 
Medium), Dexamethasone, Insulin were purchased from Lonza (Lonza Walkersville Inc., MD). 
(Lonza Walkersville, MD). Matrigel™ Matrix was purchased from BD Biosciences, Bedford, MA. 
Penicillin G/streptomycin was acquired from GIBCO Laboratories (Grand Island, NY).  3H-
Taurocholic acid (2 Ci/mmol) was obtained from PerkinElmer Life Sciences (Boston, MA).  BSA 
standard for total protein measurement by Lowry was obtained from Sigma.  Reagents for reverse 
transcription were purchased from Promega (Madison, WI). TaqMan analysis was used for all the 
genes analyzed with primers and conditions designated by Assays on Demand, Gene Expression 
Products (Applied Biosystems). Forward and reverse primers for CYP3A4, CYP3A7, MDR1, 
MDR3, OATP1B1, OATP1B3, OATP2B1, BSEP, NTCP, MRP2, MRP3, MRP4, BCRP and 
cyclophillin were synthesized by Applied Biosystems. Primers for all transporters and Taqman probe 
were purchased from Applied Biosystems. Assay IDs for each gene are listed in Table 4.  All 
solvents and other chemicals used were of HPLC grade or the highest purity available. 
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Table 4. Real-Time PCR Assay IDs for genes detected by Taqman gene expression assays 
 
 
GENE SYMBOL GENE NAME ASSAY ID 
OATP1B1 Solute carrier organic anion transporter family, member 1B1 Hs00272374_m1 
OATP1B3 Solute carrier organic anion transporter family, member 1B3 Hs00251986_m1 
OATP2B1 Solute carrier organic anion transporter family, member 2B1 Hs00200670_m1 
P-gp ATP-binding cassette, B1 (ABCB1 - MDR1) Hs00184500_m1 
MDR3 ATP-binding cassette, B4 (ABCB4) Hs00251620_m1 
BSEP ATP-binding cassette, B11 (ABCB11) Hs00184824_m1 
MRP2 ATP-binding cassette, C2 (ABCC2) Hs00166123_m1 
MRP3 ATP-binding cassette, C3 (ABCC3) Hs00358656_m1 
MRP4 ATP-binding cassette, C4 (ABCC4) Hs00195260_m1 
BCRP ATP-binding cassette, G2 (ABCG2) Hs00184979_m1 
NTCP Sodium/bile acid cotransporter 1 (SLC10A1) Hs00914889_m1 
PPIA Cyclophilin A (peptidylprolyl isomerase A) Hs99999904_m1 
CYP 3A4 Nifedipine oxidase Hs00430021_m1 
CYP 3A7 Aryl hydrocarbon hydroxylase Hs00426361_m1 
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2.2 Preparation of human liver microsome 
Liver pieces were dissected and kept in cold saline on ice. Liver microsomes were prepared by a 
standard differential centrifugation procedure with minor modifications (Court and Greenblatt, 
1997; Nelson et al., 2001). Briefly, liver pieces were homogenized with three volumes of a 
homogenization buffer (50 mM Tris-HCl buffer, 1.0% KCl and 1 mM EDTA, pH 7.4), using an 
electrical homogenizer (Polytron, Brinkman Instruments, N.Y., U.S.A.). The crude homogenate 
was centrifuged (Optima XL-100K ultracentrifuge, Beckman Instruments, Palo Alto, CA, USA) 
at 10,000g for 20 min at 4ºC. The supernatant was further centrifuged at 105,000g for 65 min at 
4ºC to sediment the microsomes. The microsomes were reconstituted using a manual 
homogenizer (Wheaton, Millville, NJ, USA) in twice their weight of Tris HCl buffer (50 mM 
Tris-HCl buffer, pH 7.4) containing 20% glycerol. Aliquots (1.0 ml) were immediately kept in 
storage at -80ºC until used. The protein content was determined by Lowry’s method (Lowry et 
al., 1951) using bovine serum albumin (Fluka, USA, 98% pure) as a standard. 
2.3 Adult Hepatocyte Isolation 
Adult human liver tissue was procured under an Institutional Review Board approved protocol 
and with support from the liver tissue cell procurement and distribution system (LTCDS). 
Primary cultures of human hepatocytes (PCHH) were prepared by a three-step collagenase 
perfusion technique (Strom et al., 1996). Viability of cells was determined by the trypan blue 
exclusion method and cells were used only when the viability was at least 65%. Briefly, equal 
volumes of trypan blue (0.4%) and cell suspension were mixed and a portion of this suspension 
was then placed on a hemocytometer. The cells were observed under a light microscopy and the 
numbers of live and dead cells (stained blue), were counted in two fields. Concentration of cells 
(number of cells / ml) was determined using the following formula: Live cells in two fields x 
10,000 = # of cells/ml. Cells were diluted to final volume of 1 x 106 cells per ml. Hepatocytes 
were plated on Falcon 6-well culture plates (1.5 x 106 cells), previously coated with rat tail 
collagen in HMM supplemented with 0.1 μM insulin, 0.1 μM dexamethasone, 0.05% 
streptomycin, 0.05% penicillin, 0.05% amphotericin B and 10% bovine calf serum. After 
allowing the cells to attach for 4 to 6 hours, medium was replaced with serumfree medium 
containing all of the supplements described above. Cells were maintained in culture at 37°C in an 
atmosphere containing 5% CO2 and 95% air. After 24 hours in culture, unattached cells were 
removed by gentle agitation and the medium was changed. For transporter studies, cells were 
overlayed with Matrigel™ (0.233 mg/mL) at this time. The medium was changed every 24 hours 
and the hepatocytes were maintained in culture between 5 and 9 days depending on the 
experimental design. 
2.4 Fetal hepatocyte isolation  
Fetal livers were obtained from planned termination of pregnancy procedures, having human 
fetal tissues with a gestational age between 18-23 weeks. The tissues were obtained from Mercy 
Women’s Hospital, Pittsburgh, PA after obtaining informed consent. The fetal tissue was kept in 
EMEM and transported on ice. The hepatic tissue was gently scraped with a sterile cell scraper in 
 55 
a 100 mm cell culture dish. HBSS (30ml) containing 0.1M EGTA was added to the tissue and 
the contents were pipetted up and down few times with a 25 ml pipette to get a homogenous mix. 
Tissue was transferred to a 50 ml falcon tube and gently rotated by hand to suspend red cells. 
The tubes were centrifuged at 60x g for 5 minutes and the supernatant poured off. Cell pellets 
were washed with 30 ml HBSS and again centrifuged using the same settings. The supernatant 
was poured off and the volume of pellet was recorded. The pellet was then resuspended in 25 ml 
EMEM (at 37ºC) containing 1 mg/ml collagenase XI, 0.2 mg/ml DNase I and penicillin/ 
streptomycin. The suspension was rotated on a rotary shaker at 37ºC, approximately 25 minutes. 
After shaking the tissue was redispersed by pipetting up and down with a 10 ml pipette. The 
suspension was spun down at 50 – 100 G for 5 minutes. The supernatant was poured off and 
resuspended in 50 ml EMEM (at 4ºC). The resulting suspension was spun down again using the 
previously described settings and supernatant poured off. The pellet was resuspended in 40 ml 
cell culture media (DMEM+) containing insulin (0.1µM), dexamethasone (0.1µM) and 
fungizone (25 µg/ml) and cell viability estimated using the trypan blue exclusion method. The 
cells were diluted to the desired concentration with DMEM (+) and 10% bovine calf serum was 
added. The cells were plated at a cell density of 0.3 - 0.5 x 106 cells per well in 12-well plates 
previously coated with 0.2 mg/ml type I collagen. Media was changed to serum free DMEM (+) 
after 3-5 hours. The media was changed once every day for the next 3-4 days until the cells 
achieved the desired confluency. The media was subsequently aspirated and the cells overlaid 
with Matrigel® (final concentration of 0.233 mg/ml) diluted in HMM (+) containing insulin 
(0.1µM), dexamethasone (0.1µM) and fungizone (25 µg/ml) 
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2.5 General hepatocyte treatment 
Briefly, hepatocytes were maintained in culture in the presence of an inducer or vehicle control 
(DMSO 0.1%) On the day of the experiment, cells were washed with HMM devoid of insulin, 
dexamethasone, antibiotics and antifungal drugs. It is assumed that this one hour period is 
sufficient to remove residual chemical from the enzyme active site. Following this period, media 
containing the appropriate probe substrate was applied to the cells with media sampled at the 
appropriate time points. Table 5 summarizes the enzymes studied with the respective probe 
substrates, concentrations used and sampling times. A number of variations on the traditional 
methods used to assess drug metabolizing enzyme activity are discussed in the subsequent 
chapters. 
2.6 Analytical methods 
Only the analytical methods used to assess enzyme activity that are used in subsequent chapters 
are described below. 
2.6.1 HPLC measurement of CYP3A4 activity 
The concentration of 6β-hydroxytestosterone in the medium was measured by HPLC as 
previously described, with the following modifications (Kostrubsky et al., 1999). One hundred 
microliters of medium were diluted with an equal volume methanol and centrifuged at 13,000 
r.p.m. for 5 minutes. One hundred microliters of this solution was injected onto a LiChrospher 
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100 RP-18 column (4.6 x 250 mm, 5 μm). 6β-hydroxytestosterone was eluted with a mobile 
phase of methanol/water (60:40, v/v) at a flow rate of 1.2 ml/min and the eluents were monitored 
at 242 nm. The concentration of the metabolite was quantitated by comparing the peak areas in 
samples to a standard curve containing known amount of the metabolite. 
 
Table 5. Probe substrates to study enzyme and transporter activity in human hepatocyte cultures 
 
 
Enzyme/ 
Transporter 
Probe 
Substrate 
Probe 
Conc. 
(µM) 
Metabolite 
Standard 
Inducer 
Inducer 
Conc. 
(µM) 
Incubation 
Time 
Analysis 
CYP3A4 Testosterone 250 
6β(OH)- 
testosterone
Rifampin 10 30 min HPLC-UV 
BSEP 
3[H]-
Taurocholate 
1 NA NA NA 20 min 
Scintillation
counter 
 
2.6.2 HPLC measurement of 17-OHPC and its metabolites 
Analysis of the unmetabolized drug and the potential metabolites obtained from HLM 
based incubations was performed using a HPLC system equipped with UV detection. The HPLC 
system comprised of an autosampler (712 WISP, Waters) and solvent delivery system (Waters 
501) attached to a UV detector (Waters 486). Chromatography was performed with a 4.6 x 250 
mm, 100Å, 5µm Symmetry C18 (Waters, Milford, MA, USA) column. Isocratic elution was 
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performed with a mobile phase of 90% (v/v) methanol in water at a flow rate of 0.8 ml/min, 
column temperature of 25°C and eluent monitored at 242 nm. The intra- and interday variation 
expressed as coefficient of variation did not exceed 10% in any of the assays. The concentration 
of 17-OHPC in samples was quantitated by comparing the peak areas in samples to a standard 
curve of the pure drug. The metabolites were quantitated by expressing them in terms of 17-
OHPC equivalents.  
2.6.3 Radio- HPLC measurement of 17-OHPC and its metabolites 
Analytical separations were achieved using conditions similar to above mentioned HPLC 
method. The metabolites were analysed using a Radiomatic Model 525TR/FLO-ONE flow-
through radioactivity detector (PerkinElmer Life Sciences, USA), and peak areas were integrated 
with Windows-based FLO-ONE version 3.61.  
2.6.4 LCMS measurement of 17-OHPC and its metabolites 
The HPLC system used for the analysis of 17-OHPC and its metabolites was a Waters 2695 
Model (Waters Corporation, MA, USA). Separation was performed on Waters C18 Symmetry 
(3.5 μm, 2.1 x 150 mm) analytical column at 40ºC with a Waters C18 Symmetry (2.1 x 10 mm) 
guard column. The mobile phases used were: [A] - 5% methanol in water containing 0.1% 
formic acid and [B] - methanol containing 0.1% formic acid. The total run time was 45 min at a 
flow rate of 0.2 ml/min. A gradient profile was used starting from a mobile phase containing 
50% solution [B], increased linearly to 95% [B], and followed by returning to the initial 
condition of 50% [B] to achieve the base line.  
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Analysis was performed on a Micromass Quattro Micro triple quadrupole mass 
spectrometer (Waters, Milford, MA, USA) with positive electrospray ionisation mode. 
Medroxyprogesterone acetate was used as the internal standard. For all analytes and internal 
standard, MS settings used were as follows: capillary voltage 3.5 kV; source temperature 100ºC; 
desolvation temperature 300ºC; cone gas flow (L/hr) 50; desolvation gas flow (L/hr) 550; argon 
pressure 20±10 psig; nitrogen pressure 100±20 psig. The LC-MS system was controlled and data 
collected with Masslynx® version 4.1. 
2.6.5 LCMS measurement of 17-OHPC in plasma samples 
The method used for the analysis of 17-OHPC in plasma samples has been published 
previously (Zhang et al., 2007; Zhang et al., 2008b). Briefly, routine daily calibration curves, 
controls and the clinical samples were thawed at room temperature. Exactly 400 µl of plasma 
was diluted with 1 ml of water, after addition of 25 µl of IS (1μg/ml), the entire solution was 
passed through SPE cartridges, previously conditioned with methanol and water, under vacuum. 
After washing with 1ml of 50% methanol, 17-OHPCwas eluted with 1ml of methanol and the 
eluent was evaporated to dryness under air. The residue was reconstituted in 100 µl of starting 
mobile phase and 20 µl was injected into the HPLC system connected to the mass spectrometer. 
The HPLC unit used for the analysis of 17-OHPC was a Waters 2695 model (Waters 
Corporation, MA, USA). Separation was performed on Waters C18 Symmetry (3.5 μm, 2.1 x 50 
mm) analytical column at 40ºC with a Waters C18 Symmetry (2.1 x 10 mm) guard column. The 
mobile phases used were: [A] - 5% methanol in water containing 0.01% ammonium hydroxide 
and [B] - methanol containing 0.01% ammonium hydroxide. The total run time was 7 min at a 
flow rate of 0.3 ml/min. A gradient profile was used starting from a mobile phase containing 
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65% solution [B], increased linearly to 97% [B], held for 2.5 min, followed by returning to the 
initial condition of 65% [B] to achieve the base line.  
Analysis was performed on a Micromass Quattro Micro triple quadrupole mass 
spectrometer (Waters, Milford, MA, USA) with positive electrospray ionisation mode using 
multiple reaction monitoring (MRM). For all analytes and internal standard, MRM setting used 
was as follows: capillary voltage 3.5 kV; source temperature 100ºC; desolvation temperature 
450ºC; cone gas flow (L/hr) 50; desolvation gas flow (L/hr) 550; argon pressure 20±10 psig; 
nitrogen pressure 100±20 psig. The extracted ions monitored following MRM transitions were 
m/z 429.24→313.25 for 17-OHPC and m/z 387.15→327.25 for MPA (IS). The cone and 
collision energy for 17-OHPC and MPA are shown in Table 6. The LC-MS system was 
controlled by Masslynx® version 4.1, and data collected with the same software. 
 
Table 6. The cone and collision energy set in LCMS for 17-OHPC and MPA (IS) 
 
   
Parent 
(m/z) 
Daughter 
(m/z) 
Dwell 
(sec) 
Cone Energy 
(V) 
Collision Energy 
(V) 
17-OHPC 429.24 313.25 0.1 24 13 
MPA 387.15 327.25 0.1 25 13 
2.7 Determination of total protein 
After sampling of the medium for metabolite measurements, the remainder of medium (0.5 mL) 
was aspirated from each well. Cells were then harvested in 150 μL of phosphate buffer and 
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stored at -80°C for protein determination by the method of Lowry (Lowry et al., 1951). Briefly, 
the proteins were dissolved in SDS/sodium hydroxide, then 1% sodium tartarate and 1% copper 
sulfate were added, followed by the addition of Folin’s reagent. The tubes were mixed gently and 
the color was allowed to develop for 45 min. At the end of 45 minutes, 200 μL aliquotes were 
transferred to 96-well plates and the absorbance was measured at 490 nm. The concentration of 
the protein was calculated using bovine serum albumin as a protein standard.  
2.8 Measurement of mRNA expression 
Total RNA was extracted from 1 x 106 cells plated on 6-well plates using 1 mL Trizol reagent 
(Invitrogen, Carlsbad, CA) according to manufacturer’s instructions. RNA was quantified 
spectrophotometrically and subjected to agarose gel electrophoresis to assess the integrity of 
RNA. Following treatment with RNase-free DNase (Promega, Madison, WI), 2 μg of RNA was 
mixed with 0.5 μg of Random Hexamers (Promega) heated to 70°C for 5 minutes then cooled to 
4°C. A reaction mixture containing 200 U MMLV-Reverse transcriptase, 1 mM dNTPs and 25 U 
RNasin (Promega) was added to the previous mixture and incubated at 37°C for 60 minutes. The 
resulting cDNA was diluted 10-fold and stored at -20°C.  
2.9 Real-Time PCR 
Real-time quantitative RT-PCR was conducted on an ABI Prism 7700 (Applied Biosystems, 
Foster City, CA). DNase-I treated total RNA of each sample was transcribed and mixed with 
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specific primer sets and PCR master mix (Applied Biosystems). TaqMan analysis was used for 
all the genes analyzed with primers and conditions designated by Assays on Demand, Gene 
Expression Products (Applied Biosystems). Data were analyzed with the ABI Prism 7700 SDS 
software (version 1.0). Expression of specific genes was normalized to an internal control 
(cyclophillin) mRNA expression. 
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3.0  Elucidation of the metabolizing enzymes and metabolic pathways involved in the 
disposition of 17-OHPC in adult human liver. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Sharma S, Ou J, Strom S, Mattison D, Caritis S and Venkataramanan R (2008) Identification of 
enzymes involved in the metabolism of 17alpha-hydroxyprogesterone caproate: an effective 
agent for prevention of preterm birth. Drug Metab Dispos 36:1896-1902] 
 
 
 64 
3.1 Abbreviations 
 
 
6β(OH)TE - 6β(OH) testosterone 
CYP - cytochrome P450 
CYP3A4 - cytochrome P4503A4 
HMM - hepatocyte maintenance medium 
FHH - primary cultures of human hepatocytes 
TE - testosterone 
17-OHPC - 17α-hydroxyprogesterone caproate 
17-OHP - 17α-hydroxyprogesterone 
P – Progesterone 
MPA – Medroxyprogesterone acetate 
FHH - Fresh human hepatocytes 
HLM - Human liver microsomes  
FMO - Flavin containing monooxygenase 
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3.2 Abstract 
Aims: Preterm delivery, that is delivery before 37 completed weeks of gestation, is the major 
determinant of neonatal morbidity and mortality. In a recent multicentered trial, 17α- 
hydroxyprogesterone caproate (17-OHPC) reduced the rate of preterm birth by 33% in a group of 
high risk women. Limited pharmacologic data exist for this drug. The recommended dose is 
empiric, the metabolic pathways are not well defined especially in pregnant women, and the fetal 
exposure has not been quantified. The purpose of this study was to define the metabolic 
pathways of 17-OHPC in human liver.  
Methods:  The model systems used were human liver microsomes, fresh human hepatocytes and 
expressed enzymes. 17-OHPC was quantified using both HPLC-UV and LC-MS systems. 
Protein content and mRNA were also measured.     
Results: Human liver microsomes (HLM) in the presence of NADPH generated three 
metabolites; whereas five metabolites were observed with fresh human hepatocytes (FHH). 
Metabolism of 17-OHPC was significantly inhibited by the CYP3A4 inhibitors, ketoconazole 
and troleandomycin, in HLM and FHH. Metabolism of 17-OHPC was significantly greater in 
FHH treated with the CYP3A inducers, rifampin and phenobarbital. Further, studies with 
expressed enzymes demonstrated that 17-OHPC is metabolized exclusively by CYP3A4 and 
CYP3A5. The caproic acid ester was intact in the major metabolites generated indicating that 17-
OHPC is not converted to the primary progesterone metabolite, 17-α hydroxyprogesterone (HP).  
Conclusions: This study demonstrates that 17-OHPC is metabolized by CYP3A. Since, CYP3A 
is involved in the oxidative metabolism of numerous commonly used drugs; 17-OHPC may be 
involved in clinically relevant metabolic drug interactions with co-administered CYP3A 
inhibitors or inducers. 
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3.3 Introduction 
Preterm delivery — that is, delivery before 37 completed weeks of gestation — is the major 
determinant of infant mortality in developed countries (Paneth, 1995). Preterm delivery is more 
common in the United States than in many other developed countries and is the factor most 
responsible for the relatively high infant mortality in this country (Mattison et al., 2001). 
However, little is known about the mechanisms especially at the molecular level which are 
responsible for this pathophysiology. 
In animal (sheep, rabbits, cows and pigs) models, decline in progesterone and rise in 
estrogen levels in plasma has been shown to precede induction of labor (Liggins et al., 1973; 
Anderson et al., 1975; Young, 2001). Thus, it was hypothesized that preterm delivery or 
spontaneous abortion occurred when body levels of progesterone dropped below the required 
level to maintain pregnancy (Keirse, 1990). These hormonal fluctuations led to various 
molecular changes especially in the myometrium (increases in gap junctions, oxytocin receptors 
and COX-2) (Gorodeski et al., 1987; Kelly et al., 1992; Chwalisz, 1994; Stjernholm et al., 1996) 
which highly increased its sensitivity to stimuli. However, the fluctuations in plasma 
progesterone levels were not observed in humans, monkeys and guinea pigs. This inter-species 
contradiction led to the concept of “functional progesterone withdrawal”. 
According to this concept, progesterone has a regulatory role in initiating labor; however, 
it is not reflected by the fluctuating plasma levels. Several models have been proposed in support 
of this concept involving downregulation of progesterone receptors, change in expression levels 
of various progesterone receptor phenotypes (Progesterone receptor A, B, C), chemical induced 
inhibition of progesterone receptor function or inhibition mediated by loss of interaction of 
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progesterone receptor with the responsive genes (Brown et al., 2004). However, the evidence so 
far is not conclusive in favor of any of the proposed models. 
One drug that has shown promise in cases of preterm birth is 17 alpha-
hydroxyprogesterone caproate (17-OHPC) (Meis, 2005; Petrini et al., 2005; Sanchez-Ramos et 
al., 2005). 17-OHPC is a synthetic hormone (Fig.3A) similar to the natural female sex hormone 
progesterone (Fig.3C) and has been proven effective in the prevention of spontaneous abortion in 
women with a history of recurrent miscarriage (habitual abortion).  
It was hypothesized that the mechanism of action of 17-OHPC may involve maintenance 
of body’s progesterone levels at desired threshold by being metabolised into hydroxy-
progesterone or progesterone (http://www.tiscali.co.uk, 2005). However, based on above 
mentioned reasons and the fact that progesterone levels required to bind to progesterone 
receptors are 1000 times less than the basal maternal levels, there is little reason to believe that 
progesterone supplementation will reduce preterm birth. In addition, administration of 17-OHPC 
did not appear to increase plasma progesterone concentrations in singletons or twins 
(Hartikainen-Sorri et al., 1980). Therefore, any benefit of 17-OHPC on preterm birth rates does 
not appear to involve an increase in plasma or tissue progesterone concentrations.  
In animal studies, 17-OHPC produces a longer lasting and more robust progestational 
effect on the endometrium than progesterone (Wu and Allen, 1959). When compared to 
injections of free progesterone, the same amount of 17-OHPC has twice the progestational 
activity and is twice as prolonged thus, favoring its use over the former in pregnancy (Junkmann, 
1953). 17-OHPC also appears to be more effective than progesterone in providing luteal support 
in patients undergoing in vitro fertilization-embryo transfer cycles (Abate et al., 1997; Costabile 
et al., 2001; Unfer et al., 2004).  
 68 
Thus, we postulate that whatever leads to this enhanced effect of 17-OHPC over progesterone 
may be responsible for the benefit in preterm birth prevention. 
Currently undergoing extensive clinical trials, 17-OHPC is usually administered 
intramuscularly once a week at a dose of 250 mg (Meis et al., 2003). However, the optimal 
dosing regimen of 17-OHPC has not yet been determined and the currently used dose is arbitrary 
(based on studies in 1950-60s, (Castelazo Ayala et al., 1959), (Eichner, 1958; Gold and Cohen, 
1958; Reifenstein, 1958) and does not have a pharmacological basis. The progestational effect of 
17-OHPC is expected to be related to its concentration in the pregnant subjects. It is possible that 
one or more metabolites of 17-OHPC may also be active.  
Limited documentation is available on the pharmacokinetics of 17-OHPC in humans or 
animals. The only study that had evaluated the pharmacokinetics of 17-OHPC was carried out in 
patients with endometrial carcinoma and used a nonspecific immunoassay to measure 17-OHPC 
(Onsrud et al., 1985). This study reported a large variability in the serum concentration vs. time 
profile after a fixed intramuscular dose to different patients and the apparent half life of 17-
OHPC appeared to be several days in these patients. Additionally, in earlier clinical studies 17-
OHPC was not demonstrated to be effective(Hartikainen-Sorri et al., 1980; Hauth et al., 1983) 
and only about 33% - 60% of patients (depending on gestational age) in the recent trials appear 
to benefit from 17-OHPC administration (Spong et al., 2005).  
It is possible that this variability in clinical response to 17-OHPC may be related to the 
variability in drug metabolism in different individuals in addition to other factors like gestational 
age. Further, the issue of drug-drug interactions needs to be addressed prior to its regular clinical 
use. Thus, it is important to identify the various enzymes (phase 1 and phase 2) involved in 17-
OHPC metabolism for not only designing an optimal dosing regimen for this agent but also to 
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determine the role of the metabolites of 17-OHPC on the progestational effects or in mediating 
any side effects.  However, to date there are no literature reports available on enzymatic 
pathways involved in the metabolism of this progestational compound and the various 
metabolites that are produced as a result.  
The purpose of the present study was to identify the various enzymes (cytochrome P450 
and FMO enzymes) involved in 17-OHPC metabolism and to characterize the metabolites of this 
compound. 
Medroxyprogesterone Acetate (Figure 3D) is a structural analog of 17-OHPC with an acetate 
ester at the C-17 position. It has been reported that CYP3A4 is mainly involved in the overall 
metabolism of MPA in human liver microsomes (Kobayashi et al., 2000). Further, oxidation 
(mono- and dihydroxy MPA metabolites) has been reported as the major metabolic pathway 
involved in the metabolism of Medroxyprogesterone Acetate (Sturm et al., 1991). Thus, based on 
structural similarity between MPA and 17-OHPC we hypothesize that CYP3A4 will be the major 
enzyme involved in the metabolism of 17-OHPC by adult human liver. Further, we believe that 
the oxidation will be the major metabolic pathway involved in 17-OHPC metabolism with the 
generation of monohydroxy-17OHPC as the major metabolite.         
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Figure 3. Chemical Structures of 17-OHPC, 17-OHP, P and MPA 
   
A) Product Name: 17α-Hydroxyprogesterone caproate (17alpha- hydroxy-4-pregnene-3, 20- 
     dione hexanoate) 
B) Product Name: 17α-Hydroxyprogesterone (17alpha- hydroxy-4-pregnene-3, 20-dione)   
C) Product Name: Progesterone (4-pregnene-3, 20-dione) 
D) Product Name: Medroxyprogesterone Acetate (Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6- 
     methyl). 
A B 
C D 
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3.4 Methods 
3.4.1 Microsomal incubations 
Optimal conditions for the evaluation of the metabolism of 17-OHPC were selected by varying 
the time of incubation (0 - 180 min) and the microsomal protein concentrations (0 – 2 mg/ml). 
Different concentrations of 17-OHPC (0 - 200 µg/ml in methanol, final concentration 0.5%) 
were incubated with human liver microsomes (0.5 mg/ml, optimum protein concentration) and 
MgCl2 (10 mM) in 0.1mM phosphate buffer (pH 7.4). The final volume was allowed to 
equilibrate in a shaking water bath for 5 min at 37 ºC. The reaction was initiated with the 
addition of NADPH (1 mM). In additional experiments, the incubations were also carried out in 
the absence of either NADPH or protein. After 60 min of incubation (optimum incubation time), 
the reaction was stopped by immediately adding equal volume of cold methanol. The mixture 
was centrifuged at 700 RCF for 20 min and supernatant was injected into the HPLC.  
Incubations of [3H], [14C] - 17-OHPC were also performed with human liver microsomes. 
Radiolabeled 17-OHPC was incubated with three individual human liver microsomal 
preparations for 10 mins using the above mentioned method and the samples analyzed directly 
by HPLC connected to a radioactivity detector.  
3.4.2 Chemical Inhibition Studies 
Various CYP inhibitors were used in the study to identify CYPs which might be involved in the 
metabolism of 17-OHPC. Human liver microsomal preparations (n=3) were used for the studies 
with the incubations being performed in triplicate. Experiments were done at different 17-OHPC 
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concentrations (0-200µg/ml expressed as 0-467 µM) spanning the concentrations seen clinically 
in order to identify the type of inhibition keeping the inhibitor concentration constant. CYP 
isoform selective chemical inhibitors were used at the following concentrations based on values 
reported in the literature (Newton et al., 1995): CYP1A2 (α – naphthoflavone, 10 μM), CYP2A6 
(coumarin, 20 μM), CYP2C9 (sulfaphenazole, 5 μM), CYP2D6 (quinidine, 5μM), CYP3A 
(ketoconazole, 1.0 μM), and FMO3 (methimazole, 200μM). Additionally, inhibition studies were 
also carried out by incubating 17-OHPC (25µM) with different concentrations of ketoconazole 
(0.01 to 10 µM) to determine the IC50 for the reaction. The formula used to determine the IC50 
for microsomal incubations involving 17-OHPC and ketoconazole involves estimating % 
inhibition which was calculated as follows: 
% Inhibition = [(17-OHPC without inhibitor  - 17-OHPC with inhibitor) / (17-OHPC without inhibitor)] * 100 
where, 17-OHPC without inhibitor  is amount of 17-OHPC metabolized in the absence of 
ketoconazole relative to the total amount of 17-OHPC. 17-OHPC with inhibitor is amount of 17-
OHPC metabolized in the presence of ketoconazole relative to the total amount of 17-OHPC. 
Subsequently, IC50 values or the inhibitor concentration resulting in 50% inhibition of 17-OHPC 
metabolism, were determined from a plot of the % inhibition versus the logarithm of 
ketoconazole concentration.  
In the case of mechanism based inhibitor like troleandomycin (TAO; 100µM), pre-
incubation was done for 30 min at 37°C prior to adding the substrate (17-OHPC, 25µM). In 
inhibition experiments with ketoconazole (1, 10 µM) the substrate was co-incubated with 
inhibitor. 
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3.4.3 Expressed enzyme microsomal incubations 
The incubations (n=3) were carried similar to the method described for human liver microsomes. 
To evaluate the involvement of CYP isoforms in 17-OHPC metabolism, 20 pmole of each 
expressed enzyme tested was incubated for 60 mins with 17-OHPC and the samples analyzed 
using HPLC-UV. 
3.4.4 Incubations with fresh human hepatocytes 
Briefly, hepatocytes were maintained in culture in the presence of the chemical under study or 
vehicle control (DMSO 0.1% or MeOH 0.1 %). On the day of the experiment, cells were washed 
with HMM devoid of insulin, dexamethasone, antibiotics and antifungal drugs. Drug stocks were 
prepared in methanol at 1000-fold incubation concentration (100 mM). Ten microliters of this 
100 mM stock was added to a vial containing 10 ml of hepatocyte maintenance media (HMM). 
Reactions were started by incubating 6-well cell culture plates containing human hepatocytes 
(1.5 million cells/well) with the drug (17-OHPC or TE) in HMM solutions for 60 min. At the end 
of that time, 1 mL of medium was sampled and stored at -80°C analysis. The remaining media 
was aspirated, the cells were harvested in phosphate buffer (0.1 M, pH 7.4) and stored at -80°C 
for protein determination.  
For acute inhibition experiments, human hepatocytes (n=4) were co-incubated with 17-
OHPC (25µM) in the presence and absence of inhibitors (troleandomycin and ketoconazole). 
The samples were incubated for 30 mins and collected as described above.   
The induction experiments were initiated 24 hrs after plating the cells. The hepatocytes 
(n=3) were incubated with the inducers (rifampin and phenobarbital) for 4 days prior to adding 
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HMM/ 17-OHPC (50µM) or Testosterone (250µM) to estimate the effect of CYP3A induction 
on 17-OHPC metabolism and TE metabolism.  Cells were also harvested for mRNA by adding 1 
mL of Trizol® reagent to each well of a 6-well plate. The RNA samples were stored at -20°C for 
Real Time PCR analysis. Primers for CYP3A4 and cyclophillin and the PCR procedure have 
been described in Chapter 2.  The mRNA expression for all genes was normalized to cyclophillin 
in each sample and expressed as fold change over control treatment. 
3.4.5 Correlation studies: 
Testosterone 6β-hydroxylation was used as the marker for CYP3A activity (Chiba et al., 
1996). Formation rates of 17-OHPC metabolite (M2) were measured using microsomes (n=7) 
and fresh human hepatocytes (n=7) at a substrate concentration of 100 µM. These rates were 
correlated with 6β(OH)TE formation activity to assess the involvement of CYP3A isoforms. 
3.4.6 Data Analysis 
Data are expressed as the mean ± SD. Student’s t-test was used to assess the significance 
of results. IC50 was calculated using GraphPad Prism 4.0 (GraphPad Software Inc., USA). 
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3.5 Results 
3.5.1 Metabolism of 17-OHPC by CYPs in human liver microsomal and fresh human 
hepatocyte preparations. 
Incubation of 17-OHPC with human liver microsomes resulted in the generation of three (M1-
M3HLM) main metabolites wherein (M2HLM) was the major metabolite (Figure 4). The formation 
of metabolites was observed to increase upto 60 minutes using a microsomal protein 
concentration of 0.5 mg/ml. Hence, the abovementioned conditions were used for all incubations 
unless specified otherwise. The formation of metabolites (M1HLM and M3 HLM) was low 
compared to M2 HLM, thus, accurate data could not be obtained for these minor metabolites and 
the paper focuses on the major metabolite (M2 HLM). Incubation of 17-OHPC with fresh human 
hepatocytes resulted in the generation of five metabolites (M1-M5HH). The major metabolite 
generated was M2HH which was used to characterize 17-OHPC metabolism in fresh human 
hepatocytes. Fig. 4 (A, B) shows the metabolism of 17-OHPC in microsomal incubates in the 
presence/ absence of NADPH detected using LC-UC analysis. All the metabolites were formed 
in a NADPH-dependent manner only. Fig. 5 (A) shows the metabolism of 17-OHPC in fresh 
human hepatocytes incubated for 1 hour detected using LC-MS analysis. 
3.5.2 Incubation of [14C, 3H] 17-OHPC with Human Liver Microsomes 
Incubation of radiolabeled 17-OHPC with HLM generated one major and two minor metabolite 
peaks (Figure 6). The recovery of radioactivity from the incubations was 85-97%.  
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Figure 4. Chromatograms (HPLC-UV) depicting 17-OHPC metabolism by HLM 
 
A) Chromatogram (HPLC-UV) showing retention times and absorption peaks for  
metabolites 1, 2, 3 (M1HLM, M2HLM, M3HLM) and 17-OHPC having retention times  
of 4.84, 5.10, 5.94 and 8.55 respectively, after microsomal incubation in the presence of  
NADPH.  
B) Chromatogram (HPLC-UV) depicting incubation of 17-OHPC with HLM in the  
absence of NADPH.  
 
 
A 
B 
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Figure 5. Chromatograms (LC-MS) depicting 17-OHPC metabolism by HLM 
 
A) Chromatogram (LC-MS) showing absorption peaks for metabolites (M1HH, M2HH,  
M3-5HH) and 17-OHPC after incubation with Fresh Human Hepatocytes (FHH) for 60  
minutes. The retention times for M1, M2 and 17-OHPC were observed to be 6.64, 7.99  
and 21.71 respectively.  
B) Chromatogram (LC-MS) showing absorption peak for 17-OHPC after incubation with  
Fresh Human Hepatocytes (FHH) for 1 minute. No metabolite formation was detected.  
The retention time for 17-OHPC was 21.97. 
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The major metabolite constituted approximately 60-65% of the metabolized 17-OHPC 
and the two minor metabolites were estimated to be approximately 15%. The remaining 20% of 
the metabolite could not be accounted for due to the limitations of analytical method used. The 
two ([14C, 3H]) labels on the 17-OHPC molecule were observed to remain intact in the 
metabolites generated confirming that the caproate side chain or the ring structure was not 
cleaved during metabolism in human livers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Radio-HPLC tracing of metabolites generated on incubating radiolabeled 17-OHPC 
with HLM. 
 (A) - [14C] label and (B) – [3H] label was observed on the major metabolites (M1, M2) on 
incubation with HLM, thus, confirming that the caproate moiety is not cleaved during 
metabolism.  
 
 
A 
B 
M2
M1
M2
M1
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3.5.3 Metabolic Profiles in Human Liver Microsomes and Hepatocytes 
Metabolism of 17-OHPC was evaluated over time using human liver microsomes and 
hepatocytes. The concentrations of unmetabolized 17-OHPC and the major metabolite 
(expressed in terms of 17-OHPC equivalent) were determined over a time period of 0 – 180 mins 
incubation. Fig. 7 (A, B) shows that the concentration of 17-OHPC decreased in a time-
dependent manner and the concentration of the metabolite increased proportionately. 
Approximately, 60% of the parent drug (17-OHPC) was metabolized within 60 minutes and 
M2(HLM, HH) accounted for almost 50% of metabolized 17-OHPC.  
 
 
 
 
 
 
 
 
 
Figure7. Metabolism of 17-OHPC and generation of major metabolite (M2) by human 
hepatocytes and human liver microsomes 
A) Incubation of 17-OHPC (150µM) with Fresh Adult Human Hepatocytes generated five 
metabolites (M1-5HH). The major metabolite (M2HH, ■) showed a time dependent increase 
throughout the incubation which corresponded with a decrease in the amount of 17-OHPC (▲). 
B) Incubation of 17-OHPC (50µM) with Human Liver Microsomes generated metabolites 1, 2 
and 3. Metabolite 2 (M2HLM, ■) was the major metabolite which depicted time dependent 
increase in concentration corresponding to a decrease in 17-OHPC concentration (▲).  
The amount of metabolite has been expressed in terms of 17-OHPC equivalents. 
A B 
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3.5.4 Identification of Human P450 Isoforms 
3.5.4.1 Incubations with human liver microsomes 
17α-hydroxyprogesterone caproate was incubated with microsomes for 60 min in the presence of 
various representative inhibitors of P450 isoforms. A similar reaction was performed in the 
absence of the inhibitors, and the rate of major metabolite (M2HLM) generated was compared 
between the two conditions to identify the isoforms responsible for 17-OHPC metabolism. As 
summarized in Fig. 8, α-naphthoflavone, sulfaphenazole, coumarin, quinidine and methimazole 
did not inhibit the metabolism of 17-OHPC by the corresponding CYPs. In contrast, the amount 
of M2HLM was significantly decreased in the presence of ketoconazole, indicating that the 
metabolism of 17-OHPC was markedly inhibited. The Vmax (0.29±0.02 nmole/min/mg) and Km 
(77.94±19.4µM) values for M2HLM were observed to decrease significantly in the presence of 
ketoconazole (Vmax=0.03±0.002, Km=15.38±3.9). An IC50 (0.17 µM) value for the inhibition 
of 17-OHPC metabolism by ketoconazole in human liver microsomes (n=3) was also calculated 
(Fig. 9). 
3.5.4.2  Incubations with baculovirus expressed human CYP isoforms 
Studies were also performed in baculovirus-infected insect cells expressing various CYPs. The 
metabolizing activity of each CYP3A isoform for 17 α-hydroxyprogesterone caproate was 
compared to control microsomes, which were devoid of any CYP activity. The results indicate 
the involvement of CYP3A4/5 in the metabolism of 17-OHPC and the formation of the major 
metabolite (M2HLM) was a result of CYP3A4/5 pathway (Table 7). 
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Figure 8. Ketoconazole inhibits 17-OHPC metabolism 
 
Of the various inhibitors evaluated, namely, Coumarin (CYP2A6, ■), α-Naphthoflavone 
(CYP1A2, ▲), Sulfaphenazole (CYP2C9, ▼), Quinidine (CYP2D6, □), Ketoconazole (CYP3A, 
♦), and Methimazole (FMO3, ●), only Ketoconazole (1µM) demonstrated significant inhibition 
of 17-OHPC (0-200 µg/ml expressed as 0-467µM) metabolism in human liver microsomes (n=3) 
when compared to control (No Inhibitor, ∆). This indicated the role of CYP3A isoforms in 
metabolizing 17-OHPC and the potential involvement of CYP3A4. Approx. 80% inhibition of 
17-OHPC was observed at 1 µM Ketoconazole (* p < 0.05). V (µmoles/min/mg microsomal 
protein) denotes the major metabolite formation (M2HLM) expressed in terms of 17-OHPC 
equivalents. 
*
3.5.4.3 Inhibition studies with Human Hepatocytes 
Results obtained from inhibition experiments performed in HLM were confirmed in fresh adult 
human hepatocytes (Fig. 10) using chemical inhibitors for CYP3A (ketoconazole and 
troleandomycin). Troleandomycin and ketoconazole inhibited 17-OHPC metabolism (M2HH 
formation) by 75 and 89%, respectively, indicating involvement of CYP3A4/5. 
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Figure 9. Estimation of IC50 
 
IC50 value for the ketoconazole mediated inhibition of 17-OHPC (25µM) metabolism was 
calculated to be 0.17 µM in human liver microsomes (n=3). Inhibition of 17-OHPC metabolism 
was evaluated by estimating the formation of M2HLM. 
3.5.4.4  Induction Studies with Human Hepatocytes 
Induction studies were performed in fresh human hepatocytes to further confirm CYP3A to be 
the primary enzyme responsible for 17-OHPC metabolism. CYP3A inducers like RIF and PB 
increased M2HH formation (Fig. 11). RIF showed the maximum (2.2 fold) increase in 17-OHPC 
metabolism and PB showed a 2.1 fold increase in human hepatocytes. The increase in CYP3A4 
expression by the inducers was confirmed by RT-PCR and the induction of CYP3A activity by 
TE metabolism (formation of 6β(OH)TE).  Treatment with these inducers, RIF (10 μM) and PB 
(2000 µM), resulted in 10.2 ± 5, 18.5 ± 4 - fold increase in the mRNA expression of CYP3A 
(Fig. 12A) and a 7.1± 1.8, 8.5 ± 3 fold increase in the formation of 6β(OH)TE (Fig. 12B), 
respectively. 
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 Table 7. Identification of cytochrome P450s involved in the metabolism of 17-OHPC 
Expressed CYPs 
Metabolite (M2HLM) 
(pmole/pmole CYP/min) 
17-OHPC Metabolized 
(pmole/pmole CYP/min) 
CTRL ND ND 
1A1 ND ND 
1A2 ND ND 
1B1 ND ND 
2A6 ND ND 
2B6 ND ND 
2C8 ND ND 
2C9*1 ND ND 
2C9*2 ND ND 
2C9*3 ND ND 
2C18 ND ND 
2D6*1 ND ND 
2D6*10 ND ND 
2E1 ND ND 
19 ND ND 
FMO1 ND ND 
FMO3 ND ND 
FMO5 ND ND 
CYP3A4 27.4±1.2 64.5±0.1 
CYP3A5 57.1±3.7 68.4±0.4 
Mean ± SD of triplicate in-vitro preparations. Amount of metabolite is expressed in terms of 
HPC equivalent. Significant levels of metabolite were detected on incubation of 17-OHPC (100 
µM) with expressed CYP3A4/5 for 120 mins, whereas no metabolite could be detected for other CYPs. 
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Figure 10. CYP3A4/5 metabolize 17-OHPC in Human Hepatocytes 
 
Ketoconazole (K, 1 and 10µM) and Troleandomycin (TAO, 100µM) demonstrated significant 
(p<0.05) inhibition of 17-OHPC (25µM) metabolism in Fresh Human Hepatocytes (n=4). This 
indicated the role of CYP3A isoforms in metabolizing 17-OHPC and the potential involvement 
of CYP3A4. Inhibition of 17-OHPC metabolism was evaluated by estimating the formation of 
M2HH. 
 
 
 
 
 
 
 
 
Figure 11. CYP3A inducers increase 17-OHPC metabolism in Human Hepatocytes 
 
Incubation of fresh human hepatocytes (n=3) with specific CYP3A4 inducers, namely, Rifampin 
(p<0.05) and Phenobarbital (p<0.05) increased the metabolism of 17-OHPC (50µM) as 
compared to control (DMSO). The estimation of induction was based on the generation of the 
major metabolite (M2HH) in hepatocytes.   
 
 85 
 RIF PB
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
20.0
22.5
C
YP
3A
4
m
R
N
A
ex
pr
es
si
on
(F
ol
d 
In
du
ct
io
n/
C
on
tr
ol
) 
 
 
 
 
 
 
 
 
 
 
 
 
 
A  
 
 
 
 
RIF PB
0.0
2.5
5.0
7.5
10.0
6 β
(O
H
) T
e 
fo
rm
at
io
n
(F
ol
d 
In
du
ct
io
n)
 
 
 
 
 
 
 
 
 
 
 
 
 
 B  
 
Figure 12. Effect of CYP3A inducers on CYP3A4 mRNA expression (A) and activity (B) in 
Human Hepatocytes 
 
Hepatocytes were exposed to Rifampin (RIF) and Phenobarbital (PB) for 72 hours and mRNA 
expression and activity were determined.   
(A) An increase in CYP3A4 expression was observed in the presence of the inducers as 
compared to control (DMSO). 
(B) An increase in CYP3A4 activity was observed in the presence of the inducers as 
determined by estimating the formation of 6beta-hydroxytestosterone. 
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3.5.5 Correlation studies     
Rates of formation of 17-OHPC metabolite (M2) with liver microsomes and adult human 
hepatocytes were measured at a substrate concentration of 100 μM. There was considerable 
interindividual variation in the values of metabolite generated (Fig. 8). Formation of M2(HLM) and 
M2(HH) correlated significantly with the testosterone 6-β-hydroxylation activity (CYP3A4) in 
both microsomes (r=0.89) and hepatocytes (r=0.91), respectively. 
 
 
 
 
 
 
 
 
 
 
A B  
 
 
Figure 13. Correlation analysis of 17-OHPC metabolite M2 with CYP3A dependent 6β-
hydroxytestosterone formation 
 
(A) Correlation analysis in fresh human hepatocytes (FHH); n=7 
(B) Correlation analysis in human liver microsomes (HLM); n=7  
 
CYP3A activity was estimated by incubating 17-OHPC (100µM) and Testosterone (100 µM) in 
individual human liver microsomal preparations and fresh human hepatocyte cultures. The 
experiment was carried out in triplicate in both cases. 
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3.6 Discussion 
To the best of our knowledge, this is the first report identifying the human hepatic enzymes, 
which play a major role in the metabolic pathway of 17-OHPC. The metabolism of 17-OHPC 
was evaluated using human liver microsomes, fresh human adult hepatocytes and recombinant 
systems expressing cytochrome P450s and FMOs. Incubation of 17-OHPC with heat-inactivated 
microsomes did not result in any loss of 17-OHPC or generation of any 17-OHPC metabolites. 
Significant metabolism of 17-OHPC however was seen in all the three systems that were 
tested. Generation of metabolites as well as loss of parent drug confirmed this observation. No 
metabolites were observed in the absence of NADPH thus confirming the metabolism to be CYP 
mediated. Incubation of 17-OHPC with human liver microsomes under the conditions for direct 
generation of conjugates did not alter 17-OHPC concentrations or yield any 17-OHPC 
metabolites, ruling out a direct role of UGT mediated pathway. However, studies evaluating the 
role of UGT as a sequential pathway in 17-OHPC metabolism are being carried out currently. 
Multiple approaches were used to identify the cytochrome P450 enzymes involved in the 
metabolism of 17α-hydroxyprogesterone caproate. Metabolism of MPA, a potent progestogenic 
compound, has been reported in literature (Kobayashi et al., 2000) to be catalyzed mainly by 
CYP3A4. Since, MPA is structurally similar to 17-OHPC it was expected that the metabolic 
pathways for both compounds would likely be similar. The results obtained in this study 
confirmed this expectation. In human liver microsomes, 17α-hydroxyprogesterone caproate was 
metabolised to one major and two minor metabolites. CYP inhibition experiments indicated 
CYP3A4/5 to form the main metabolic pathway. Ketoconazole (CYP3A inhibitor) at 1.0 µM 
inhibited 90% of 17-OHPC biotransformation in human liver microsomes. These findings and 
the lack of effect of α – naphthoflavone, quinidine, coumarin, sulphaphenazole (inhibitors for 
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CYP1A2, CYP2D6, CYP2A6, and CYP2C9) suggest a major role for CYP3As in 17-OHPC 
metabolism. 
In fresh human adult hepatocytes, five (M1-5HH) metabolites were observed on 
incubation of 17-OHPC with M2HH being the major metabolite. Ketoconazole and 
Troleandomycin (a known CYP3A inhibitor) significantly inhibited 17-OHPC metabolism. 
Inducers of CYP3A namely; rifampicin, phenobarbital and clotrimazole significantly increased 
17-OHPC metabolism in comparison to control. Thus, the results in human liver microsomes 
were successfully reproduced in fresh human hepatocytes. This showed CYP3A to play the 
major role in 17-OHPC metabolism in hepatocytes as well.  
To further confirm our results we conducted experiments to check the ability of 
expressed enzyme systems to catalyze the biotransformation of 17-OHPC. CYP3A isoforms 
were the only enzyme systems that metabolized 17-OHPC significantly. The enzyme activity for 
17-OHPC metabolism was observed to be higher for CYP3A5 isoform than CYP3A4. The 
reason for the differential activity is not known at this time. 
The CYP3A subfamily is known to be expressed most abundantly (i.e., from 10-60% of 
total CYPs) in human liver and plays a pivotal role in the oxidative metabolism of many 
clinically important drugs. Among the CYP3A isoforms tested (i.e., CYP3A4 and 3A5), 
CYP3A4 is the major isoform in adult humans. CYP3A5 is polymorphically expressed in 
approximately  10 to 20% of the adult liver (Wrighton et al., 1990). Overall, we can predict that 
CYP3A4 would be the major CYP isoform responsible for the hepatic metabolism of 17-OHPC 
in the majority of adult patients given 17-OHPC. Given that CYP3A5 has higher activity for 17-
OHPC, genetic polymorphism in CYP3A5 may have a significant role in 17-OHPC metabolism 
and pharmacokinetics, but this remains to be evaluated. It has been proposed that the prolonged 
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and more potent action of 17-OHPC over progesterone involves the cleavage of 17-OHPC 
molecule to 17-OHP (Fig.1B) and release of free caproic acid. It was also suggested that caproic 
acid could affect genomic pathways and hence have an effect of progesterone signaling pathways 
(Attardi et al., 2007). However, results of radio-HPLC based method confirmed that the structure 
of 17-OHPC remained intact during metabolism by human enzymes. Our observation does not 
support the hypothesis that 17-OHPC is a prodrug that gets metabolized to progesterone or 
hydroxyprogesterone and thus prevents pre-term labor. Further, LC-MS based analysis of the 
major metabolite (M2HLM, m/z=445) generated from incubations in human liver microsomes 
indicated possible mono-hydroxylation or an oxidation product. Identity of the major metabolite 
(M2HH) generated from human hepatocytes needs to be elucidated although preliminary data 
based on retention time and LCMS data analysis indicates M2HH (m/z=445) to be similar to 
M2HLM.  
Our study demonstrates that the metabolism of 17-OHPC is predominantly mediated by 
CYP3A isoforms, mainly CYP3A4. Given that the activity of CYP3A enzyme is known to vary 
between subjects, one would expect large variation in the pharmacokinetics of 17-OHPC in 
pregnant subjects. CYP3A4 plays a major role in the metabolism of various drugs due to its 
abundance in the liver and its broad substrate specificity. Numerous clinically important drugs 
are known as substrates of CYP3A4 (Rendic and Di Carlo, 1997). Thus, further in-vitro and 
clinical studies are required to assess 17-OHPC associated clinically relevant metabolic drug 
interaction with any co-administered CYP3A4 substrates/ inhibitors.    
Pregnancy is a dynamic state of the human body which is characterized by significant 
variations in the physiology and metabolism. Changes in the metabolizing activity of CYPs 
especially CYP3A4 has been reported in literature (Tracy et al., 2005). Activity of CYP3A4 has 
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been shown to increase significantly in all trimesters in humans. Further, the expression level of 
CYP3A isoforms varies from individual to individual. Thus, we expect significant inter-
individual fluctuations in 17-OHPC plasma concentrations in pregnant patients over time. In 
clinical studies, 17α-Hydroxyprogesterone Caproate is administered as a fixed dose regimen of 
250mg weekly. The therapy was observed to be effective in 33% of the patients in the study of 
Meis et al. It is possible that the low success rate of 17-OHPC may be attributable to the 
significant variation in CYP3A mediated metabolism of 17-OHPC in these patients. On the basis 
of the abovementioned facts, it may be necessary to investigate various dosing regimen and 
individualize the therapy with 17-OHPC.  
 
Clinical Implications:  
1) CYP3A4 is the major isoform (of total CYPs) expressed in the human intestine. Since, 
17-OHPC is a CYP3A4 substrate and likely a BCS Class II compound; the oral 
bioavailability of this drug is expected to be low. 
2) Significant interindividual variability (10 fold) in the plasma concentrations of CYP3A4 
substrates has been reported. Thus, monitoring 17-OHPC plasma levels and adjustment 
of dose accordingly may be needed to improve therapeutic outcomes. 
3) Potential for drug interactions with other CYP3A substrates exists when multiple 
medications that are CYP3A substrates are co-administered. 
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4.0  Elucidation of the metabolizing enzymes and metabolic pathways involved in the 
disposition of 17-OHPC in fetal human liver 
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birth, by fetal hepatocytes. Drug Metab Dispos 38:723-727] 
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Metabolism of 17α-hydroxyprogesterone caproate in Mice, Rats, Dogs, Pigs, Rabbits and 
Baboons. A comparison with human liver microsomes and human hepatocytes. Submitted to 
Xenobiotica] 
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4.1 Abbreviations 
6β(OH)TE - 6β(OH) testosterone 
CYP - cytochrome P450 
CYP3A7 - cytochrome P4503A7 
CYP3A4 - cytochrome P4503A4 
FHH - primary cultures of human hepatocytes 
TE - testosterone 
17-OHPC - 17α-hydroxyprogesterone caproate 
MPA – Medroxyprogesterone acetate 
EMEM - Eagle’s Minimum Essential Medium 
HBSS - Hank's balanced salt solution 
HMM - Hepatocyte Maintenance Medium 
DMEM - Dulbecco’s Modified Eagle Medium. 
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4.2 Abstract 
Aims: Weekly injections of 17-OHPC are commonly utilized for the prevention of preterm birth 
(PTB).  Recent evidence of transplacental transport of 17-OHPC raises questions about how the 
fetus might respond to this agent.  In adults, hepatic mono-oxidation via the cytochrome P450 
enzymes CYP3A4 and 3A5 is the primary metabolic pathway. Whether or not the human fetal 
liver can metabolize 17-OHPC is not known.  In this study, we evaluated the metabolism and 
kinetics of 17-OHPC in adult and fetal human hepatocytes and in expressed CYP enzymes.  
Methods: The model systems used were expressed enzymes and primary hepatocyte cultures 
isolated from human adult and fetal livers. 17-OHPC and metabolites were quantified using LC-
MS systems. Protein content and mRNA were also measured.     
Results: 17-OHPC was metabolized by expressed CYP3A7 and by fetal hepatocytes. Expressed 
CYP3A4 demonstrated a significantly higher capacity to metabolize 17-OHPC than CYP3A7. 
The metabolite profile was qualitatively different between expressed CYP3A4 and CYP3A7. 
Based on retention times, two unique metabolites were observed in fetal hepatocytes as 
compared to adult hepatocytes along with one metabolite which was common to both. The 
intrinsic clearance of 17-OHPC by fetal hepatocytes was similar to that in adults.  
Conclusion: This study demonstrates that fetal hepatocytes and in particular fetal form of 
CYP3A i.e. CYP3A7 can metabolize 17-OHPC.  Further, fetal specific metabolites (M1 and M3) 
were generated, which were not observed in the adult hepatocyte system. Future studies are 
needed to investigate the effect of accumulation of these 17-OHPC metabolites on the fetal 
hepatic elimination processes and any associated toxicity.    
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4.3 Introduction 
Fetal drug exposure is an unavoidable risk associated with drug therapies in pregnant 
subjects. The role of metabolism, via phase I and II pathways, in regulating fetal exposure is 
relatively lesser known. Fetal metabolism and the presence of cytochrome P-450s in the fetal 
liver has been previously documented in the literature (Ackermann and Richter, 1977; Aranda et 
al., 1979; Rollins et al., 1979; Rane and Tomson, 1980; Wiebkin et al., 1985; Komori et al., 
1990; Chiba et al., 1997; Ladona et al., 2000).  
Since, almost all lipid-soluble xenobiotics enter the fetal system through placental 
transfer there is a high probability that 17-OHPC will penetrate through the placental barrier and 
gain access to the fetal circulation. Studies performed using the dual perfused placental lobule 
(DPPL) technique have shown that 17-OHPC is transferred to the fetal circulation (Hemauer et 
al., 2008). Further, analysis of fetal cord blood has shown significant 17-OHPC levels 
(unpublished data) thus confirming the transplacental transport from the mother to the fetus.  
Although teratology studies have shown the safety of 17-OHPC in rodents and non-
human primates, difference in drug metabolism between animals and humans is well known. For 
example, the drug oxidizing capacities have been reported to develop relatively early in human 
fetuses whereas this capability is only reported postnatally in experimental animals, especially 
non-primates (Rane and Tomson, 1980). Thus, it is important to investigate the pathway(s) 
involved in the metabolism of 17-OHPC in both the adult and fetal liver. Further, the major 
pathways by which the fetus can eliminate drugs and their metabolites include placental 
diffusion and active transport back to the maternal circulation. Since the permeability of placenta 
to relatively polar metabolites is lower, these metabolites may accumulate in the fetus; especially 
in the liver where the drug is metabolised. This may be disadvantageous to the fetus if these 
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metabolites induce cellular toxicity or interfere with the various hepatic transport processes in 
liver and kidney. Thus, studies are needed to identify the metabolites of drugs administered 
during pregnancy and their concentrations in fetal circulation. Identification of the metabolic 
pathways will help to make informed decisions regarding drug therapy for pregnant women. 
The objectives of the study presented here are 1) to investigate the metabolism of 17-OHPC in 
fetal hepatocyte cultures, 2) identify the major enzyme and metabolic pathway(s) involved, and 
3) to compare the kinetics and metabolism of 17-OHPC in fetal hepatocytes with adult human 
hepatocytes in culture. 
In chapter 1, we have shown that CYP3A4 is the major enzyme involved in the 
metabolism of 17-OHPC. Further, monohydroxylated-17-OHPC constituted the major 
metabolites generated by its metabolism. Cytochrome P450 3A family consists of four genes 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43, encoded at an approximate 270-kbp locus on 
human chromosome 7q21.1. CYP3A4, CYP3A5 and CYP3A7 share at least 85% sequence 
identity which has imparted considerable overlapping substrate specificities to these isoforms 
although the catalytic efficiency has been reported to vary significantly for the common 
substrates. Many substrates which are metabolized by both CYP3A4 and CYP3A7 have been 
reported in the literature including, testosterone, dextromethorphan, dehydroepiandrosterone and 
codeine (Hines, 2008). It has also been observed that CYP3A4 is the major isoform (10 to 50% 
of total CYP) expressed in the adult human liver whereas CYP3A7 is the dominant enzyme in 
the fetal liver. Thus, based on the overlap in substrate specificities we hypothesize that the fetal 
liver will metabolize 17-OHPC with CYP3A7 being the major isoform involved in its 
metabolism.    
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4.4 Methods 
4.4.1 Hepatocyte Incubations 
Adult and fetal hepatocytes (n=4) were incubated with 17-OHPC (5 µM methanolic solution) in 
HMM for clearance studies. Samples were taken at different time points (15-120 minutes) to 
assess 17-OHPC metabolism. Kinetic analysis in adult and fetal hepatocytes (n=4) was evaluated 
by incubating different 17-OHPC concentrations (0-80 µM methanolic solutions) in HMM with 
cells for 30 and 60 mins, respectively. Control cultures were exposed to HMM containing 
methanol alone. The final concentration of methanol in all incubations was 0.1%. The 
supernatant media was collected and stored at -80ºC until analysis by LC-MS. The remaining 
cells were harvested in phosphate buffer for protein determination. 
The induction experiments were initiated 24 hrs after plating the cells. The fetal 
hepatocytes (n=2) were incubated with the inducers (rifampin and phenobarbital) for 4 days prior 
to adding HMM/ 17-OHPC (50µM) or Testosterone (250µM) to estimate the effect of CYP3A 
induction on 17-OHPC and TE metabolism. TE was used as a positive control in these 
experiments since it is widely used as a CYP3A probe substrate. Cells were harvested for mRNA 
by adding 1 mL of Trizol® reagent to each well. The RNA samples were stored at -20°C for 
Real Time PCR analysis. Primers for CYP3A4, CYP3A7 and cyclophillin and the PCR 
procedure have been described in Chapter 2.  The mRNA expression for all genes was 
normalized to cyclophillin in each sample and expressed as fold change over control treatment. 
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4.4.2 Expressed enzyme microsomal incubations 
Expressed CYP3A4/3A7 (20pmole) microsomes were incubated with 17-OHPC (100µM) and 
MgCl2 (10 mM) in 0.1mM phosphate buffer (pH 7.4). The final volume of 0.25 ml was allowed 
to equilibrate in a shaking water bath for 5 min at 37 ºC. The reaction was initiated by the 
addition of NADPH (1 mM). After 120 mins of incubation, the reaction was stopped by adding 
0.25ml of cold methanol. The mixture was centrifuged at 3000 rpm for 20 min and supernatant 
was injected into the HPLC. The final concentration of methanol was less than 2%. For 
elucidating the kinetics of 17-OHPC metabolism, incubations of expressed CYP3A4 and 3A7 
(20 pmole, 10 mins) were carried out using the abovementioned method with increasing 
concentrations of 17-OHPC (0-200µM).  
   
4.4.3 Data Analysis 
Data are expressed as the mean ± SD. Apparent kinetic parameters for 17-OHPC metabolism 
were estimated by the non-linear least square regression analysis using GraphPad Prism 4.0 
(GraphPad Software Inc.). Half life estimates were obtained by non-compartmental analysis with 
WinNonlin 4.1 (Pharsight Corp.). Intrinsic clearance was calculated using the equation - Clint = 
(ln2/t1/2)*(ml incubation/106cells). 
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4.5 Results 
4.5.1 Metabolism of 17-OHPC by human fetal hepatocytes 
Incubation of 17-OHPC with fresh human fetal hepatocytes (Fig. 14A) generated three major 
metabolites (M1-17.60, M2-17.86, M3-19.18) as identified using LC-MS. Incubation of 17-
OHPC with fresh human adult hepatocytes (Fig. 14B) also generated three major metabolites 
(M2-17.84, M4-16.55 and M5-16.84). Metabolite M2 was common to adult and fetal 
hepatocytes. Two metabolites (M1, M3) were generated by fetal hepatocytes that were either 
absent or below the detection limit in the adults. All the metabolites observed in the fetal 
hepatocyte based incubations displayed the same m/z ratio (m/z=445.0, Fig.15B). A significant 
amount of sodium adduct formation (m/z=467.0) was observed at the same retention time as the 
major metabolites (M1-M3, Fig. 15A).  Induction studies were performed in fetal hepatocytes to 
investigate the role of CYP3A (primarily CYP3A4 or CYP3A7) as the primary enzyme 
responsible for 17-OHPC metabolism in the fetal liver. CYP3A inducers, RIF and PB, increased 
the formation of all 17-OHPC metabolites (Fig. 16). RIF showed a 1.5 fold increase in 17-OHPC 
metabolism and PB showed a 1.8 fold increase in fetal hepatocytes. The increase in CYP3A4 and 
CYP3A7 expression by the inducers was also confirmed by RT-PCR and the induction of 
CYP3A activity by TE metabolism (formation of 6β(OH)TE).  Treatment with these inducers, 
RIF (10 μM) and PB (2000 µM), resulted in 4.0 ± 1.5, 2.5 ± 0.8 - fold increase in the mRNA 
expression of CYP3A4 and a 2.2 ± 0.7, 1.8 ± 0.3 - fold increase in the mRNA expression of 
CYP3A7 (Fig. 18). Further, both RIF and PB showed ~ 2 fold increase in TE metabolism in fetal 
hepatocytes (Fig. 17).   
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4.5.2 Metabolism of 17-OHPC by expressed CYP3A7 
Incubation of 17-α-hydroxyprogesterone caproate (17-OHPC) with baculovirus expressed 
CYP3A7 (60pmole/ml) generated three (M1, M2, M3) major metabolites (Fig. 19A). The major 
metabolites accounted for 90 % of the total substrate (17-OHPC) metabolized by the enzyme. 
Further, studies were carried out to identify and compare the metabolites generated by expressed 
CYP3A4. The metabolites - M2, M4 and M5 were generated by expressed CYP3A4 (Fig. 19B). 
The common metabolite, based on similar retention time, which was observed in both CYP3A 
isoforms, was M2 with a mass/charge (m/z) value of 445.0 (Fig. 20B). Metabolites (M1 and M3) 
generated by CYP3A7 were observed to have similar m/z value (445.0) to CYP3A4 metabolites 
(M4 and M5), however, the relative retention times were different in both cases and thus, were 
concluded to be fetal specific metabolites. Further, a significant sodium adduct (m/z=467.0) was 
observed at the same retention time as the major metabolites (M1-M3, Fig. 20A).   
4.5.3 Relative Metabolic Capacities of CYP3A isoforms 
To evaluate the relative 17-OHPC metabolizing capabilities of CYP3A isoforms (CYP3A4 and 
CYP3A7), incubations of 17-OHPC and TE (100µM and 250 µM, equimolar quantities, 
respectively) were carried out in individual expressed enzyme systems. Comparison of the 
isoforms’ 17-OHPC metabolizing capability showed CYP3A7 to metabolize ≈7% of the 
substrate (Fig. 21A) at the rate of 3.2 pmole/min/pmole CYP3A7. CYP3A4 metabolized ≈83% 
of total 17-OHPC added to the incubation at a rate of 47.1 pmole/min/pmole CYP3A4. The 
results were calculated based on estimating the metabolism of 17-OHPC (loss of parent drug) 
during incubations.  
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Further, a comparison of the amount of major metabolites generated (M1-M5) by various 
isoforms was done (Fig. 21B). The total major metabolites (M1+M2+M3) generated by CYP3A7 
isoform were ≈6 times less than those observed for the CYP3A4 (M2+M4+M5) isoform.  
Similarly, comparison of the isoforms’ TE metabolizing capability showed CYP3A7 to 
metabolize ≈7% of the substrate whereas CYP3A4 metabolized ≈92% of total TE (Fig. 22A). 
The total major metabolites generated by CYP3A7 isoform were ≈15 times less than those 
observed for the CYP3A4 isoform. Thus, CYP3A7 consistently depicted a lower intrinsic 
capacity to metabolize substrates than CYP3A4.     
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Figure 14. LC-MS chromatograms of 17-OHPC and its metabolites derived from incubation of 17-OHPC with fresh human fetal and 
adult hepatocytes 
A: Incubation of 17-OHPC with fresh human cultured fetal hepatocytes. The incubation generated 6 metabolites of which 3 were the 
major metabolites (M1, M2 and M3). The retention times of 17-OHPC and its metabolites- M1, M2 and M3 in this analytical 
condition were 26.45, 17.60, 17.86 and 19.18 min, respectively. 
B: Incubation of 17-OHPC with fresh human cultured adult hepatocytes. The incubation generated 3 major metabolites (M2, M4 and 
M5). The retention times of 17-OHPC and its metabolites- M4, M5 and M2 in this analytical condition were 26.43, 16.55, 16.84 and 
17.84 min, respectively. 
C: Incubation of 17-OHPC in media without hepatocytes. No metabolites were generated. The retention time of 17-OHPC was 26.41. 
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Figure 15. LC-MS chromatograms of 17-OHPC metabolites derived from incubation of 17-OHPC with fresh human fetal hepatocytes 
The incubation generated a number of metabolites of which 3 were the major metabolites (M1, M2 and M3). 
A: The extracted ion chromatogram depicting the major metabolites (M1, M2 and M3) having a m/z = 467.0. This m/z value depicts a 
sodium adduct of the mono-hydroxylated products of 17-OHPC metabolism. 
B: The extracted ion chromatogram depicting the major metabolites (M1, M2 and M3) having a m/z = 445.0. This m/z value depicts a 
mono-hydroxylated product of 17-OHPC metabolism. 
C: The total ion chromatogram (TIC) depicting the major metabolites (M1, M2 and M3). 
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Figure 16. CYP3A inducers increase 17-OHPC metabolism in Fetal Hepatocytes 
 
Incubation of fetal hepatocytes (n=2) with specific CYP3A4 inducers, namely, Rifampin and 
Phenobarbital increased the metabolism of 17-OHPC (50µM) as compared to control (DMSO). 
The estimation of induction was based on the total metabolites generated in hepatocytes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Effect of CYP3A inducers on Testosterone metabolism in Fetal Hepatocytes 
 
Fetal Hepatocytes (n=2) were exposed to Rifampin (RIF) and Phenobarbital (PB) for 72 hours 
and mRNA expression and activity were determined. An increase in CYP3A4 activity was 
observed in the presence of the inducers as determined by estimating the formation of 6beta-
hydroxytestosterone. 
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Figure 18. Effect of CYP3A inducers on CYP3A4 and CYP3A7 mRNA expression in Fetal 
Hepatocytes 
 
Fetal Hepatocytes (n=2) were exposed to Rifampin (RIF) and Phenobarbital (PB) for 72 hours 
and mRNA expression and activity were determined.   
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(A) An increase in CYP3A4 expression was observed in the presence of the inducers as 
compared to control (DMSO). 
(B) An increase in CYP3A4 expression was observed in the presence of the inducers as 
compared to control (DMSO). 
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Figure 19. LC-MS chromatograms of 17-OHPC and its metabolites (M1-M5) derived from incubation with expressed CYP3A 
isoforms  
 
A: The retention times (mins) observed for CYP3A7 mediated metabolic pathway were – 26.07 (17-OHPC), 17.13 (M1), 17.41 (M2) 
and 18.73 (M3).   
B: The retention times (mins) observed for CYP3A4 mediated metabolic pathway were – 26.08 (17-OHPC), 17.43 (M2), 16.14 (M4) 
and 16.40 (M5).   
C. The retention time (mins) observed for 17-OHPC in the absence of NADPH – 26.08.   
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Figure 20. LC-MS chromatograms of 17-OHPC and its metabolites derived from incubation of 17-OHPC with expressed CYP3A7.  
 
A: The extracted ion chromatogram depicting the major metabolites (M1, M2 and M3) having a m/z = 445.0. This m/z value depicts a 
mono-hydroxylated product of 17-OHPC metabolism. 
B: The extracted ion chromatogram depicting the major metabolites (M1, M2 and M3) having a m/z = 467.0. This m/z value depicts a 
sodium adduct of the mono-hydroxylated products of 17-OHPC metabolism. 
C: The total ion chromatogram (TIC) depicting the major metabolites (M1, M2 and M3). 
D: The total ion chromatogram (TIC) generated on incubation of 17-OHPC in the absence of NADPH. 
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4.5.4 Estimation of 17-OHPC clearance in fetal human hepatocytes in comparison with 
adult human hepatocytes 
The time course of 17-OHPC metabolism in freshly isolated human fetal and adult hepatocytes 
has been illustrated in Fig. 23A. 17-OHPC was incubated for a total period of 120 mins and 
samples taken at various time points. At each sampling time point, the amount of 17-OHPC 
unmetabolized decreased and corresponded to an increase in total major metabolites generated 
(Fig. 23B). The drug depletion profiles at 5 µM depicted a linear log concentration decline, thus, 
showing that the metabolism follows first-order kinetics under these conditions. The result has 
been reported in terms of 17-OHPC equivalents for the metabolites since the identity of the 
metabolites has not been confirmed. Similar profiles were observed in both fetal and adult 
hepatocytes although the amount of metabolites varied depending on the metabolic efficiency of 
individual cases. The half life and intrinsic clearance for the drug depletion in the case of fetal 
hepatocytes (Table 8) was not significantly different from that observed for adult hepatocytes.  
4.5.5 Kinetics of 17-OHPC metabolism by Fetal and Adult Human Hepatocytes 
The kinetics of metabolism of 17-OHPC was characterized in human fetal and adult hepatocytes 
(n=4).  Kinetics of 17-OHPC was evaluated using the rate of generation of metabolite expressed 
in terms of 17-OHPC equivalent. An incubation time of 60 mins was used in fetal hepatocytes 
since all three metabolites were readily detectable beyond this time point in hepatocytes. M2 was 
the major metabolite followed by M3 and M1. The generation of all three major metabolites of 
17-OHPC by fetal hepatocytes displayed Michaelis -Menten kinetics and the kinetic parameters 
for adult and fetal hepatocytes are reported in Table 9. Michaelis menten kinetics was also 
observed for the major metabolites generated by expressed CYP3A7 and the calculated kinetic 
parameters for CYP3A7 and CYP3A4 are reported in Table 10. 
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Figure 21. Comparative evaluation of (A) 17-OHPC metabolism and (B) total major metabolites 
(M1-M4) generated by expressed CYP3A4 and CYP3A7 isoforms  
 
Recombinant P450 isozymes (80 pmol/ml) were incubated with 17-OHPC (100µM) at 37°C for 
120 min. The incubation was performed in the presence of NADPH. Each column in the bar 
diagram represents the mean of two independent analyses. The amount of metabolites generated 
is expressed in terms of 17-OHPC equivalents. 
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Figure 22. Comparative evaluation of (A) TE metabolism and (B) total major metabolites 
generated by CYP3A4 and CYP3A7 
 
Recombinant P450 isozymes (80 pmol/ml) were incubated with Testosterone (250µM) at 37°C 
for 120 min. The incubation was performed in the presence of NADPH. Each column in the bar 
diagram represents the mean of two independent analyses.  
 
 
A 
B 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Metabolism of 17-OHPC and generation of major metabolites by fetal (dashed line, 
n=4) and adult hepatocytes (solid line, n=4) 
Fresh fetal and adult hepatocytes were incubated with 17-OHPC (5µM) and all three metabolites 
quantified by sampling at various time points. The graph depicts depletion of 17-OHPC with 
time corresponding to a similar increase in the metabolite levels. The major metabolites 
generated have been expressed in terms of 17-OHPC equivalents.   
A) The figure depicts the amount of 17-OHPC (expressed as % remaining) metabolized as a 
function of incubation time.  
B) The figure depicts the amount of major metabolites generated by fetal hepatocytes [M1 (?), 
M2 (●) and M3 (♦)] and adult hepatocytes [M2 (□), M4 (∆) and M5 (○)] as a function of 
incubation time. 
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Table 8. Half Life (T-Half) estimation of 17-OHPC metabolism by human fetal and adult 
hepatocytes 
 
 T-HALF (mins) 
Clint  
(ml/min/million cells) 
ADULT 57±31 0.041±0.02 
FETAL 66±40 0.035±0.01 
 
Table 9. Kinetics of 17-OHPC metabolism in fetal and adult hepatocytes 
 
 
Metabolite # 
Vmax 
(nmole/min/million cells) 
Km 
(µM) 
Fetal_M1 0.46 ± 0.16 12.3 ± 5.1 
Fetal_M2 0.50 ± 0.11 11.7 ± 5.3 
Fetal_M3 0.65 ± 0.10 25.2 ± 11.0 
Adult_M2 1.3±0.52 32.60±49.4 
Adult_M4 0.35±0.23 33.10±25.1 
Adult_M5 0.79±0.50 38.80±25.7 
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Table 10. Kinetics of 17-OHPC metabolism in recombinant CYP3A7 and CYP3A4 
Metabolism of 17-OHPC demonstrated a Michaelis-Menten type kinetics. 
 
Metabolite # 
Vmax 
(nmole/min/pmoleCYP) 
Km (µM) 
CYP3A7_M1 0.0103 ± 0.002 1.8 ± 0.90 
CYP3A7_M2 0.0104 ± 0.001 1.7 ± 0.50 
CYP3A7_M3 0.0130 ± 0.002 5.2 ± 2.1 
CYP3A4_M2 0.20±0.02 57.5±14.7 
CYP3A4_M4 0.04±0.006 40.1±16.1 
CYP3A4_M5 0.032±0.003 10.5±4.8 
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Figure 24. Expression of CYP3A4 and CYP3A7 in primary fetal hepatocyte cultures (n=3) 
 
The results are expressed as Mean ± SD. The expression levels of CYP3A7 were observed to be 
~100 fold higher than the CYP3A4 expression thus making CYP3A7 the major isoform in fetal 
liver.  
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4.6 Discussion 
The present study shows that 17-OHPC is metabolized by hepatocytes obtained from human 
fetuses in the second trimester of gestation. This report adds to, and confirms the existing data on 
the ability of the human fetus to metabolize some drugs administered during pregnancy 
(Ackermann and Richter, 1977; Aranda et al., 1979; Rollins et al., 1979; Chiba et al., 1997; 
Ladona et al., 2000). 
Incubation of 17-OHPC with fresh human fetal hepatocytes in culture generated three 
major metabolites (M1, M2 and M3) having a similar m/z values of 445.0 but different retention 
times. These m/z values suggest the formation of mono-hydroxylated metabolites (429+16=445) 
which were isomers having the hydroxylation at different carbon positions. Increase in the 
metabolism of 17-OHPC in the presence of CYP3A inducers, RIF and PB, provided the first 
indication that CYP3A (primarily 3A7 or 3A4) isoforms are likely to be involved. Further, 
metabolism of 17-OHPC by expressed CYP3A7 to three major metabolites (M1, M2 and M3) 
confirmed the role of CYP3A7.  
Metabolites (M1 and M3) generated by CYP3A7 were observed to be isoform specific 
based on the relative retention times and preliminary fragmentation data. These CYP3A7 
specific metabolites are likely to be structural isomers of CYP3A4 metabolites. Metabolite 
structure elucidation involving “Ion Trap” based fragmentations and NMR studies are currently 
being carried out to confirm the structure. 
CYP3A7 is the major CYP3A isoform expressed in the fetal liver (Komori et al., 1990; 
de Wildt et al., 1999). The metabolite profile in fetal hepatocytes was observed to match the 
profile generated on incubating 17-OHPC with expressed CYP3A7. Further, metabolism of 17-
OHPC by fresh adult human hepatocytes generated a metabolite profile which was similar to the 
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profile observed in incubations with expressed CYP3A4. It can be concluded that CYP3A7 
expressed in fetal hepatocytes and CYP3A4 in adult hepatocytes form the major pathway in the 
metabolism of 17-OHPC. Comparison of the two expressed CYP3A isoforms’ 17-OHPC 
metabolizing capacity showed CYP3A7 to have a much lower metabolic capacity (based on % 
17-OHPC metabolised) than CYP3A4. RT-PCR based analysis of mRNA expression in the fetal 
livers that were utilized in our study has shown CYP3A7 expression level to be ~100 times 
higher than CYP3A4 (Figure 24). Thus, inspite of the lower 17-OHPC metabolizing capability, 
the results suggest that CYP3A7 may play a major role in the fetal disposition of 17-OHPC. 
Although CYP3A5 has been observed to metabolize 17-OHPC (Sharma et al., 2008) much more 
efficiently than CYP3A4, it is less likely to play a significant role in fetal metabolism since the 
expression level of CYP3A5 is almost negligible in the fetal liver (Hakkola et al., 2001). 
Metabolism of 17-OHPC by human fetal hepatocytes displayed a regular Michaelis-
Menten profile. The estimated Vmax values for the major metabolites (M1-M3) in fetal 
hepatocytes were observed to be ~3-4 fold lower than adult human hepatocytes (M2 – 2.0, M4 - 
0.4, M5 – 1.0). Similar results were also observed in studies involving expressed CYP3A4 and 
CYP3A7. The total metabolites generated by incubating 17-OHPC (100µM) with CYP3A7 
(major isoform in fetal liver) were observed to be ~5 fold less than CYP3A4 (major isoform in 
adult liver). 
The relative metabolic capacities of adult and fetal hepatocytes was evaluated by 
estimating the half-life and intrinsic clearance of 17-OHPC (5µM) based on loss of parent drug 
experiments. The results indicated the adults to have a similar capacity to metabolize 17-OHPC 
as compared to the fetus. The intrinsic clearance (Vmax/Km) for fetal hepatocytes for the major 
metabolites (M1=0.04, M2=0.05, M3=0.02) was also comparable to that calculated for adult 
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hepatocytes (M2=0.04, M4=0.02, M5=0.03). Similar results were observed in experiments with 
expressed CYP3A isoforms. The intrinsic clearance (Vmax/Km) for expressed CYP3A7 
(M1=0.006, M2=0.006, M3=0.002), the major isoform in fetal liver, was comparable to 
expressed CYP3A4 (M2=0.004, M4=0.001, M5=0.003), the major isoform in adult liver. 
In summary, the intrinsic clearance of 17-OHPC was similar in adult and fetal hepatocyte 
cultures. Further, the kinetics of 17-OHPC metabolism was also observed to be similar in 
hepatocytes and expressed enzyme systems.  
A number of factors can affect the kinetics of a drug in fetal hepatocytes. It is known that 
both adult and fetal livers express similar set of transporters which are responsible for the uptake 
and efflux of various endogenous and exogenous chemicals but differ in their level of expression 
(Chen et al., 2005; Cizkova et al., 2005). Thus, kinetic differences (or lack thereof) observed 
between adult and fetal hepatocytes for a drug could be related to the levels of expression of 
these transport proteins. For example, clearance of a drug by hepatocytes at non-saturating 
concentrations (<1µM) may be more dependent on the total uptake or other factors that influence 
the intracellular concentration rather than simply on the intrinsic metabolic capacity of the CYPs 
expressed. Thus, evaluation of the transport processes that may be involved in the disposition of 
a drug in adult and fetal cells needs to be investigated as well. Other possibilities could include 
differences in tissue protein binding between adult and fetal hepatocytes.   
The capacity of the fetus to metabolize drugs is a critical component in understanding the 
maternal and fetal bioavailability of drugs administered during pregnancy. The amount of drug 
or metabolite accumulation in the fetal circulation largely depends on the placental permeability 
or transport and fetal nonplacental clearance pathways. Hence, determining the contribution of 
metabolism to fetal nonplacental clearance pathways (hepatic metabolism) is essential in 
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understanding fetal drug disposition. We report here that human fetal hepatocytes are capable of 
significantly metabolizing 17-OHPC with CYP3A7 being the major enzyme involved. Further, 
fetal specific metabolites (M1 and M3) were generated, which were not observed in the adult 
hepatocyte system. Level of 17-OHPC in the cord blood from pregnant subjects undergoing 
treatment for preterm birth was observed to range from 1-8 ng/ml (<20 nM). Thus, given the 
capacity of fetal hepatocytes to metabolize 17-OHPC (Km>1µM), it is likely that metabolism by 
human fetal liver will be a significant contributor to fetal drug disposition of 17-OHPC. Further, 
17-OHPC metabolism will also lead to the generation and possible accumulation of the 
monohydroxylated metabolites in the fetal circulation.  
The ratio of 17-OHPC in the maternal plasma to cord blood was observed to range from 
0.1 to 0.3. Thus, as the amount of 17-OHPC transferred to the fetal compartment is significantly 
lower as compared to the mother, the contribution of fetal metabolism to the overall disposition 
is likely to be insignificant. However, studies in suitable animal models (using infusions of the 
17-OHPC and its major metabolites) are needed to evaluate and confirm the role of fetal 
metabolism in the overall disposition of 17-OHPC. 
 
Clinical Implications: 
1) Human fetus can metabolize 17-OHPC to 3 major metabolites. Accumulation of 
these metabolites can affect the fetal hepatic elimination processes and be a 
potential cause for any associated toxicity. 
2) A short half life of ~ 57 mins was observed in adult hepatocyte cultures. Thus, a 
short in-vivo half life is expected of this intermediate clearance compound.  
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5.0  Evaluation of the role of transporters in the disposition of 17-OHPC and the effect of 17-
OHPC on bile salt transport. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Sharma S, Ellis E, Marongiu F, Mattison D, Caritis S, Venkataramanan R and Strom S (2009). 
Expression and activity of transporters in fetal human hepatocytes: A comparison with adult 
human hepatocytes. Submitted to DMD] 
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5.1 Abbreviations 
FHH - primary cultures of human hepatocytes 
17-OHPC - 17α-hydroxyprogesterone caproate 
EMEM - Eagle’s Minimum Essential Medium 
HBSS - Hank's balanced salt solution 
HMM - Hepatocyte Maintenance Medium 
DMEM - Dulbecco’s Modified Eagle Medium 
RIF – Rifampin 
CYC – Cyclosporine 
VER - Verapamil 
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5.2 Abstract 
Aim: 17-OHPC has been reported to traverse the placental barrier and gain access to fetal 
circulation. Further, 17-OHPC is metabolized by the fetal liver.  Little information is available in 
literature regarding the expression and activity of transporters in fetal human liver or cultured 
cells. In this study, the role of transporters in the disposition of 17-OHPC in fetal and adult 
human hepatocytes was examined. Progesterone metabolites have been reported to induce trans-
inhibition of BSEP. Thus, the purpose of the study was to investigate the effect of 17-OHPC (a 
structural analog of progesterone) or its metabolites on [3H]-taurocholic acid transport. 
Methods: The transport activity was evaluated using sandwich cultured human fetal and adult 
human hepatocytes. Aliquots of media were counted in a liquid scintillation counter to estimate 
the activity. Protein content and mRNA were also measured.     
Results: 17-OHPC was taken up rapidly into the cells, mostly by passive diffusion. The drug 
was transported out of hepatocytes partially by an active efflux process which was significantly 
inhibited by cyclosporine, rifampin, verapamil and cold temperature. Active efflux was observed 
in both adult and fetal hepatocyte cultures. Further, we evaluated the expression of various 
hepatic transporters (MDR1, MDR3, OATP1B1, OATP1B3, OATP2B1, BSEP, NTCP, MRP2, 
MRP3, MRP4 and BCRP) in fetal and adult hepatocytes. With the exception of MDR3 and 
NTCP, all transporters evaluated were found to be expressed in significant amounts in fetal 
hepatocytes as compared to adults. 17-OHPC produced a concentration-dependent inhibition of 
taurocholate (TC) efflux into canaliculi in fresh cultures of adult and fetal human hepatocytes.  
Conclusion: The study demonstrates the functional expression of both sinusoidal and canalicular 
transporters responsible for transport of taurocholate and 17-OHPC in fetal human hepatocytes. 
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Further, results from a competition assay show the inhibitory potential of 17-OHPC towards 
taurocholate transport. 
5.3 Introduction 
Drug therapy during pregnancy exposes both the mother and fetus to the potential adverse effects 
associated with therapy. Despite the presence of a placental barrier to drug transfer, certain 
drugs, depending on their physicochemical properties, are able to gain access to the fetal 
circulation. The fetus like the adult has detoxifying mechanisms in the form phase 1, 2 and 3 
pathways to eliminate these xenobiotics. Little is known regarding the expression and activity of 
various enzymes and transporters in fetal liver which mediate xenobiotic elimination. Fetal 
metabolism and the expression of cytochrome P-450s in the fetal liver has been documented in 
the literature (Ackermann and Richter, 1977; Aranda et al., 1979; Rollins et al., 1979; Rane and 
Tomson, 1980; Wiebkin et al., 1985; Komori et al., 1990; Chiba et al., 1997; Ladona et al., 
2000). However, little to no information is available regarding the expression (Chen et al., 2005) 
and activity of hepatic transporters in fetal human hepatocyte cultures. Biliary excretion of 
therapeutic drugs plays an important role as one of the detoxification mechanism and for certain 
drugs, inhibition of biliary transport can explain the adverse hepatic effects associated with them. 
The hepatic transporter, bile salt export pump (BSEP, ABCB11), is responsible for the transport 
of unconjugated bile acids such as taurocholic acid. Inhibition of the BSEP activity can lead to 
the accumulation of these toxic unconjugated bile acids leading to pathological conditions like 
intrahepatic cholestasis of pregnancy (Fattinger et al., 2001; Funk et al., 2001; Kroumpouzos, 
2002). Besides BSEP, other efflux and uptake hepatic transporters like MDR1, MRP2, OATP 
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and BCRP are also expressed in the adults and have been implicated in hepatotoxicity due to 
transporter based drug-drug interactions.  
Our first aim was to establish the functional activity of hepatic transporters (mainly 
NTCP and BSEP) in primary cultures of fetal hepatocytes using sodium taurocholate a substrate 
of sodium dependent uptake transporter, NTCP, and the efflux transporter, BSEP. Our second 
aim was to determine if transport processes were involved in the disposition of 17alpha-
hydroxyprogesterone caproate (17-OHPC), a new agent administered to pregnant subjects to 
prevent pre-term birth. The final aim was to evaluate the interaction between 17-OHPC and 
taurocholate to determine if there was the potential for hepatotoxicity due to transporter mediated 
drug-drug interactions involving 17-OHPC or its metabolites in the fetus. This was achieved via 
minor modification of a well established transport assay (Kostrubsky et al., 2006) which 
identified competition between the 17-OHPC and radioactively labeled Taurocholic Acid. For 
the present study we used sandwich cultures of fresh human adult and fetal hepatocytes which 
were overlaid with Matrigel®. The use of sandwich cultures has been widely used for the 
evaluation of uptake and efflux processes involved in bile and xenobiotic transport. Sandwich 
cultures of hepatocytes overlaid with Matrigel® establish tight junction complexes and cell 
polarity leading to the formation of canalicular spaces which have been characterized by the 
transport of various radiolabeled or fluorescent substrates in adult hepatocytes. 
We have previously demonstrated the ability of fetal and adult hepatocytes to metabolize 
17-OHPC. We have also shown the presence of novel fetal metabolites that were not observed in 
adult hepatocytes. Further, we have reported the transplacental transfer of 17-OHPC and the 
presence of significant levels of this drug in the fetal circulation (unpublished data). The 
cholestatic effect of certain steroids, such as estradiol 17β-D-glucuronide (E217βG), has been 
 124 
suggested to be due to trans-inhibition of the major mechanism accounting for bile acid (BA) 
transport across the canalicular membrane of hepatocytes, i.e. the bile salt export pump (BSEP, 
gene symbol ABCB11) (Kroumpouzos, 2002). Further, the role of progesterone metabolites 
(PMs) in the etiology of Intrahepatic Cholestasis of Pregnancy (ICP) has been suggested. Rise in 
the serum concentrations of PMs has been associated with impaired biliary excretion. 
Progesterone metabolites have been reported to inhibit BSEP activity (Kroumpouzos, 2002; 
Vallejo et al., 2006). Also, progesterone is reported to be an inhibitor of Pgp, a transporter 
expressed on the canalicular membrane of hepatocytes (Barnes et al., 1996). Thus, we 
hypothesize that 17-OHPC and/or its metabolites will inhibit bile salt transporter (BSEP) in adult 
and fetal human hepatocytes. 
5.4 Methods   
5.4.1 Uptake and Release Studies 
1. Transport assay for 17-OHPC and taurocholate was conducted in sandwich cultures of 
hepatocytes as described by Kostrubsky et al., (Kostrubsky et al., 2003) with the exception that 
rather than collagen, the cells were overlaid with Matrigel® at a concentration of 0.233 mg/ml. 
The hepatocytes were incubated for different time intervals in medium (HBSS (+) – HBSS 
supplemented with Ca2+/Mg2+) containing test compound, 17-OHPC - 1µM and Taurocholic acid 
- 1µM, in the presence or absence of inhibitors, Cyclosporine - 40µM, Rifampin - 100µM and 
Verapamil – 40µM (Loading Phase). The transport was stopped by removing the buffer and 
washing cells with ice-cold media. The efflux of the test compound was initiated by adding 
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HBSS (-) i.e. HBSS depleted of Ca2+/Mg2+, with and without inhibitor to the cells. Aliquots of 
media were harvested at different time intervals and counted in a liquid scintillation counter to 
estimate the efflux. Subsequently, the remaining media was aspirated and cell lysis buffer was 
added to the cells. The cell lysates were collected and counted in a liquid scintillation counter to 
estimate the uptake. Results were normalized to total cellular protein. 
2. Transport of the test compounds was also evaluated in warm (37ºC) and cold (4ºC) 
media using a method similar to the one mentioned above. Briefly, the hepatocytes were 
incubated in warm or cold media (HBSS+) containing test compound, 17-OHPC - 1µM and 
Taurocholic acid - 1µM, for different time intervals (Loading Phase). The transport was stopped 
by removing the buffer and washing cells with ice-cold media. The efflux of the test compound 
was initiated by adding (warm or cold) buffer (HBSS-) to the cells. Aliquots of media and cell 
lysates were harvested and counted in a liquid scintillation counter to estimate efflux and uptake 
as described before. Results were corrected for total protein content.  
5.4.2 Inhibition of Bile Acid Transport 
Inhibition of bile acid transport in sandwich cultures of hepatocytes was conducted according to 
previously described protocol (Kostrubsky et al., 2003) except that cells were overlaid with 
Matrigel® rather than collagen. Briefly, 1 μM [3H]-taurocholic acid, with or without increasing 
concentrations of test compound (17-OHPC, CYA) was added to hepatocytes for different time 
intervals at 37oC. The transport was stopped by removing the buffer and washing cells with cold 
media. The taurocholate efflux from canalicular spaces was initiated by adding HBSS (+) or 
HBSS (-) to the cells. Aliquots of media were collected and counted in a liquid scintillation 
counter. The difference in amount of radioactivity between two buffer conditions in the absence 
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of test compound was defined as a 100% taurocholate efflux in canaliculi. In the presence of 
compound, this difference became smaller and was used to calculate the percent inhibition of 
bile acid efflux (Kostrubsky et al., 2003). All values were normalized to total cellular protein. 
5.4.3 Hepatobiliary transport in adult and fetal human hepatocytes 
Hepatobiliary transport of drugs in human hepatocytes was assessed based on the protocol 
described previously (Bi et al., 2006; Kalgutkar et al., 2007). Briefly, fresh human hepatocytes in 
culture were rinsed twice with 1ml of HBSS (+) or HBSS (-) and then equilibrated in the same 
buffers for 10 min at 37ºC. [3H]-taurocholic acid (1µM) or [3H] 17-OHPC (1µM) in HBSS (+) 
was then added to both sets of cultures. Aliquots of media were collected after 15 mins and 
counted in a liquid scintillation counter. Taurocholate transport was used as a positive control for 
active hepatic uptake and efflux and also to quantify the activity of bile transporters in fetal 
hepatocytes. All values were normalized to total cellular protein. The equation (1) used to 
calculate biliary excretion index (BEI) is shown below (Liu et al., 1999b). In the presence of 
Ca2+/Mg2+, the integrity of the biliary canaliculi remains intact, whereas in the absence of 
Ca2+/Mg2+, the canalicular tight junctions are disrupted. Therefore, quantifying the accumulation 
of a test compound in the presence and absence of Ca2+/Mg2+ allows one to determine the 
amount of test compound in the bile canaliculi. 
 
 
 
 
 
…….(1) 
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5.4.4 Reverse Transcription–Polymerase Chain Reaction and Real-Time Quantitative 
Polymerase Chain Reaction 
Primers for MDR1, MDR3, OATP1B1, OATP1B3, OATP2B1, BSEP, NTCP, MRP2, MRP3, 
MRP4 and BCRP and the Real Time PCR procedure were described in Chapter 2. The relative 
cDNA content was determined from standard curves constructed from serially diluted cDNA and all 
genes were normalized to an internal control (cyclophillin) mRNA in each sample. 
5.4.5 Data Analysis 
Data are expressed as the mean ± SD. Student’s t-test was used to assess the significance of the 
results (17-OHPC transport in the presence vs absence of cyclosporine, verapamil, rifampin and 
temperature OR Taurocholate transport in the presence or absence of 17-OHPC (GraphPad 
Software Inc., USA).  
5.5 Results 
5.5.1 Effect of Cyclosporin on the transport of 17-OHPC and Taurocholate in primary 
human hepatocytes 
To confirm the involvement of an active, transporter mediated process in the disposition of [3H]-
17-OHPC in primary human hepatocytes, Cyclosporin, a well known inhibitor, was co-incubated 
with fetal and adult human hepatocytes.  
 128 
The amount of [3H]-17-OHPC transported into the media (Figure 25A), estimated by 
counting the media aliquots, was observed to be significantly (p<0.05) lower in the presence of 
Cyclosporin for both fetal and adult human hepatocytes. In fetal hepatocytes, the % inhibition of 
[3H]-17-OHPC transport into the media was observed to vary from 17 to 45% whereas it ranged 
from 30 to 52% in the adult human hepatocytes. The results indicate the involvement of a 
significant transport mediated process in the efflux of [3H]-17-OHPC in both adult and fetal 
human hepatocytes.    
The total uptake of [3H]-17-OHPC was calculated by taking sum of the amount of 
radiolabeled drug in the cell lysate (Figure 25B) and the amount effluxed (Figure 25A). The total 
amount of [3H]-17-OHPC accumulated by adult and fetal human hepatocytes was not observed 
to be significantly (p>0.05) higher in the presence of Cyclosporin. These observations suggest 
the presence of a significant efflux process rather than active uptake in the disposition of [3H]-
17-OHPC in both adult and fetal human hepatocytes. 
We also carried out timed incubations of [3H]-17-OHPC with Cyclosporin in fetal and 
adult hepatocytes to further characterize the uptake and efflux process. Data presented in Figure 
26A shows the increase in efflux, with time, into the media in the presence and absence of 
Cyclosporine. Data presented in Figure 26B shows the change in the amount of intracellular drug 
with time. A time dependent decrease in intracellular levels of 17-OHPC was observed in the 
absence of cyclosporine, whereas, an increase with time was seen in co-incubations with 
Cyclosporine. In fetal hepatocytes, the % inhibition of [3H]-17-OHPC efflux observed with 
Cyclosporine varied from 5% at 5 mins to 30% at 30 mins whereas the intracellular 
accumulation increased from 0.8 fold at 5 mins to 1.8 fold at 30 minutes. These observations 
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confirm the results from previous experiments indicating the role of active efflux transporters in the 
disposition of 17-OHPC in fetal hepatocytes. 
 
 
 
 
 
 
 
 
[A] 
 
 
 
 
 
 
 
[B] 
Figure 25. Transport of 17-OHPC in the presence (solid bars) and absence of Cyclosporine 
(CYA) in primary human fetal and adult hepatocytes 
The cells were incubated for 15 mins with 17-OHPC in the presence and absence of CYA during 
the loading phase. DMSO (0.1%) in buffer was used as the control. Cells were then washed with 
ice-cold media and reincubated in standard buffer in the presence or absence of CYA. The total 
efflux and accumulation were estimated by scintillation counting and expressed on the basis of 
total protein content. Each bar represents the mean of triplicate treatments (±SD). * - p<0.05 
(A) Media: Significant (p<0.05) inhibition of 17-OHPC efflux was observed in the presence of 17-OHPC.  
(B) Cell Lysate: Cyclosporine significantly (p<0.05) increased the accumulation of 17-OHPC. 
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[B] 
Figure 26. Effect of Cyclosporine (CYA) on the time course of transport of 17-OHPC in primary 
human fetal and adult hepatocytes 
DMSO (0.1%) in buffer was used as the control. Each bar represents the mean of duplicate 
treatments (±SD). * - p<0.05 
(A) Efflux of 17-OHPC into the media was observed to increase with time. Cyclosporine 
significantly (p<0.05) inhibited the efflux of 17-OHPC at all time points except at 5 mins.  
(B) Accumulation of 17-OHPC was observed to decrease with time in the absence (0.1%DMSO) 
of Cyclosporine. However, a significant (p<0.05) increase in the accumulation of 17-OHPC with 
time was observed in the presence of Cyclosporine. 
  
*
*
*
**
*
*
0
50
100
150
200
250
300
No CYA
CYA
F F A A Ae
ta
4_
5` 15
`
30
`
eta
l#5
_5
`
15
`
30
`
du
lt#
6_
5` 15
`
30
`
du
lt#
7_
5` 15
`
30
`
du
lt#
9_
5` 15
`
30
`
17
-O
H
PC
_M
ed
ia
(p
m
ol
/m
g 
pr
ot
ei
n)
l#
* * 
* *
*
*
0
100
200
300
400
500
600
700
800
Fe
tal
#4
_5
`
15
`
30
`
Fe
tal
#5
_5
`
15
`
30
`
Ad
ult
#6
_5
`
15
`
30
`
Ad
ult
#7
_5
`
15
`
30
`
Ad
ult
#9
_5
`
15
`
30
`
17
-O
H
PC
_L
ys
at
e
(p
m
ol
/m
g 
pr
ot
ei
n)
No CYA
CYA
*
 131 
 Hepatic taurocholate transport is well characterized with its uptake being mediated by 
NTCP (~80%) and OATP (~20%) and efflux into the canalicular space by BSEP (Kemp et al., 
2005). The role of transporters in the hepatic uptake and efflux of taurocholate was estimated by 
measuring the radioactivity levels in the media and cell lysate, respectively, as mentioned above 
for 17-OHPC. 
The amount of canalicular transport of taurocholate into the media (Figure 27A) and the 
total cellular accumulation (Figure 27B) was observed to be significantly (p<0.05) lower in the 
presence of Cyclosporin in fetal and adult human hepatocytes. The % inhibition of taurocholate 
transport into the media was observed to vary from 30 to 60% for fetal cells and ~ 10% in the 
adult human hepatocytes. Also, the % inhibition of taurocholate accumulation was observed to 
range from 60-90% for fetal hepatocytes and >90% for adult human hepatocytes. Thus, the 
results not only confirm the presence of active taurocholate transporters (BSEP and NTCP) in 
fetal hepatocytes but also suggest that drugs that interfere with normal bile transport function in 
the fetal liver might be hepatotoxic. 
5.5.2 Effect of Rifampin on the transport of 17-OHPC in primary human hepatocytes 
The organic anion transporting family of proteins (OATPs; SLCO gene family) has been 
reported to play a role in the uptake transport of bile salts and xenobiotics. Rifampin has been 
reported to inhibit human liver OATPs and thus interfere with carrier mediated organic anion 
uptake (Fardel et al., 1995). To evaluate the involvement of an active, transporter mediated 
uptake process in the disposition of 17-OHPC in primary human hepatocytes, Rifampin was co-
incubated with fetal and adult human hepatocytes. 
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Figure 27. Transport of Taurocholate (TCA) in the presence (solid bars) and absence of 
Cyclosporine (CYA) in primary human adult and fetal hepatocytes 
Hepatocytes were incubated for 15 minutes during the loading phase, washed with ice-cold 
buffer followed by efflux for 15 minutes. DMSO (0.1%) in buffer was used as the control. Each 
bar represents the mean of triplicate treatments (±SD). * - p<0.05 
(A) Significant (p<0.05) inhibition of TCA efflux was observed in the presence of CYA.  
(B) Cyclosporine significantly (p<0.05) reduced the accumulation of TCA. 
 
* 
* * * 
0
5
10
15
20
25
30
Fetal#3 Fetal#5 Adult#4 Adult#9
TC
A
_M
ed
ia
 
(p
m
ol
 p
er
 m
g 
pr
ot
ei
n)
No CYA
CYA
*
* *
*
0
5
10
15
20
25
30
35
40
45
Fetal#3 Fetal#5 Adult#4 Adult#9
TC
A
_L
ys
at
e 
(p
m
ol
 p
er
 m
g 
pr
ot
ei
n)
No CYA
CYA
 133 
 
 
In fetal hepatocytes, time dependent inhibition of 17-OHPC transport into media was 
observed in the presence of Rifampin with the % inhibition ranging from ~40% at 5 mins to 
~60% at 30 mins (Figure 28A). Further, a time dependent increase in the intracellular amount of 
17-OHPC was observed in the presence of Rifampin. The accumulation increased from ~1.6 fold 
at 5 mins to ~2.3 fold at 30 minutes (Figure 28B). In adult hepatocytes, similar results to fetal 
hepatocytes were observed. In the presence of Rifampin the % inhibition was observed to range 
from ~25% at 5 mins to ~50% at 30 mins (Figure 28A). Also, a higher intracellular amount of 
17-OHPC was observed in the presence of Rifampin. The accumulation varied from ~1.01 fold 
at 5 mins to ~1.4 fold at 30 minutes (Figure 28B).           
5.5.3 Effect of Verapamil on the transport of 17-OHPC in primary human hepatocytes 
P-glycoprotein (P-gp) is a member of the ATP-binding cassette transporter superfamily that has 
been shown to be involved in the efflux of various chemical compounds. Verapamil has been 
reported to inhibit the drug efflux activity mediated by P-gp (Zong and Pollack, 2003). To 
evaluate the involvement of an active, transporter mediated efflux process in the disposition of 
17-OHPC in primary human hepatocytes, Verapamil was co-incubated with fetal and adult 
human hepatocytes.  In adult hepatocytes, inhibition of 17-OHPC efflux was observed in the 
presence of Verapamil with the % inhibition ranging from ~35% at 10 mins to ~45% at 40 mins 
(Figure 29A). Further, a time dependent increase in the intracellular amount of 17-OHPC was 
observed in the presence of Verapamil. The accumulation increased from ~1.01 fold at 10 mins 
to ~1.6 fold at 40 minutes (Figure 29B). In fetal hepatocytes, similar results to adult hepatocytes 
were observed. 
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Figure 28. Effect of Rifampicin (RIF) on the time course of 17-OHPC efflux from primary 
human fetal hepatocyte cultures 
The cells were incubated for different time intervals with 17-OHPC in the presence and absence 
of Rifampicin during the loading phase, washed with ice-cold media and subsequently 
reincubated in standard buffer in the presence or absence of Rifampicin (RIF). DMSO (0.1%) in 
buffer was used as the control. Each bar represents the mean of duplicate treatments (±SD). * - p<0.05 
(A) Significant (p<0.05) inhibition of 17-OHPC efflux was observed in the presence of RIF.  
(B) RIF significantly (p<0.05) increased the accumulation of 17-OHPC. 
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Figure 29. Effect of Verapamil (VER) on the time course of 17-OHPC efflux from primary 
human fetal hepatocyte cultures 
The cells were incubated for different time intervals with 17-OHPC in the presence and absence 
of Verapamil during the loading phase, washed with ice-cold media and subsequently 
reincubated in standard buffer in the presence or absence of Verapamil (VER). DMSO (0.1%) in 
buffer was used as the control. Each bar represents the mean of duplicate treatments (±SD) in 
adults and a single treatment in fetal. * - p<0.05 
(A) Significant (p<0.05) inhibition of 17-OHPC efflux was observed in the presence of VER. 
(B) VER significantly (p<0.05) increased the accumulation of 17-OHPC. 
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In the presence of Verapamil the % inhibition was observed to range from ~60% at 10 
mins to ~70% at 40 mins (Figure 29A). No data was available for estimating the counts in the 
cell lysate. 
5.5.4 Effect of temperature on the transport of 17-OHPC and taurocholate in primary 
human hepatocytes 
To further investigate the mechanisms of hepatic transport of 17-OHPC (passive diffusion or 
active uptake process), the effect of temperature (4ºC vs. 37ºC) on the transport of 17-OHPC into 
hepatocytes was evaluated.  
In fetal hepatocytes, significant (p<0.05) inhibition of 17-OHPC efflux was observed in 
cold media (4ºC) as compared to warm media (37ºC). Further, a time dependent decrease in the 
efflux of 17-OHPC was observed in cold media. The % inhibition due to cold temperature was 
observed to be 10-48% at 5 mins and increased to 20-60% at 30 mins (Figure 30A). The total 
uptake of 17-OHPC in hepatocytes was 1.6 fold higher at 37ºC at 5 minutes and decreased to 0.9 
fold at 40 minutes. A time dependent increase in the intracellular amount was observed at 4ºC 
whereas the intracellular amount showed a net decrease at 37ºC. The accumulation at 4ºC was 
observed to be less than or equal to 37ºC at 5 mins and increased to 1.2-2 fold at 30 mins (Figure 
30B). 
Similar results were observed in adult hepatocytes (Figure 30A). The % inhibition of 17-
OHPC efflux observed at 4ºC was ~45% at 5 mins and increased to ~60% at 30 mins. The 
intracellular amount of 17-OHPC at 4ºC was observed to increase from 1.3 fold at 5 mins to >3 
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fold at 30 mins. The total uptake of 17-OHPC in hepatocytes was 0.9 fold lower at 37ºC (than 
4ºC) at 5 minutes and decreased to 0.8 fold at 40 minutes. The results suggest the presence of an 
active efflux process in the disposition of 17-OHPC and further confirm the results from 
previous experiments.  Effect of temperature on the transport of Taurocholate was also evaluated 
in fetal hepatocytes. The efflux of taurocholate was observed to be less at 4ºC than 37ºC and 
showed a time dependent inhibition profile. The % inhibition of efflux was observed to increase 
from no significant inhibition at 5 mins to ~20% inhibition at 30 mins (Figure 31A). The 
intracellular accumulation of taurocholate was also observed to be inhibited at 4ºC with a % 
inhibition of 30-75% at 5 mins which increased to 60-90% at 30 mins (Figure 31B). The total 
uptake (media + lysate) was also inhibited ranging from 30-80% at 5 mins to 60-90% at 30 mins. 
These results further confirm the observations from previous chemical inhibitor based 
experiments and indicate the presence of an active transport process for the uptake (NTCP, 
OATP) and efflux (BSEP) of taurocholate in fetal hepatocytes. 
5.5.5 Effect of 17-OHPC on the bile salt transport in adult and fetal hepatocytes 
To evaluate the inhibitory potential of 17-OHPC on bile salt efflux, we pre- and co-incubated 
different concentrations of the drug with taurocholate. In fetal hepatocytes, 17-OHPC was 
observed to reduce the efflux of taurocholate in a concentration dependent manner with a 
significant decrease observed at 0.5 µM, 1.0 µM and 10.0 µM concentrations (Figure 32A). The 
total uptake of taurocholate was not significantly inhibited by 17-OHPC at any concentration 
(Figure 32B). Cyclosporine (CYA; 40µM) was used as the positive control and depicted a 
significant (p<0.05) inhibition of both efflux and the total uptake of taurocholate. 
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[B] 
Figure 30. Effect of temperature on the time course of 17-OHPC transport from primary human 
fetal and adult hepatocytes 
Each bar represents the mean of duplicate treatments (±SD). * - p<0.05 
(A) Efflux of 17-OHPC into the media was observed to increase with time. The efflux of 17-
OHPC was significantly (p<0.05) inhibited at all time points in cold media.  
(B) Accumulation of 17-OHPC was observed to increase significantly (p<005) or remain 
constant with time in cold media. Further, the accumulation was observed to decrease in warm 
media conditions. 
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Figure 31. Effect of temperature on the time course of Taurocholate (TCA) transport from 
primary human fetal hepatocytes 
The cells were incubated for different time intervals with TCA in WARM (37ºC) and COLD 
(4ºC) media during the loading phase, washed with ice-cold media and subsequently reincubated 
in the warm and cold media. Each bar represents a single treatment (±SD). 
(A) Efflux of TCA into the media was observed to increase with time. The efflux of 17-OHPC 
was inhibited in cold media. 
(B) Accumulation of 17-OHPC was also observed to decrease or remain constant with time in 
cold media as compared to warm media.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Effect of 17-OHPC on taurocholate disposition in cultured FETAL human 
hepatocytes (n=8) 
Taurocholate efflux or uptake in the absence of 17-OHPC or CYA was defined as control having 
100% efflux or uptake. DMSO (0.1%) in buffer was used in the control. Each bar represents 
treatments in triplicate (±SD). CYA was employed as the positive control. * - p<0.05  
(A) Significant decrease (p<0.05) in taurocholate efflux was observed at 0.5 µM, 1.0 µM and 
10.0 µM 17-OHPC concentration and depicted a dose dependent inhibition. CYA significantly 
(p<0.05) decreased taurocholate efflux. 
(B) No significant decrease (p<0.05) in taurocholate uptake was observed at all 17-OHPC 
concentrations, 10 µM (p=0.07), 1 µM (p=0.062) and 0.5 µM (p=0.053) due to the large inter-
individual variations in the total uptake of 17-OHPC. CYA significantly (p<0.05) decreased 
taurocholate uptake. 
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In adult hepatocytes, 17-OHPC decreased the efflux of taurocholate in a concentration 
dependent manner. Significant decrease in the efflux was observed at 100µM, 50µM and 5µM 
17-OHPC concentrations (Figure 33A). The total uptake of taurocholate was also inhibited by 
17-OHPC with significant inhibition at 100µM concentration (Figure 33B). Similar to fetal 
hepatocytes, cyclosporine (CYA; 40µM) was used as the positive control and showed a 
significant (p<0.05) inhibition of both taurocholate efflux and uptake.  
Biliary excretion index (BEI) represents the percentage of substrate accumulated in the 
monolayer hepatocyte culture that is localized in bile canaliculi. A large biliary excretion index 
(as high as taurocholate) indicates extensive excretion of substrate into the canalicular space via 
transporters (Liu et al., 1999b). The BEI for 17-OHPC in adult and fetal hepatocyte cultures were 
similar (Figure 34A). The BEI for taurocholate in adult and fetal hepatocyte cultures were 
significantly (p<0.05) different (Figure 34B). The biliary excretion for taurocholate was 
observed to be ~ 2 fold higher in adult cultures as compared to fetal cells. 
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Figure 33. Effect of 17-OHPC on taurocholate disposition in cultured ADULT human 
hepatocytes (n=5)  
Taurocholate efflux or uptake in the absence of 17-OHPC or CYA (0.1%DMSO) was defined as 
control having 100% efflux or uptake. DMSO (0.1%) in buffer was used in the control. Each bar 
represents treatments in triplicate (±SD). CYA was employed as the positive control. * - p<0.05  
(A) Significant decrease (p<0.05) in taurocholate efflux was observed at 100 µM, 50.0 µM and 
5.0 µM 17-OHPC concentration and depicted a dose dependent inhibition. CYA significantly 
(p<0.05) decreased taurocholate efflux. 
(B) Significant decrease (p<0.05) in taurocholate uptake was observed only at 100.0 µM 17-
OHPC concentration. Significant difference was not observed at 50 µM (p=0.051) due to the 
large inter-individual variations in the total uptake of 17-OHPC. CYA significantly (p<0.05) 
decreased taurocholate uptake. 
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Figure 34. Comparison of the biliary excretion index (BEI) in fetal and adult human hepatocytes 
cultures 
BEI was calculated based on equation 1. Each bar represents treatments in triplicate (±SD). * - p<0.05 
(A) BEI estimate for 17-OHPC in adult human (n=3) and fetal (n=3) hepatocyte cultures. No 
significant difference was observed between adults and fetal cells. 
(B) BEI estimate for taurocholate in adult human (n=3) and fetal (n=3) hepatocyte cultures. 
Significant (p<0.05) difference was observed between adults and fetal cells. 
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5.5.6 Expression of transporters in Fetal and Adult hepatocytes 
Quantitative-real time RT-PCR based estimates of the mRNA levels of transporters in fetal 
hepatocyte cultures were measured and compared with results with adult hepatocytes (Figure 
35). The relative mRNA levels were normalized to the endogenous reference, cyclophillin. The 
mean expression for all the transporters was significantly higher (p<0.05) in adults than fetals 
except OATP1B3 (p=0.1) and MRP4 (p=0.09). In adult hepatocytes, MRP2 showed the highest 
expression level followed by MDR1 and BSEP. In fetal hepatocytes, a similar profile was 
observed with MRP2 transporter depicting the highest expression (~30% of adults) followed by 
MDR1 (~45% of adults) and BSEP (~30% of adults). MDR3 was the only transporter that was 
not detected on a consistent basis in the fetal hepatocytes. Relative to adults, the transporters 
with the lowest expression in fetal liver were MDR3 (~2% of adults) and NTCP (~4% of adults). 
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Figure 35. Expression of transporters based on RT-PCR analysis in adult (n=3) and fetal (n=3) hepatocytes 
Expression of hepatic transporters in adults was observed to be significantly higher (p<0.05) as compared to fetals except for 
OATP1B3 (p=0.1) and MRP4 (p=0.09). Each bar represents the mean of triplicate observations (±SD). * - p<0.05  
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5.6 Discussion 
The current study was designed to evaluate the expression and functional activity of 
sinusoidal and canalicular membrane transporters in primary cultures of fetal human hepatocytes. 
Parallel studies were also performed in adult human primary hepatocyte cultures to provide a 
fetal vs adult comparison. Treatment with 17-OHPC for preventing pre-term labor is initiated in 
pregnant subjects at the start of second trimester in the current regimen. Thus, primary cultures 
of hepatocytes isolated from fetal livers at 21-23 weeks of age were studied. Cholestatic liver 
disease affects not only the mother but also the fetus and the neonate due to the immaturity of the 
biliary excretion system. Thus, it is important to investigate the uptake and efflux of drugs and 
xenobiotics which can gain access to the fetal circulation. The dual-labeled 17-OHPC used in our 
study was observed to retain both (14C, 3H) labels on being metabolized to mono-, di-, and tri-
hydroxy metabolites. These metabolites were observed to be the major metabolites generated on 
incubations with adult and fetal hepatocyte cultures. Thus, the findings in our study refer to the 
disposition of 17-OHPC and its metabolites and in its current form the study cannot differentiate 
between the two products.  
Cyclosporin, a known inhibitor, was used to evaluate the role of active transporters in the 
disposition of 17-OHPC. Significant inhibition of 17-OHPC efflux and an increase in the total 
uptake of 17-OHPC was observed in both adult and fetal hepatocytes. The results indicate that an 
active efflux process seems to be involved in the disposition of 17-OHPC. Similar results were 
also observed with time based incubations. In presence of cyclosporin, the total amount of 17-
OHPC accumulated in hepatocytes was observed to increased significantly with time whereas a 
consistent decrease in the intracellular drug concentration was seen in the absence of inhibitor, 
which can be ascribed to an uninhibited efflux process.   
Hepatic transport of taurocholate, a known substrate for NTCP (uptake) and BSEP 
(efflux) was characterized to evaluate the functional activity of these transporters in fetal 
hepatocytes. Significant inhibition taurocholate efflux was observed in the presence of 
cyclosporin in both adult and fetal hepatocytes. Also, the total accumulation of taurocholate was 
significantly inhibited in the presence of cyclosporine in both adult and fetal hepatocytes. This 
observation was in contrast to what was observed for 17-OHPC. The results indicate that 
functional uptake and efflux processes are involved in the transport of taurocholate in fetal 
hepatocytes, whereas with 17-OHPC only an efflux process was observed. 
The organic anion-transporting polypeptide (OATP1B1, 2B1, 1B3) transporters are 
uptake proteins with broad substrate specificities including bile salts, prostaglandins, and steroid 
conjugates. Recently, it was reported that the sulfate conjugate of pregnenolone, precursor to 
endogenous hormones including dehydroepiandrosterone (DHEA) and progesterone, is a 
substrate of OATP2B1. To investigate the involvement of an uptake process mediated by the 
OATPs in addition to the predominant efflux process in the transport of 17-OHPC, a structural 
analog of pregnenolone, we used rifampin which is a known inhibitor of OATPs. If OATPs 
played a role in the disposition of 17-OHPC or its metabolites we expected to observe a decrease 
in the total intracellular accumulation of 17-OHPC in the presence of rifampin. However, a time 
dependent increase in the total uptake of 17-OHPC was observed along with a similar decrease 
in the % efflux which was contrary to the expected results. Previous literature reports (Fardel et 
al., 1995) have indicated that rifampin has the ability to bind to Pgp-drug binding sites and thus 
cause an inhibition in the Pgp mediated basolateral efflux of substrates (digoxin, vinblastine). 
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Thus, the results suggest the involvement of Pgp as the efflux transporter in the disposition of 
17-OHPC. 
In support of the previous experiments using chemical inhibitors, we evaluated the effect 
of temperature (4ºC vs. 37ºC) on the transport of 17-OHPC in hepatocytes. A decrease in 
transport into the media and a time dependent increase in the intracellular amount of 17-OHPC 
was observed in both adult and fetal hepatocytes at cold temperature (4ºC). In warm temperature 
(37ºC), a time dependent increase in the efflux of 17-OHPC and a decrease in the intracellular 
concentration was observed which again can be explained by an uninhibited efflux process. The 
results suggest that an active efflux process is likely to be the main mechanism involved the 
transport of 17-OHPC. However, on evaluating the effect of temperature on taurocholate 
transport in fetal hepatocytes, the results were in contrast to 17-OHPC. At 4ºC, significant 
inhibition of both total uptake and efflux of taurocholate was observed. Thus, unlike 17-OHPC, 
the effect of temperature on taurocholate confirms the involvement of functional uptake (NTCP, 
OATP) and efflux (BSEP) processes involved in the transport of taurocholate. 
In addition to evaluating the functional activity of hepatic transporters in fetal 
hepatocytes, we performed RTPCR based analysis to compare the mRNA expression of various 
hepatic transporters (MDR1, MDR3, OATP1B1, OATP1B3, OATP2B1, BSEP, NTCP, MRP2, 
MRP3, MRP4 and BCRP), known to be important for the disposition of xenobiotics and bile 
salts, in adult liver and isolated hepatocytes. With the exception of MDR3 and NTCP, all 
transporters examined were found to be expressed in fetal hepatocytes as well as adults.     
Hepatic clinical toxicity due to various xenobiotics in humans has been reported to be 
associated with the inhibition of bile salt transporters, especially NTCP and BSEP. Kostrubsky et 
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al., using a sandwich culture inhibition model, have reported three factors that are associated 
with clinical hepatotoxicity:  
1) high-molecular weight compounds with expected biliary excretion of parent and 
metabolites,  
2) affinity for biliary transporters as shown by a concentration-dependent inhibition of bile 
acid transport in vitro, and  
3) plasma concentration at or above 1 μg/ml.  
The maximum plasma concentrations reported for 17-OHPC is 30ng/ml in adults and 
10ng/ml in the cord blood. These concentrations are much lower than the 1µg/ml threshold 
reported for clinically significant hepatotoxicity. However, the abovementioned factors are based 
on evaluations carried out in adult human hepatocytes and the model had to be validated for fetal 
human hepatocyte cultures. To the best of our knowledge, this is the first report that tests the 
applicability of the in-vitro hepatotoxicity model in fetal hepatocyte cultures. In experiments 
conducted previously, the expression and function of transporters involved in the disposition of 
taurocholate and 17-OHPC in fetal hepatocytes was confirmed. Subsequently, we decided to 
evaluate the potential of 17-OHPC to interfere with the transport of taurocholate.  
To test the role of biliary excretion pathway in the disposition of 17-OHPC (Mol. Wt. 
428.7) or its metabolites, we estimated the biliary excretion index (BEI) for 17-OHPC in both 
adult and fetal hepatocytes and compared it with taurocholate. Biliary excretion index (BEI) 
represents the percentage of substrate accumulated in the monolayer hepatocyte culture that is 
localized in bile canaliculi. A large biliary excretion index (as high as taurocholate) indicates 
extensive excretion of substrate into the canalicular space via transporters (Liu et al., 1999b). 
Biliary excretion of 17-OHPC was observed to be similar in fetal and adult hepatocytes although 
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it was 5-10 times less than the BEI for taurocholate. The BEI for taurocholate was significantly 
(p<0.05) higher in adults than fetal hepatocytes which can be explained by the higher expression 
level of NTCP and BSEP proteins in adult cells. The results indicate that biliary excretion 
pathway might play a limited role that in the disposition of 17-OHPC.  
To evaluate the affinity of 17-OHPC for the bile salt transporters, we tested the ability of 
17-OHPC to inhibit taurocholate transport in a concentration dependent manner. Significant 
inhibition of taurocholate transport by 17-OHPC was observed at ≥ 0.5 µM in fetal hepatocytes 
indicating the potential for inhibiting bile transport. The uptake was observed to decrease with 
increasing concentrations of 17-OHPC (although not statistically significant) thus indicating 
potential for inhibition of both canalicular uptake and basolateral efflux processes. In adult 
hepatocytes, similar trend was observed with both efflux and total uptake decreasing with 
increasing 17-OHPC concentrations. The IC50 calculated for 17-OHPC mediated inhibition of 
taurocholate efflux in fetal hepatocytes was ~20µM which was ~ 4 fold lower than the IC50 
(80µM) observed in adult hepatocytes. This observation highlights the fact that the fetal liver 
will develop toxicity to xenobiotics more readily than the adult liver, largely due to its lower 
expression of bile salt and other sinusoidal/ canalicular transporters which play an important role 
in the detoxification mechanism. Cyclosporine, used as positive control, showed significant 
inhibition of both the uptake and efflux of taurocholate in adult and fetal hepatocytes thus 
confirming the functional activity of bile transporters. Although, inhibition of taurocholate 
transport was observed in fetal and adult hepatocytes, the inhibition is not likely to be clinically 
significant given the very low 17-OHPC levels observed in human plasma under the current 
dosing regimen.  
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In conclusion, the study demonstrates the functional expression of both sinusoidal and 
canalicular transporters responsible for transport of taurocholate and 17-OHPC in fetal human 
hepatocytes. Results from a competition assay show the inhibitory potential of 17-OHPC on 
taurocholate transport. It is likely that the presence of an active efflux process in fetal 
hepatocytes prevents the accumulation of 17-OHPC or its metabolites in fetal hepatocytes thus 
preventing any adverse event. The bile transport inhibition assay is a proven indicator of 
hepatotoxicity with adult hepatocytes and can also be used in fetal hepatocytes to evaluate drugs 
which traverse the placental barrier and gain access to the fetal circulation after being 
administered to pregnant subjects.    
 
Clinical Implications: 
1) Pgp is likely to be the major efflux transporter involved in the transport of 17-
OHPC in adult and fetal liver. Direct competition of 17-OHPC with other Pgp 
substrates (xenobiotics or endogenous hormones like progesterone) can lead to 
clinically significant drug-drug interactions, especially, in the fetus. 
2) Induction and/or Inhibition of Pgp (and CYP3A7) in the fetal liver can affect 
the elimination of 17-OHPC and/or its metabolites, thus, leading to their 
accumulation in the fetal circulation. Accumulation of these xenobiotics 
alongwith the increased level of endogenous compounds like progesterone 
metabolites can work in an additive (or synergistic) manner leading to 
significant inhibition of bile salt transport mediated by BSEP. Thus, the 
potential of an adverse event like cholestasis in the fetus is very likely under 
this scenario. 
 152 
  
Acknowledgements:  
This project was supported in part by the Obstetrical-Fetal Pharmacology Research Units 
Network (OPRU). This work is supported in part by NICHD grant HD-047905-2 and the Liver 
Tissue and Cell Distribution System, funded by NIH Contract # N01-DK-7-
0004/HHSN26700700004C  (SCS).  
 
 153 
6.0  Clinical Pharmacology of 17alpha-hydroxyprogesterone caproate in women with twin gestation 
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6.1 Abbreviations 
17-OHPC - 17α-hydroxyprogesterone caproate 
PTB – Preterm Birth 
17-OHP - 17α-hydroxyprogesterone 
P – Progesterone 
MPA – Medroxyprogesterone acetate 
BMI – Body Mass Index 
AUC – Area Under Curve 
Cmax – Maximum plasma concentration  
Tmax – Time to reach Cmax 
Cl – Clearance 
T1/2 – Half life 
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6.2 Abstract 
Aim: 17alpha-hydroxyprogesterone caproate (17-OHPC) reduces the rate of preterm birth in 
women with a prior preterm birth.  Despite the widespread clinical use of this agent, no data exist 
describing the pharmacokinetics of 17-OHPC in pregnancy or the plasma concentrations 
achieved during therapy for preterm birth prevention.  In this study, we evaluated the 
pharmacokinetics (PK) of 17-OHPC in a group of women with either twin (Trial 1) or triplet 
(Trial 2) gestation who were receiving 17-OHPC in two separate placebo controlled trials aimed 
at determining the utility of this agent in reducing preterm birth rates. 
Methods: Samples from women with twins (n=71) were studied in the trial. Subjects received 
weekly intramuscular injections of 250 mg 17-OHPC in 1 ml castor oil from the time of 
enrollment (16 0/7 weeks – 20 6/7 weeks) until delivery. The subjects were studied twice i.e. two 
blood samples were drawn during pregnancy, one between 24-28 weeks (epoch1) and one 
between 32-35 weeks (epoch 2) for measurement of plasma concentration of 17-OHPC. Data 
analysis was performed by non-linear mixed effects modeling implemented by the Monolix® 
software. 
Results: The average Cmax observed in the pregnant subjects was 18ng/ml. Steady state 
concentrations were not achieved during epoch 1 since the plasma concentrations at period 2 (32-
35 weeks) were higher than at period 1 (24-28 weeks).  The apparent half-life of 9.1 days 
suggested that depot release from the castor oil regulated the apparent terminal half-life of the 
drug.  The pharmacokinetics of 17-OHPC was best described by a one-compartment model with 
first-order absorption and elimination. BMI and plasma levels of progesterone and 
hydroxyprogesterone were observed to be significant covariates. Simulations of plasma 
concentration time profiles showed that by starting the regimen with a loading dose of 1000 mg, 
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steady state concentrations could be achieved within the first week of therapy as compared to 11-
12 weeks with the current schedule. Further, administering a dose of 500 mg once in 2 weeks 
was observed to achieve steady state concentrations similar to the current regimen although with 
lower trough concentrations. Race, although not significant in this study, may play a role in the 
pharmacokinetics of 17-OHPC. African American subjects may require a higher dose as 
compared to subjects of other ethnicities due to their higher metabolic capacity for 17-OHPC as 
evident by their higher average clearance values. 
Conclusions: This is the first report of plasma concentrations of 17-hydroxyprogesterone 
caproate in pregnant women.  This report defines for the first time the pharmacokinetic behavior 
of 17-hydroxyprogesterone caproate in twins. 
6.3 Introduction 
17alpha-hydroxyprogesterone caproate (17-OHPC) has been shown to reduce the rate of 
PTB in women with a prior history of preterm birth (Meis et al., 2003).  The effectiveness of 17-
OHPC in preventing PTB has been evaluated in other associated conditions including multifetal 
gestation (Rouse et al., 2007; Caritis et al., 2009) and cervical cerclage (Rebarber et al., 2008).  
Although this agent has been widely used clinically, no data describing the pharmacokinetics of 
17-OHPC in pregnancy or the plasma concentrations achieved during therapy exists in the 
literature.  Only a single study by Onsrud et al. has reported the drug concentrations achieved 
during administration of this agent (Onsrud et al., 1985).  However, in that study 17-OHPC was 
indicated for the treatment of endometrial cancer in non-pregnant women. A complete 
understanding of the pharmacokinetics of 17-OHPC will help in designing an optimal dosing 
 157 
regimen for this agent. In the current study, our objective was to evaluate the pharmacokinetics 
(PK) of 17-OHPC in a group of women with twin gestation who were receiving 17-OHPC. 
We have previously shown that 17-OHPC is metabolized by human liver microsomes and 
primary hepatocyte cultures with CYP3A4 being the major enzyme involved.  Highly variable 
expression and function of CYP3A has been observed between individuals. Intersubject 
variability in CYP3A-mediated activity has been reported to be large (approximately 10-fold 
difference). Some studies have reported variability of greater than 20-fold (Lin et al., 2001; Zhu 
et al., 2003; Chen et al., 2006). In earlier clinical studies 17-OHPC was not demonstrated to be 
effective and only about 33% of patients in the recent trials appear to benefit from 17-OHPC 
administration. Inter-individual variability in the metabolism is an important factor contributing 
to the variability in the pharmacokinetics of several drugs. Thus, it is possible that the variability 
in clinical response to 17-OHPC may be related to the concentration of 17-OHPC. Further, based 
on in-vitro studies in adult human liver microsomes, hepatocytes cultures (Chapter 1) and 
suspensions, we have shown 17-OHPC to be an intermediate clearance compound (Hepatic 
Clearance, CLH (in-vitro) ~ 4ml/min/kg) with an average half life of ~ 70 mins. However, 
steroidal intramuscular injections (Medroxyprogesterone acetate and Nandrolone decanoate, 
vehicle – castor oil), have been reported to have half lives of 50 and 20 days, respectively. This 
has been attributed to their half life being absorption rate limited. 17-OHPC is administered as an 
intramuscular injection (vehicle - castor oil) once a week at a dose of 250 mg.    
We hypothesize that a large variability due to interindividual variability in CYP3A and 
long half life due to slow release from the intramuscular depot will be observed for 17-OHPC in 
pregnant women receiving i.m. injections of 17-OHPC for treatment of preterm birth.  
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6.4 Methods 
6.4.1 Patients and Drug administration 
A total of 71 women with twins were studied.  Subjects received weekly injections of 250 mg 
17-OHPC in 1 ml castor oil from the time of enrollment (16 0/7 weeks – 20 6/7 weeks) until 35 
weeks or until delivery. Data recorded for each patient included maternal age, gestational age at 
each blood sampling and delivery, plasma levels of 17alpha-hydroxyprogesterone (17-OHP), 
progesterone (P), race and BMI. These data were evaluated as covariates in the pharmacokinetic 
analysis.    
6.4.2 Pharmacokinetic sampling schedule 
Sparse sampling - Two blood samples were drawn during pregnancy from each subject, one 
between 24-28 weeks (EPOCH1) and one between 32-35 weeks (EPOCH 2) for measurement 
of plasma concentration of 17-OHPC.  
Intensive sampling - For the study of 17-OHPC pharmacokinetics (PK), six women were 
recruited to have a single blood sample removed daily for seven consecutive days between 24-28 
weeks.  The first blood sample was drawn minutes prior to the next scheduled injection.  These 
six subjects had already received a minimum of four weekly injections from the time of 
enrollment in anticipation that steady state concentration would be achieved by the start of the 
PK study.   
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6.4.3 Sample Analysis 
For all 17-OHPC measurements, blood was collected in 10 ml tubes with heparin and 
centrifuged within one hour at 3500 x g for 10 minutes.  The supernatant plasma was aliquoted to 
1 ml tubes and was frozen at -70ºC until analysis.  Analyses of 17-OHPC was performed using 
high performance liquid chromatography with tandem mass spectrometry (LC-MS).  The assay 
methodology, developed in our lab, has been reported elsewhere (Zhang et al., 2007).  At the 
time of the analysis, the analyst and the clinical centers involved in recruitment were blinded to 
the treatment assigned.  The lower assay limit of detection was 1 ng/ml, inter and intra assay 
variability at 10 ng/ml was 7.9 and 5.2% respectively. 
6.4.4 Noncompartmental Pharmacokinetic Analysis 
Pharmacokinetic parameters for the 6 subjects undergoing ‘’intensive sampling” were estimated 
using the standard noncompartmental approach implemented using WinNonlin (ver 4.0).  
Maximum concentration (Cmax) and time to maximum concentration (Tmax) were determined 
from the observed data. The elimination rate constant (λz) was determined by log-linear 
regression of terminal linear disposition phase. Half-life (T1/2) was estimated by 0.693/ λz. Area 
under curve (AUC)0T was calculated using the linear trapezoidal method. Since, the trough 
concentrations between the 2 consecutive doses during the pharmacokinetic study were not 
significantly different; the area was calculated for one dosing interval. Apparent clearance 
(CL/F) was estimated by Dose/(AUC)0T.   
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6.4.5 Compartmental Pharmacokinetic Analysis 
For sparse sampling data, analysis was performed by means of non-linear mixed effects 
modeling implemented by the Monolix® software. MONOLIX provides an estimate of the 
parameters (fixed effects and variance of the random effects) as well as an estimate of the 
estimation error via the Fisher information matrix.  
Preliminary analysis for evaluating the structural model was performed by comparing 
one-compartment model with first-order absorption and elimination with two and three 
compartment models. Further, first order absorption under the one compartment model was also 
compared to mixed order absorption. A proportional variance model was used for the residual 
error. The parameters that were evaluated by the model included ka, Cl/F and V/F. 
Interindividual variability was assumed to have a log-normal distribution. The covariance 
between clearance and volume of distribution was examined by testing a full covariance matrix. 
The patient characteristics (BMI and race) were evaluated as covariates during the model 
building process as described by Lavielle and Mentre (Lavielle and Mentre, 2007). Briefly, the 
effect of each covariate was tested on each individual parameter and evaluated for significance 
using both a Wald test and a LRT test. All population models with all combinations of covariates 
found significant in the first analysis were fitted and the best ones were subsequently chosen 
according to the Bayesian Information Criteria (BIC). Finally, each covariate remaining in the 
model was tested for significance using both a Wald test and a LRT. Further, the change in inter-
patient and residual variability in the presence and absence of this covariate was also taken into 
account before deciding on the final model.  
The goodness of fit of the final model was evaluated by inspecting the following charts 
including, scatterplots of predictions (population and individual) versus individual observations; 
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population weighted residuals versus predictions and independent variable (time); absolute 
individual weighted residuals versus individual predictions. In addition, model validation was 
performed using prediction distribution errors and visual predictive check, obtained by 
performing 1000 simulations of the data set for the final model. 
Further, simulations were carried out based on the final model to evaluate the effect of 
changes in BMI and dosing regimen on the plasma concentration time profiles of 17-OHPC. To 
evaluate the effect of BMI on plasma concentration time profiles we selected 3 BMI values 
(highest, average and lowest) based on the range observed in our sample set which were 45, 27 
and 18, respectively. Possible modifications in dosing regimen (for achieving the same 
therapeutic effect) were evaluated, including: 
a) the effect of increasing the dose from 250 mg once weekly to 500mg or 750 mg once 
weekly, 
b) the effect of adding a loading dose of 1000 mg to the regimen in order to rapidly achieve 
the intended steady state concentrations, and, 
c) the effect of changing the dosing schedule from 250 mg once weekly to 500 mg every 
two weeks. 
6.4.6 Statistical Analysis: 
GraphPad Prism (4.01) was used for performing the statistical tests for significance. Non-
parametric (Wilcoxon signed rank and Mann Whitney U) tests were used for group comparisons. 
Kruskal-Wallis test with Dunn’s multiple comparison was used for testing equality of population 
medians in multiple groups. We considered p-values < 0.05 to be significant. All results are 
reported as (±) standard deviation (s.d.). 
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6.5 Results 
6.5.1 Pharmacokinetics 
Figure 36 depicts the mean plasma concentration (±SD) of 17-OHPC in the six women with 
twins who had blood removed daily for seven days after an injection (intensive sampling).  Each 
woman had received at least 4 injections at a weekly interval from the time of randomization 
prior to performance of the PK study.  Average peak concentrations of 18 ng/ml were noted at 
the first post injection sample at 24 hours.  Over the ensuing 6 days, plasma concentrations 
declined slowly to a nadir of 9 ng/ml at 7 days post injection. Selected pharmacokinetic 
parameters (mean, SD and range) for 17-OHPC in these 6 subjects are summarized in Table 11.  
The peak concentration (Tmax) occurred 1.2 days after the injection.  The wide range of AUC 
values indicates considerable interindividual variation in release and metabolism of 17-OHPC.  
The apparent half-life of 9.1 days suggests that depot release from the castor oil regulates the 
apparent half-life of the drug.  Clearance (apparent) varied seven fold with a mean of 1924 l/day. 
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Figure 36. Average 17-OHPC concentration–time profiles for 6 subjects with twins who had 
sampling done daily for seven days after an injection 
 
Error bars represent (±) standard deviations. 
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Table 11. Mean pharmacokinetic parameters (± sd) of 17-OHPC in pregnant subjects with twins 
 
These subjects had sampling done daily for seven days after an injection. Non-compartmental 
analysis was used for the estimation of the parameters. The observed range for each parameter 
calculated is reported below in parenthesis. 
 
 
 
 
 
AUC ng/ml/day 
(range) 
t ½  (days) 
(range) 
CMAX ng/ml 
(range) 
TMAX (Days) 
(range) 
Cl/F (l/day) 
(range) 
67.2 + 25.3 
(35-105) 
9.1 +  4.2 
(5-34) 
13.3 + 6.2 
(9-24) 
1.2 + 0.45 
(1-2) 
1924 + 1000 
(534-3500) 
 
6.5.2 Impact of BMI and Race on 17-OHPC concentrations 
We evaluated the impact of BMI and race on plasma 17-OHPC concentrations in women with 
twins.  Figure 37 depicts the relationship between plasma 17-OHPC concentrations and body 
mass index (BMI - recorded at the time of registration for prenatal care) during epoch 1 and 2 in 
women with twins.  A significant linear relationship was observed for plasma 17-OHPC and 
BMI in the pregnant women.  The race of the subjects was not observed to affect 17-OHPC 
levels significantly (Figure 38) although the average concentrations in African-Americans (AA) 
were observed to be lower than Caucasians (CA) during epoch 2 (p=0.052). 
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          (A)            (B) 
Figure 37. Relationship between the plasma levels of 17-OHPC and BMI 
(A): Epoch 1 - A significant correlation was observed with p<0.01, R2 = 0.08 for epoch 1  
(B): Epoch 2 - A significant correlation was observed with p<0.01, R2 = 0.10 for epoch 2  
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(A)            (B) 
Figure 38. Relationship between the plasma levels of 17-OHPC and Race 
AA – African-Americans, CA - Caucasians 
(A): Epoch 1 – No significant difference was observed between AA and CA for epoch 1  
(B): Epoch 2 – The plasma levels of 17-OHPC were higher in CA than AA although the 
difference was not significant (p=0.052). Mann Whitney U test was used for the comparisons.     
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6.5.3 Steady State Concentration 
We also evaluated whether steady state concentrations of 17-OHPC were achieved over the 
course of therapy.  For this analysis only women who received all their scheduled injections and 
remained undelivered through period 1 (24-28 weeks) and period 2 (32-35 weeks) were included.  
In 71 pregnant women with twins that were studied, the plasma concentrations of 17-OHPC were 
significantly higher (p<0.05) in period 2 than in period 1 (Figure 39).  The mean time from first 
injection to first blood draw was 42.9 (sd 12.6) days and the mean time between first and second 
blood draw was 46 (sd 8.2) days.  Clearly, since plasma concentrations at period 2 (32-35 weeks) 
were higher than at period 1 (24-28 weeks) steady state concentrations were not achieved. 
6.5.4 Population Pharmacokinetics (POP-PK) 
A total of 71 patients, who had at least two samples drawn during the study, were included in the 
POP-PK model building process. The population (POP-PK) consisted of only subjects with twin 
gestation; four racial groups were in the cohort: Caucasians (46), African-Americans (15), 
Hispanics (9) and Asians (2). A total of 190 observational data points were collected and utilized 
for the population analysis.  
The pharmacokinetic behavior of 17-OHPC was best described by a one-compartment 
model with first-order absorption and elimination. The scatter plot of the observed 17-OHPC 
concentrations vs model predicted individual concentrations is shown in Figure 40. Visual 
predictive check generated from Monte Carlo simulations (n = 1000) showed that the estimated 
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Figure 39. Mean (±sd) 17-OHPC concentrations in subjects with twins (n=71) 
 
Mean 17-OHPC concentration in subjects with twins in epoch 2 (32-35 weeks) was observed to 
be significantly (p<0.05, *) higher than epoch 1 (24-28 weeks) suggesting that the steady state 
concentrations were not achieved.  
Mann Whitney U test was used for the comparisons.  
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Figure 40. Scatter plot of the individual predicted vs observed concentrations of 17-OHPC.  
The correlation coefficient was 0.87.  
The figure shows the individual data points for the entire population and the line of identity.  
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population PK model had adequate predictive performance. The estimates of the 
pharmacokinetic parameters and their respective standard errors are shown in Table 12. The 
inter-individual variability (IIV) was observed to be 20% for clearance and 51% for volume of 
distribution estimation, indicating wide inter-subject variability in the pharmacokinetics of 17-
OHPC.  
Correlation between pharmacokinetic estimates of 17-OHPC and patients’ demographic 
variables was examined. Of the various covariates tested in building the final model, BMI and 
 
 
Table 12. Population pharmacokinetic parameter estimates obtained from the final model 
 
Ka: absorption rate constant, V/F: volume of distribution/ bioavailability, CL/F: 
clearance/bioavailability, IIV: Interindividual variability in estimated pharmacokinetic 
parameters, SE, standard error of the estimate, r.s.e.: relative SE (%). 
 
 
 
 
Parameter Mean SE (r.s.e. %) 
Ka (day-1) 0.41 0.29 (72) 
V/F ( x103 ltr) 58.9 7.9 (13) 
Cl/F ( x103 ltr/d) 2.09 0.47 (23) 
IIV_ka 1.04 1 (97) 
IIV_V 0.51 0.13 (26) 
IIV_Cl 0.20 0.04 (20) 
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plasma levels of progesterone and 17-hydroxyprogesterone were observed to have a significant 
effect on the estimation of 17-OHPC clearance as indicated by the Wald test, LRT test and BIC 
value.   
Although race was not observed to be a significant covariate in the final model, however, 
individual estimate of plasma clearance in African Americans was significantly higher than in 
Caucasians (p<0.05) (Fig.41).   
Simulations were carried out to explore the effect of changes in BMI and dosing regimen 
on the plasma concentration time profiles of 17-OHPC (Figure 42). The plasma concentration of 
17-OHPC varied significantly with BMI (Figure 42A) showing a 2.5-fold concentration 
difference over a BMI range of 18-45.  The relationship between BMI and 17-OHPC 
concentration was linear.  When we evaluated the impact of dose on plasma 17-OHPC 
concentrations without considering BMI, plasma concentrations were linearly related to dose. A 
500 mg dose of 17-OHPC increased plasma concentrations two-fold over the 250 mg dose and a 
750 mg weekly dose increased 17-OHPC concentration three-fold (Figure 42B).  
The effect of a loading dose on time needed to reach steady state concentrations was also 
evaluated. A loading dose of 1000 mg reached steady state and maintained it from the beginning 
(Figure 42C). The final steady state concentrations achieved by a loading dose of 1000 mg were 
comparable to those observed without a loading dose. We also evaluated the effect of changing 
the dosing schedule on the concentration time profile. Administering a dose of 500 mg once 
every 2 weeks achieved steady state concentrations similar to those with a 250 mg weekly 
injection although peaks were ≈ 15% higher and trough concentrations were ≈ 15% lower with 
the 500 mg dose (Figure 42D).  
 
 170 
  
 
AA CA HIS ASIAN
0
1
2
3
4
5
6
C
le
ar
an
ce
 (x
10
3
L/
d)
* 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. A boxplot depicting the median 17-OHPC clearance (individual) estimates associated 
with different ethnicities. 
The bars represent (±) standard deviation. 
AA – African Americans (n= 15), CA – Caucasians (n=46), HIS – Hispanics (n=9) and Asians 
(n=2).  
The mean clearance in the Caucasians was observed to be significantly (p=0.025, *) less than 
African Americans. No other group was found to differ significantly. The individual estimates 
were obtained with the final model which included the covariates – BMI, 17-OHP and 
Progesterone.  
Kruskal-Wallis one-way analysis of variance with Dunn’s post test was used for the comparison.
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Figure 42. Characteristics of simulated plasma concentration time profiles of 17-OHPC in pregnant subjects 
 
The bold line is the current standard therapeutic regimen involving a 250 mg once weekly i.m. depot of 17-OHPC. 
 
(A) effect of BMI (18, 45 and 27) on plasma concentration time profiles, 
(B) effect of increasing dose from 250 mg once weekly to 500mg or 750 mg once weekly, 
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     (C)          (D) 
 
Figure 42 contd. Characteristics of simulated plasma concentration time profiles of 17-OHPC in pregnant subjects 
 
The bold line is the current standard therapeutic regimen involving a 250 mg once weekly i.m. depot of 17-OHPC. 
(C) effect of adding a loading dose of 1000 mg to the regimen, and, 
(D) effect of changing the dosing schedule from 250 mg once weekly to 500 mg once in 2 weeks. 
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6.6 Discussion 
Here we report the results of a multiple dose pharmacokinetic study of 17-OHPC conducted in 
pregnant women with twin gestation. The average peak plasma concentration of 17-OHPC 
observed in the six subjects who were sampled intensively for seven days was 18 ng/ml 
(%CV~40). The interindividual variability in the plasma concentrations was also reflected in the 
area under the concentration-time curve (AUC) measurement (%CV~40). In the sparsely 
sampled subjects, the trough concentration of 17-OHPC were observed to range from 3 ng/ml to 
28 ng/ml. Furthermore, wide interindividual variability (Epoch 1 - 8 fold, Epoch 2 – 6 fold) was 
also observed in the trough concentrations of 17-OHPC measured in 71 pregnant subject who 
were sparsely sampled.  
We have previously reported on the role of CYP3A4 as the major enzyme involved in the 
metabolism of 17-OHPC (Sharma et al., 2008). Thus, given the widely reported interindividual 
variability (10-20 fold) observed with CYP3A4 substrates (e.g. Midazolam), we can explain the 
variability in plasma levels of 17-OHPC by concluding that the pharmacokinetics of 17-OHPC in 
humans is affected by its hepatic clearance, mediated largely by CYP3A4. 
The apparent half life of 17-OHPC, estimated by non-compartmental analysis of the 
intensively sampled data set, was observed to be 9.1 days. The half life of a compound in the 
human body is determined by its total body clearance (and volume of distribution) which is 
basically the sum of hepatic (primarily metabolism) and extra-hepatic (primarily renal) 
elimination pathways. The pharmacokinetics of 17-OHPC using radiolabeled drug has been 
reported in  rats (Kimbel et al., 1958; Wiener et al., 1961). The study observed that 85% of the 
drug (or its metabolite) was eliminated within the first 8 days of injection of 17-OHPC 
(100mg/kg) via the subcutaneous route. Almost 85% of the excreted drug (or its metabolite) was 
found in the feces and the remaining in the urine. Further, during the first 2 days of the study, 
most of the radioactivity (due to the drug or its metabolite) was observed in the liver and kidney. 
However, analysis of urine samples obtained from pregnant human subjects did not show 
detectable 17-OHPC levels. Thus, the role of renal elimination pathway in the overall clearance 
of 17-OHPC in humans is considered to be limited in comparison to the hepatic pathway.  
In-vitro estimation of the clearance and half life of 17-OHPC in primary human 
hepatocyte cultures depicted 17-OHPC as an intermediate clearance compound with a half life of 
~ 70 minutes. However, the in-vivo estimate of half life (9 days) suggests otherwise. This 
observation can be explained using the concept of flip-flop kinetics. In the case of “normal” 
kinetics (e.g. intravenous injection), the rate of elimination is much smaller than the rate of 
absorption i.e. Ke <<< Ka. Thus, the half life of a compound in the body depends on the rate at 
which it is eliminated. However, with certain routes of administration or formulations 
(intramuscular depots, slow release tablets) the elimination a drug is much faster than the rate at 
which it is absorbed or Ka <<< Ke. In such cases, the decline of the terminal slope depends on 
how fast the absorption is taking place. Thus, the terminal slope reflects Ka rather than Ke and is 
termed as "flip-flop" kinetics. We believe that a similar mechanism is involved in the 
pharmacokinetics of 17-OHPC which is administered as an intramuscular depot injection 
constituted in castor oil. Based on the plasma concentration-time profile depicted in figure 36, it 
is likely that two different mechanisms, simultaneous zero and first order or two parallel first 
order processes, maybe involved in the absorption of 17-OHPC from the i.m. depot. Between 
day 0 (time of injection) and day 1, zero order or fast first order absorption will be the primary 
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mechanism (characterized by rapid absorption i.e. Ka>>Ke) followed by the slower first order 
release between day 1 and the next dose (characterized by slow absorption or Ka <<< Ke). 
However, due to insufficient sampling time points between day 0 and 1, these absorption models 
were found to be statistically insignificant in a non-linear mixed effects model and a simpler first 
order absorption model was chosen. 
Based on the abovementioned discussion we conclude that despite hepatic metabolism 
being the primary mechanism involved in the overall clearance of 17-OHPC, the apparent half 
life observed in-vivo is also regulated by the release rate of the drug from the intramuscular 
depot. However, to confirm that flip-flop kinetics is indeed responsible for the prolonged half 
life, a single dose pharmacokinetic study comparing the terminal slope of 17-OHPC after 
intravenous and intramuscular administration needs to conducted. It is important to note that 
since absorption of 17-OHPC from the depot is slower than its elimination by hepatic pathway, 
especially in the terminal phase of the sampling, the release from the depot will affect the plasma 
levels and possibly contribute to the observed inter-individual variability. However, as noted 
previously, a pilot study involving administration of a single dose of 17-OHPC needs to be 
conducted to accurately determine the pharmacokinetics (Cmax, Tmax, Half-life) of 17-OHPC. 
Estimation of clearance in intensively and sparsely sampled subjects depicted a value of 
~ 2000 l/d. This estimated value is uncharacteristically high for 17-OHPC which has a long half 
life of 9 days. The primary reason for this observation is the fact that despite being administered 
a high dose of 250 mg, a peak plasma level of only 18ng/ml was observed in the clinical study. 
The reasons behind this discrepancy can be: 1) the first sample from the pregnant subjects was 
taken one day after administration of the dose. However, it is likely that a Cmax, much higher 
than 18ng/ml, was achieved between day 0 and day 1. Thus, the lack of a true estimate of Cmax 
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may explain the high estimated clearance value. 2) It is also likely that the stability of 17-OHPC 
in the muscle tissue at body temperature is affected. Degradation of 17-OHPC in the depot will 
lead to very low bioavailability with less amounts of the drug being released into the circulation 
and can explain the low plasma levels observed.   
In the women who were sparsely sampled, steady state concentrations were not achieved 
as indicated by the significant difference in the average plasma concentrations of 17-OHPC 
(Epoch 1 – 10.8 ng/ml vs Epoch 2 – 13 ng/ml). Although steady state concentrations are usually 
achieved in 4-5 half lives, however, this was not observed with 17-OHPC. This is likely due to 
the continuous, slow release of the drug from the castor oil depots that were augmented with 
each successive injection.   
Body mass index (BMI) was observed to have a significant impact on the plasma levels 
of 17-OPHC. A decrease in the plasma levels was observed with increasing BMI which can be 
explained by the associated change in volume of distribution. 
Although race was not a significant covariate in the final model, however, the estimated 
individual 17-OHPC clearance was observed to be higher in African Americans than Caucasians. 
Based on in-vitro estimations in expressed enzyme systems, the intrinsic clearance (Vmax/Km) 
of 17-OHPC in CYP3A5 was observed to be ~10 fold of CYP3A4. CYP3A5 protein has been 
reported to represent more than 50% of the total CYP3A content in ~33% of Caucasian livers 
and > 50% of African American livers (Kuehl et al., 2001). Thus, CYP3A5 represents a 
significant proportion of total CYP3A content and is more frequently expressed in African 
Americans. Thus, CYP3A5 can contribute significantly to CYP3A content and catalytic activity 
in African Americans as compared to Caucasians and explain not only the interracial differences 
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in CYP3A-dependent 17-OHPC clearance (based on the higher metabolic capacity of CYP3A5 
than 3A4) but also the interindividual variability observed.   
Simulations were conducted to evaluate the effect of different doses of 17-OHPC on 
plasma concentrations. The results showed a dose dependent increase in the plasma 17-OHPC 
levels thus providing an estimate for doses required for achieving a certain target concentration. 
However, caution needs to be exercised in case of dose escalation as the resulting increase in the 
fetal 17-OHPC concentrations can lead to hepatotoxicity, primarily due to inhibition of BSEP as 
demonstrated in Chapter 3.  
Simulations with different dosing regimens showed that by starting the regimen with a 
loading dose of 1000 mg followed by maintenance doses of 250 mg once a week, steady state 
concentrations could be achieved within the first week of therapy. This could help achieve the 
intended “therapeutic” concentrations more rapidly and possibly improve the clinical outcome. 
Further, a dosing schedule of 500 mg injection administered once every two weeks could also be 
utilized to achieve plasma concentrations comparable with the currently utilized regimen of 250 
mg weekly. This could improve patient acceptability and reduce the number of visits to 
healthcare providers. However, this schedule needs to be evaluated carefully since the peak/ 
trough fluctuations were greater in this case as compared to the standard regimen. 
17alpha-hydroxyprogesterone caproate is widely used to reduce the rate of preterm birth.  
Despite the widespread use of this agent, very little pharmacologic information exists as to its 
mechanism of action and the proper dosing regimen.  The optimization of 17-OHPC dosing 
(from the current fixed dose of 250mg) is severely constrained because the target organ of 17-
OHPC in reducing preterm birth rates is not known. However, the pharmacokinetic study 
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reported here and the subsequent simulation based dosing recommendations represent the first 
step in understanding and optimizing 17-OHPC therapy for preventing preterm birth. 
 
Clinical Implications: 
1) Variability observed in the plasma levels of 17-OHPC suggests that 
individualization of 17-OHPC dosing regimen can help in enhancing the 
therapeutic effectiveness.  
2) Individualization of the dosing regimen can be done on the basis of BMI 
which was observed to have a significant impact on the plasma levels of 
17-OHPC. 
3) Individualization of the dosing regimen can be also be done on the basis of 
race as higher clearance of 17-OHPC was observed in African-Americans. 
However, further studies with more subjects need to be done to confirm this 
observation. 
4) Adjustments in dosing regimen including, addition of a loading dose and 
changes in dosing frequency are recommended to achieve better clinical 
outcome.   
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7.0  Conclusions and Future Directions 
7.1 Discussion and Summary 
The objective of the work carried out in this dissertation was to evaluate the pre-clinical 
and clinical pharmacology of 17alpha-hydroxyprogesterone caproate (17-OHPC), a new agent 
that has been used for the prevention of preterm birth. Currently very limited documentation is 
available on the pharmacokinetics of 17-OHPC in humans or animals.  
In this research work, we studied the metabolism and transport of 17-OHPC in adult and 
fetal (human) model systems. Extending our findings from the pre-clinical experiments, we also 
investigated the pharmacology of 17-OHPC in a clinical study. Several key findings were 
generated in this work, which are summarized in the following section. 
We have used primary cultures of human hepatocytes (PCHH) isolated from adult and 
fetal livers, which provide several advantages over other systems used to study drug metabolism 
and drug transporters. The PCHH contain all the necessary cofactors for oxidative, reductive and 
conjugative metabolism as well as various regulatory elements required to maintain and 
induce/inhibit the expression of enzymes. Our research on investigating the interaction between 17-
OHPC and hepatic transporters in human adult and fetal hepatocytes is limited to BSEP. While other 
investigators have had success measuring the activity of MRP2 and MDR1 in rat hepatocytes 
(Hoffmaster et al., 2004), the lower expression of these transporters in human hepatocyte cultures has 
 180 
prevented us from characterizing their activity in PCHH using known substrates like rhodamine 123 
and 5,6-dicarboxy-2',7'-dichlorofluorescein diacetate, respectively. 
In the first part of the study, we studied the metabolism of 17-OHPC in human liver 
preparations in order to elucidate the pathways involved in its disposition. This was evaluated 
using human liver microsomes, fresh human adult hepatocytes and recombinant systems 
expressing cytochrome P450s. We demonstrated that the metabolism of 17-OHPC is 
predominantly mediated by CYP3A isoforms, mainly CYP3A4. Results of radio-HPLC and LC-
MS analysis of the metabolites confirmed that the structure of 17-OHPC remained intact during 
metabolism by human enzymes with no cleavage of the caproate side chain. Further, LC-MS 
based analysis of the major metabolites indicated mono-hydroxylation or oxidation as the major 
metabolic pathway. These findings suggest that 1) biotransformation of 17-OHPC to the 
endogenous hormone, hydroxyprogesterone, is not the mechanism by which 17-OHPC works, 2) 
caution needs to be exercised when co-administering CYP3A4 substrates/ inhibitors with 17-
OHPC to prevent any associated clinically relevant drug interactions, and 3) significant inter-
individual variability in the pharmacokinetics of 17-OHPC is likely to be observed with the fixed 
dosing regimen. 
In the second part of the study, we evaluated the metabolism and enzyme kinetics of 17-
OHPC in the human fetal liver and compared the results with adult liver. This was done using 
primary cultures of human fetal hepatocytes and adult hepatocytes and recombinant enzyme 
systems. We demonstrated that 17-OHPC is metabolized by fetal human hepatocytes with 
CYP3A7 being the major enzyme involved. Incubation of 17-OHPC with fresh human fetal 
hepatocytes generated three major monohydroxylated metabolites of which two were observed to 
be fetal specific. The intrinsic clearance of 17-OHPC was observed to be similar in adult and 
fetal hepatocyte cultures. Further, the kinetics of 17-OHPC metabolism was also observed to be 
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similar in hepatocytes and expressed enzyme systems. Our findings suggest that 1) metabolism 
by human fetal liver will be a significant contributor to fetal drug disposition of 17-OHPC, and 
2) 17-OHPC metabolism will lead to the accumulation of metabolites in the fetal circulation that 
can affect the fetal hepatic elimination processes and be a potential cause for any associated 
toxicity. 
In the third part of the study we evaluated the role of transporters in the disposition of 17-
OHPC and the effect of 17-OHPC on bile salt transport. This was done using sandwich culture 
preparations of primary human adult and fetal hepatocytes. We demonstrated, for the first time, 
the functional expression of both sinusoidal and canalicular transporters responsible for transport 
of taurocholate and 17-OHPC in fetal human hepatocytes. The results indicated an active efflux 
process as the main mechanism involved in the transport of 17-OHPC, possibly mediated by 
Pgp. Further, we also confirmed the expression of various hepatic transporters (MDR1, 
OATP1B1, OATP1B3, OATP2B1, BSEP, MRP2, MRP3, MRP4 and BCRP) in fetal hepatocytes 
in comparison with adults. Results from the competition assay demonstrated the inhibitory 
potential of 17-OHPC towards taurocholate transport. Our findings suggest that the presence of 
an active efflux process in fetal hepatocytes prevents the accumulation of 17-OHPC or its 
metabolites in fetal hepatocytes thus preventing any adverse event due to the ability of 17-OHPC 
and/or its metabolites to inhibit BSEP. However, inhibition of the efflux process (possibly Pgp) 
by xenobiotics or endogenous compounds like progesterone can lead to the accumulation of 17-
OHPC or its metabolites which can subsequently lead to hepatotoxicity.       
In the final part of this study we evaluated the pharmacokinetics of 17-OHPC in pregnant 
subjects with twin gestation. This study is the first report of plasma concentrations of 17-
hydroxyprogesterone caproate in pregnant women and defined for the first time the 
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pharmacokinetic behavior of 17-hydroxyprogesterone caproate in twins. Wide inter-individual 
variation in the pharmacology of 17-OHPC was observed.  Plasma concentrations of 17-OHPC 
did not achieve steady state concentrations but rather continued to increase with added injections. 
A long half life of 9.1 days was observed in the subjects which coupled with the rapid 
metabolism of 17-OPHC in vitro by human hepatocytes and liver microsomes suggested that the 
slow release from the castor oil depot was the half-life determining step rather than the drug’s 
metabolic or elimination characteristics. Body mass index (BMI) was observed to have a 
significant impact on the plasma levels of 17-OPHC. Also, the clearance of 17-OHPC was 
observed to be higher in African-Americans than in Caucasians. These findings indicate that the 
therapeutic effectiveness can be improved by individualizing the drug administration regimen 
based on BMI and race of the subject which will minimize the inter-individual variation in 
pharmacokinetics. Further, changes in the dosing schedule frequency and addition of a loading 
dose can also improve the outcome by affecting patient compliance and medical costs.   
7.2 Clinical Implications 
1) CYP3A4 is the major isoform (of total CYPs) expressed in the human intestine. Since, 
17-OHPC is a CYP3A4 substrate; the oral bioavailability of this drug is expected to be 
low. 
2) Significant interindividual variability (10 fold) in the plasma concentrations of CYP3A4 
substrates has been reported. Thus, significant inter-individual variation in the plasma 
concentrations of 17-OHPC is expected and monitoring of plasma levels and adjustment 
of dose accordingly may be needed to improve therapeutic outcomes. 
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3) Potential for drug interactions with other CYP3A substrates exists when multiple 
medications are being administered. 
4) Human fetus can metabolize 17-OHPC to 3 major metabolites. Accumulation of these 
metabolites can affect the fetal hepatic elimination processes and be a potential cause for 
any associated toxicity. 
5) A short half life of ~ 57 mins was observed in adult hepatocyte cultures. Thus, a short in-
vivo half life is expected of this intermediate clearance compound when administered IV 
or PO.  
6) Pgp is involved in the transport of 17-OHPC in adult and fetal liver. Direct competition 
of 17-OHPC with other Pgp substrates (xenobiotics or endogenous hormones like 
progesterone) can lead to clinically significant drug-drug interactions, especially, in the 
fetus. 
7) Induction and/or Inhibition of Pgp (and CYP3A7) in the fetal liver can affect the 
elimination of 17-OHPC and/or its metabolites, thus, leading to their accumulation in the 
fetal circulation. Accumulation of these xenobiotics alongwith the increased level of 
endogenous compounds like progesterone metabolites can work in an additive (or 
synergistic) manner leading to significant inhibition of bile salt transport mediated by 
BSEP. Thus, the potential of an adverse event like cholestasis in the fetus is very likely 
under this scenario. 
8) Inspite of the short half life of 57 mins observed in adult hepatocyte cultures, a long half 
life of 9.1 days was observed in the pregnant subjects. This suggests that the slow release 
from the castor oil depot is the half-life determining step rather than the drug’s metabolic 
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or elimination characteristics. The long time needed for the elimination of this compound 
needs to be taken into account when designing a multiple dose regimen. 
9) Variability observed in the plasma levels of 17-OHPC suggests that individualization of 
17-OHPC dosing regimen can help in enhancing the therapeutic effectiveness.  
10) Individualization of the dosing regimen can be done on the basis of BMI which was 
observed to have a significant impact on the plasma levels of 17-OHPC. 
11) Individualization of the dosing regimen can be also be done on the basis of Race as 
higher clearance of 17-OHPC was observed in African-Americans. However, further 
studies with more subjects need to be done to confirm this observation. 
12) Adjustments in dosing regimen including, addition of a loading dose and changes in 
dosing frequency are recommended to achieve better clinical outcome.   
7.3 Limitations and Future Directions 
1) Limited information is available regarding the molecular mechanisms that cause preterm 
birth. Extensive research needs to be done to elucidate these mechanisms which will help 
not only in better predicting preterm birth but also in designing effective and targeted 
therapies. 
2) The mechanism of action of 17-OHPC leading to the prevention of preterm birth is 
unknown. The success rate of 17-OHPC in preventing preterm birth is only 33% as per a 
recent trial by Meis et al. Conflicting reports exist regarding its effectiveness. Thus, 
studies done to understand the mechanisms that cause preterm birth can help us 
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understand how 17-OHPC works. Without the background knowledge, the optimal 
therapeutic concentration and dose cannot be determined.  
3) The potential for clinically relevant drug-drug interactions between 17-OHPC and other 
CYP3A4 substrates needs to be studied in human hepatocytes using clinically relevant 
concentrations of 17-OHPC. Primary cultures of human hepatocytes are an intact cellular 
system that is valuable in characterizing the regulation and activity of a variety of drug 
metabolizing enzymes and transporters. Though much has been done to standardize this 
model, further work is needed to optimize variables that enable for the better prediction of in 
vivo situation.  
4) Synthesis of the various metabolites of 17-OHPC and confirmation of their chemical 
structure needs to be done by LC-MS and NMR studies. It is likely that 17-OHPC works via 
a bioactivation mechanism wherein the metabolite(s) generated are the active products.      
5) Confirmation of Pgp as the transporter involved in the disposition of 17-OHPC needs to 
be carried out in cell lines selectively expressing the MDR1 protein. Further, hepatocyte 
based assays for Pgp, MRP and other transporters using transporter specific substrates 
needs to be set up and optimized for both adult and fetal cultures. 
6) LC-MS based analysis needs to be set up for estimating the intracellular concentrations of 
17-OHPC and its metabolites in hepatocyte cultures. This will help in understanding the 
mechanism of inhibition of BSEP by these xenobiotics in taurocholate assays that is 
important especially in the case of the fetus.  
7) To provide better estimates of the pharmacokinetic parameters of 17-OHPC in pregnant 
subjects, a pilot study needs to be conducted designed to include more intensive sampling 
during the first dosing interval in order to capture the absorption phase of the plasma 
concentration-time curve. 
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APPENDIX A 
Pharmacokinetic Behavior of 17 Alpha-Hydroxyprogesterone Caproate on Multifetal Gestation 
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A. Principal Investigator: Steve N. Caritis, MD 
Co-Investigators: Hyagriv Simhan, MD; Raman Venkataramanan, PhD; Ashi Daftary, MD; Peg 
Watt-Morse, MD; Arundhathi Jeyabalan, MD; Kristiina Parviainen, MD; Margaret Cotroneo, 
RN, CCRC  
 
B. Protocol Title:   
Pharmacokinetic Behavior of 17α-Hydroxyprogesterone Caproate on Multifetal Gestation 
  
Research Protocol Abstract:  This study is an ancillary study for an NIH-sponsored Maternal-
Fetal Medicine Units Network trial entitled “A Randomized Trial of 17 Alpha-
Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation” 
(STTARS Trial, IRB #0412048), which is a randomized, double-masked, placebo-controlled, 
multi-centered clinical trial of 17 alpha-hydroxyprogesterone caproate (17OPHC) for prevention 
of preterm birth in multifetal gestation.  The primary objective of this study is to define the 
pharmacokinetic behavior of 17OHPC after intramuscular injection in women with twin or triplet 
gestation.  We will obtain blood prior to and daily for one week after injection of 17OHPC (8 
samples total) for determination of 17OHPC concentrations.  Additionally, blood samples will be 
drawn at 24-28 weeks and at 32-35 weeks to measure concentrations of 17OHPC, estradiol, 
progesterone, and 17- hydroxyprogesterone.  These measurements will define the 
pharmacokinetic behavior of 17OHPC in multifetal gestation for the first time, enable the 
determination of steady state 17OHPC concentrations after repeated doses, and evaluate the 
effect of 17OHPC on other pregnancy hormones.  Subjects must be participating in the IRB 
#0412048 study (whose eligibility criteria includes multifetal gestation between 16 weeks and 0 
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days to 20 weeks and 6 days) to qualify for participation in this ancillary study.  Approximately 
20 subjects (ages 15-45) will be accrued at Magee-Womens Hospital (MWH) or one of the other 
13 MFMU Network sites.  Study treatment will be administered through 35 weeks gestation or 
delivery.  The total duration of this multi-center study is 5 years.   
  
C. Hypothesis and Specific Aims:  
The objective of this study is to provide preliminary information about the pharmacokinetic 
behavior of 17 OHPC so that the optimal dose of the drug for women pregnant with twins or 
triplets eventually can be determined.  Specifically, we hope to:  
• Determine the pharmacokinetic profile of 17OHPC among women with twin or triplet 
gestation who are receiving 17 OHPC (or placebo) as part of a multicenter study   
• Determine if the weekly injection of 17OHPC increases plasma progesterone, estradiol, 
or plasma 17-hydroxyprogesterone.  
 
The specific aims for this study include: 
a) Measuring the concentration of 17OHPC 7 times over one week after an injection of 17 
OHPC (or placebo) in women with twin or triplet gestation. 
b) Measuring steady state concentrations of 17OHPC and pregnancy-specific hormones 
(progesterone, 17-hydroxyproesterone, and estradiol) at 24 to 28 weeks and 32 to 35 
weeks in women receiving weekly injection of 17OHPC (or placebo). 
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D. Background Information and Significance:   
In a recently completed multicenter study (MWH #97-051) by the National Institute of Child 
Health and Human Development (NICHD) sponsored Maternal-Fetal Medicine Units (MFMU) 
Network, a marked reduction in preterm birth was noted among high risk women who received 
17 alpha-hydroxyprogesterone caproate (17OHPC) rather than placebo.1 A one-third reduction in 
preterm birth was observed regardless of whether an endpoint of 37, 35 or 32 weeks gestation 
was used.  The mechanism by which 17OHPC exerts its beneficial effect is unclear, particularly 
since there is little evidence that progesterone deficiency has a causal role in preterm birth or that 
injections of 17OHPC increase plasma progesterone concentrations either in singletons or 
twins.2,3 The high and rising rate of twin pregnancy, and the disproportionate perinatal morbidity 
and mortality attributable to preterm twin birth, argue for a preterm birth prevention trial in 
multifetal pregnancies.  Moreover, the promising results of the cited MFMU Network 17OHPC 
trial suggest the value of evaluation of 17OHPC in pregnancies at high risk of preterm birth for 
reasons other than prior preterm birth.  Given the beneficial effect of progesterone 
supplementation in singleton gestations, it is reasonable to consider that a similar benefit may 
occur in multifetal gestations.  Hence, the MFMU Network opened the multicenter study entitled 
“A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm 
Birth in Multifetal Gestation” (STTARS Trial, IRB #0412048) in 2003. 
The pharmacokinetic behavior of 17OHPC has not been evaluated in pregnancy.  Only a 
single study has measured concentrations of 17OHPC in non-pregnant women receiving this 
agent intramuscularly.5 The dose of 17OHPC used to prevent preterm birth in singleton gestation 
has varied from 250 mg to 1000 mg every week and there are no data to provide guidance as to 
what the appropriate dose should be either in singletons or in multifetal gestation.1, 4, 6 In general, 
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metabolism of pharmacologic agents in pregnancy differs considerably between pregnant and 
non-pregnant women.  For example, the volume of distribution, renal blood flow and hepatic 
metabolism are markedly affected by pregnancy and especially in women with multifetal 
gestation. 
17OHPC has potent progestational effects7, which occur without alterations in the plasma 
progesterone concentrations and may be key to the agent’s effectiveness.  Progestational effects 
that may be relevant to preterm birth prevention include an effect on the inflammatory response 
associated with term and preterm labor, binding to nuclear progesterone receptors in the 
myometrium or to other non-myometrial tissue.2, 8, 9 
Labor is characterized by an inflammatory response in the lower uterine segment and 
cervix.10-12 Leukocytes are found at these sites in increasing numbers as labor nears.  This 
leukocytic infiltration is associated with increased cytokine production and with cervical 
ripening.  Progesterone inhibits the leukocytic infiltration of the cervix and prevents the increase 
in cytokine concentration.  Progesterone also inhibits CRH (which is associated with preterm 
birth) and expression of oxytocin receptors and gap junctions.2, 13 Thus, if 17OHPC binds to 
nuclear progesterone receptors more avidly than endogenous progesterone, a biologically 
plausible explanation for the beneficial effect of 17OHPC therapy can be proposed. 
 
Significance: The significance of this study is that it will establish the appropriate dose of 17-
hydroxyprogesterone caproate to be used in multifetal gestation.   
 
E. Progress Report and Preliminary Studies: Not applicable 
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 F. Research Design and Methods:   
 
Drug/Device Information: 17 Alpha-Hydroxyprogesterone Caproate (17OHPC)(IND #69,094) is 
a synthetic hormone produced from progesterone that is being utilized in the main study (IRB 
#0412048).  The FDA has not approved this drug for use in this setting.  Subjects participating in 
IRB #0412048 already will have been randomized to receive either study drug or placebo (inert 
castor oil).  The dose of 17P (or placebo) is 250 mg and will be given by the study nurse as a 1 
ml IM injection into the upper quadrant of the gluteus maximus.  No study drug (or placebo) will 
be administered in this ancillary study.      
 
Study Design: This study is an ancillary study for an NIH-sponsored Maternal-Fetal Medicine 
Units Network trial entitled “A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate 
for Prevention of Preterm Birth in Multifetal Gestation” (STTARS Trial, IRB #0412048), which 
is a randomized, double-masked, placebo-controlled, multi-centered clinical trial of 17 alpha-
hydroxyprogesterone caproate (17OPHC) for prevention of preterm birth in multifetal gestation. 
Subjects participating in this ancillary study will have blood drawn immediately prior to 
17OHPC injection and once a day for seven days after injection for determination of 17OHPC 
concentrations (Specific Aim #1).   
A secondary objective of this study is to evaluate the effect of 17OHPC on selected 
pregnancy hormones (Specific Aim #2).  Blood will be drawn from subjects on two occasions 
(once between 24 and 28 weeks and once between 32 and 35 weeks) to determine the steady 
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state concentration of 17OHPC on pregnancy-specific hormones (progesterone, 17-
hydroxyproesterone, and estradiol).    
Subjects must be participating in the IRB #0412048 study (whose eligibility criteria 
includes multifetal gestation between 16 weeks and 0 days to 20 weeks and 6 days) to qualify for 
participation in this ancillary study.  Approximately 20 subjects (ages 15-45) will be accrued at 
Magee-Womens Hospital (MWH) or one of the other 13 MFMU Network sites.  Study treatment 
will be administered through 35 weeks gestation or delivery.  The total duration of this multi-
center study is 5 years.   
 
Screening Procedures for Eligibility and Consent:  There are no screening procedures for this 
study.  Only subjects participating in “A Randomized Trial of 17 Alpha-Hydroxyprogesterone 
Caproate for Prevention of Preterm Birth in Multifetal Gestation” (STTARS Trial, IRB 
#0412048) are eligible for participation in this study.  Subjects participating in IRB #0412048 
who express an interest in this ancillary study will be told about this study and asked to sign an 
informed consent form.  Subjects ideally will be consented for this study when they are 
consented for participation in IRB #0412048 because we hope to perform the pharmacokinetic 
(PK) analysis in conjunction with the first injection of 17OHPC (or placebo) in order to evaluate 
accurately the absorption and effect on hormonal and inflammatory markers.  No study 
procedures will be performed unless/until informed consent in obtained.   
 
Study Procedures:  The following procedures will be performed during this study:  
• A baseline blood sample (6cc) will be obtained at a study visit prior to an IM injection of 
250 mg 17OHPC (or placebo).  Since the half-life of 17OHPC in non-pregnant subjects is 
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? Samples will be centrifuged at 3000 x g for 15 minutes and the supernatant 
aliquotted into 1 ml tubes, labeled and frozen at -80οC until analyzed.  For 
17OHPC, analysis will be by HPLC which has a sensitivity of <1 ng/ml and will 
differentiate 17-OHPC from progesterone and 17-OH progesterone.  Expected 
concentrations will be 20 ng/ml at peak and 5 ng/ml at trough.  The results of the 
PK analysis will be blinded from the investigators as to group assignment (study 
drug or placebo) and all assays will be performed at the University of Pittsburgh, 
Pittsburgh, PA.   
• Approximately 10 cc blood will be drawn for measurement of 17OHPC, 17-
hydroxyprogesterone, progesterone, and estradiol during study visits between 24-28 
weeks and 32-35 weeks (please reference Specific Aim #2).     
? Samples will be centrifuged at 3000 x g for 15 minutes and the supernatant 
aliquotted into 1 ml tubes, labeled and frozen at -80οC until analyzed.  Analysis 
will be by radio immunoassay or HPLC.  All assays will be performed at the 
University of Pittsburgh, Pittsburgh, PA, and results will be blinded from the 
investigators as to group assignment (study drug or placebo). 
 
Storage of Samples: Analysis of blood samples will be performed at the University of Pittsburgh.  
These samples will be stored for 5 years and then discarded.  The principal investigator will be 
responsible for control of the storage area.  Samples will be stored to include assigned code 
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numbers (using bar-coding software entitled “Freezerworks”), and the information linking these 
code numbers to the corresponding subject’s identity will be kept in a separate, secure location.  
De-identified samples will be made available to secondary investigators and may be used for 
future research on preterm birth or other pregnancy problems.  If subject decides to withdraw 
consent for this study, her samples will be destroyed within 5 business days of receipt of notice 
of withdrawal. 
These study visits and blood draws will be completed as outpatient procedures in the Ambulatory 
Care Research Center (ACRC) of the General Clinical Research Center (GCRC) of MWH 
(subjects also have the option of having blood samples after the injection of 17OHPC [or 
placebo] drawn in their home or office if more convenient than attending MWH), should take 
approximately 10 minutes to complete, are considered research-only procedures.   
At the completion of the study, the investigators may contact the subject to discuss a 
follow-up study on her and her baby. 
 
Endpoints for Discontinuation of Study Treatment: Regarding “A Randomized Trial of 17 
Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation” 
(STTARS Trial, IRB #0412048), there are no recognized reasons (including preeclampsia, 
hypertension, abruptio placenta, or preterm labor) not to administer 17OHPC to pregnant women 
based on the specific medical condition, unless the subject has a reaction to 17OHPC, which 
would be an indication to stop.  Unless the subject has a reaction to 17OHPC, withdraws consent 
from IRB #0412048, or withdraws consent from this proposed ancillary study, the study 
procedures (blood draws) will occur as scheduled.  There are no dose modifications since study 
drug is not being administered in this ancillary study.  
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 Adverse Event Reporting: Subjects will be questioned in a non-directed manner at each study 
visit regarding side effects or symptoms associated with study procedures.  The data will be 
captured on the Study Visit Form.  In addition, an Adverse Event Form will be completed for 
any event that is serious, deemed related to the study, and/or unexpected in nature, severity, or 
frequency.  The Adverse Event Form will be sent by facsimile to the NICHD program scientists, 
Biostatistical Coordinating Center (BCC) of George Washington University, and University of 
Pittsburgh IRB according to guidelines (within 24 hours in the case of maternal, fetal, or 
neonatal death).  If a death is reported, a copy of the subject’s medical record will be made, and 
in the case of a miscarriage or intrauterine demise, the pathology report on examination of the 
fetus and placenta must be included and forwarded to the BCC. 
 
G. Biostatistical Design and Analysis:  
Sample size estimation 
1. Specific Aim #1 (measuring the concentration of 17OHPC 7 times over one week after an 
injection of 17 OHPC [or placebo] in women with twin or triplet gestation): There are limited 
studies of 17OHPC in humans and no studies in pregnant women in which pharmacokinetic data 
are reported.5  Steady state concentration among five non-pregnant subjects following injections 
of 1000 ml ranged from 30 to 75 ng/ml.  The variation in steady state concentrations was 
approximately 40%. Sample size estimates for pharmacokinetic studies depend on the degree of 
variation tolerated.  Given only 40% variation with 5 subjects, approximately 16 patients should 
be sufficient in order to define, with an adequate level of confidence, the average 
pharmacokinetic behavior of 17OHPC in pregnancy assuming that half of these women would be 
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receiving placebo.  We will recruit at least 16 subjects pregnant with twins and as many as 4 
subjects pregnant with triplets.  We may enroll too few subject pregnant with triplets for any 
comparisons, but even 1-2 such subjects will provide useful pilot information. 
2. Specific Aim #2 (measuring steady state concentrations of 17OHPC and 
pregnancy-specific hormones [progesterone, 17-hydroxyproesterone, and estradiol] at 24-28 
weeks and 32-35 weeks in women receiving weekly injection of 17OHPC [or placebo]): Blood 
samples will be obtained at 24-28 and at 32-35 weeks for the measurement of 17OHPC steady 
state concentrations.  In order to demonstrate that 17OHPC concentrations are not zero, only 4 
subjects receiving 17OHPC are needed because the assay sensitivity is <1 ng/ml.  For 17OHPC 
progesterone, 17-hydroxyprogesterone, and estradiol, we will use a simple t-test to compare 
differences between groups.  Given the variation in hormone concentrations the sample size will 
allow us to detect differences of 40% or greater.   
 
Feasibility: At the University of Pittsburgh, there were 134 twin gestations delivered in 1999.  
Approximately 600 patients with twin gestation and 120 with triplet gestation will be recruited to 
the main study (IRB #0412048).  There are 14 centers participating in the main study, thus, each 
center will be expected to recruit 40-50 twins and 8 triplets.  Given the large number of 
multifetal gestation, it is our expectations that MWH will recruit above an average amount of 
patients to this main study.  Therefore, a sufficient subject population should be available for this 
ancillary study. 
All sample size estimates are for subjects pregnant with twins.  When possible, we will 
also collect data on subjects pregnant with triplets.  For Specific Aim #1, sample size is small 
and therefore recruitment should not be difficult.  Blood samples will be drawn once a day for 
 197 
seven days.  This may limit our recruitment, but with appropriate incentives (such as offering to 
draw blood in the subject’s home), we hope to overcome this potential problem.  For Specific 
Aim #2, an adequate sample size can be achieved if the assumed recruitment occurs at the 
projected rate.  There is a possibility that a number of enrolled subjects will be placebo (i.e., a 
bad distribution of subjects), but no statistical difference will be noted in this preliminary study.  
Even if bad distribution occurs, pharmacokinetic analysis will be possible, and any information 
collected from pharmacokinetic analysis will be of value to investigators.  The MFMU Network 
has approved this sample size estimate.   
The Biostatistics Coordinating Center (BCC) of George Washington University is 
responsible for all aspects of biostatistical design, analysis, and data management of the study, in 
addition to the interim and final statistical analyses and preparation of publications based on the 
study results. The Principal Investigator of the BCC reports to the Steering Committee and the 
Data Monitoring and Safety Committee. 
 
H.  Human Subjects:  
1. Subject Population: The racial, gender, and ethnic characteristics of the proposed subject 
population reflects the demographics of Pittsburgh and the surrounding areas and/or the patient 
population of the University of Pittsburgh Medical Center/MWH.  We shall attempt to recruit 
subjects in respective proportion to these demographics.  No exclusion criteria shall be based on 
race, ethnicity, or HIV status.  Since this study involves pregnancy, only women will be 
included.  Approximately 20 subjects (ages 15-45) will be accrued at Magee-Womens Hospital 
(MWH).  Pregnant children from ages 15-17 may be included as long as parental consent is 
obtained.  In other multicenter studies, most subjects have presented ≥ 15 years of age; therefore, 
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age 15 is the minimum age for inclusion.  This research study meets the standards for Criterion 1 
of permitted research for minors, whereby the research involves no greater than minimal risk to 
subjects.  MWH and the investigators listed on this research study have extensive experience in 
treating pregnant minors.  The risk-benefit ratio for minor subjects is the same as described in 
this protocol for adult subjects.        
 
Eligibility Criteria: 
? Inclusion Criteria: 1) Subjects enrolled in the main study, entitled “A Randomized Trial 
of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal 
Gestation” (STTARS Trial, IRB #0412048).  2) Subjects willing to undergo additional 
blood draws. 
? Exclusion criteria: 1) Subjects unwilling to sign informed consent.  2) Pregnant minors < 
15 years of age or pregnant women > 45 years of age. 
 
2. Targeted/Planned Enrollment Table (20 subjects to be accrued at MWH):  
 
Ethnic Category Females Males Total 
Hispanic or Latino 1 0 1 
Non Hispanic or 
Latino 19 0 19 
Ethnic 20 0 20 
Racial Categories    
American Indian 0 0 0 
Asian 0 0 0 
Native Hawaiian or 
other Pacific Islander 0 0 0 
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Black or African 
American 4 0 4 
White 16 0 16 
Racial Categories: 
total of all Subjects* 20  20 
*Must be equal to the Racial Categories Total of all subjects 
 
3. Sources of Research Material: This research study will involve obtaining medical information 
from hospital and/or other health care provider (e.g. physician office) records.  The information 
that will be obtained will be limited to information concerning treatment of the subject’s 
pregnancy.  This information will be used to determine the subject’s eligibility for this study and 
to follow their study response.  The confidentiality of collected specimens will be maintained 
through adherence to HIPAA standards, and the information obtained from subject interview and 
chart review is illustrated in the full protocol and Manual of Operations.  The following 
procedures will be performed as part of this research study:  
 
Procedure Research-Only Standard of Care 
Blood draws (x10), study visits 
(x10) 
  
  
4. Recruitment Methods and Consent Procedure: Subjects will be recruited for this ancillary 
study only from the population participating in the main study, entitled “A Randomized Trial of 
17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal 
Gestation” (STTARS Trial, IRB #0412048).  Information about subjects’ family members is not 
required for this ancillary study.  Subjects for the main study (IRB #0412048) will be recruited 
from the MWH outpatient clinics and private physician offices in the following manner: 1) 
Subjects that have signed up for the Women and Infant's Research Registry (MWH #23-072) 
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will be approached/contacted by the research staff to determine if they are interested in the study; 
2) Clinicians directly involved in the patient’s/potential subject’s clinical care will approach all 
patients/potential subjects.  If the clinician is also an investigator, he/she will obtain written 
informed consent.  If the clinician is not an investigator, it will be noted that he/she and the 
researcher to whom the information is being provided both work for UPMC.  The referring 
clinician will document the verbal permission of the patient for the sharing of her protected 
health information with the researchers.  The sharing of the patient’s/potential subject’s contact 
information (linked to medical diagnosis or condition) between the referring health care provider 
and the researchers involves no more than a minimal risk to the privacy of the patient since the 
referring health care provider, who introduces the research study to his/her patient, will obtain 
and appropriately document the verbal permission of the patients to provide the patient’s contact 
information to the researchers.  To further ensure that the risk to the privacy of the involved 
patients remains minimal: (A) the patient’s/potential subject’s recorded contact information will 
be stored by the researchers in a secure manner (e.g., locked file cabinet, password protected 
database) accessible only to the researcher who was provided this information and other 
members of the research team involved in the conduct of the research study (studies) for which 
this information was originally provided; and (B) the patient’s recorded contact information will 
be destroyed immediately after the researchers have contacted the patient to discuss the research 
study (studies) for which this information was originally provided; unless, upon such contact, the 
patient/potential subject indicates a further interest in study participation.  For patients/potential 
subjects who indicate a further interest in study participation, the patient will be engaged in an 
informed consent process to further determine research study eligibility and/or study interest. 
The patient’s recorded contact information will be destroyed immediately after ascertaining that 
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the patient is not eligible for or declines participation in the research study (studies).  We hereby 
provide our assurance that the recorded patient contact information will not be reused or 
redisclosed to any other person or entity (i.e., other than the members of the research team 
involved in the conduct of the research study [studies] for which the contact information was 
originally provided) except as required by law or for authorized oversight of the research study.  
Other subjects are referred in specifically for possible participation in a particular study, which 
they or their physician are aware of based on publications, which list clinical trials at 
UPMC/MWH. ”Cold-calling” will not be used to recruit subjects.  Potential subjects will be 
approached by clinicians who are directly involved in their care. “Finder’s fees” for referring a 
potential subject for participation in a research study are prohibited.   
Once a subject is identified as a potential participant in a research study as indicated 
above, she is screened for eligibility. No research-related procedures (including review of the 
subject’s medical records) will be performed until the subject has provided written informed 
consent.  The consent process will be carried out as a joint effort among the subject’s physician, 
the study coordinator, and a physician who is listed as an investigator on the study and the 
Informed Consent Form will be signed by an investigator who is a physician. 
 
5. Potential Risks and Discomforts:  
Risks of Intravenous Blood Draw: 
Likely (occurs in more than 25% of subjects, or more than 25 out of 100 subjects): bruising, 
bleeding, swelling, and discomfort at the injection site 
Rare (occurs in less than 1% of subjects, or less than 1 out of 100 subjects): infection at injection 
site; fainting; lightheadedness 
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6. Risk Management Procedures: Risk will be managed by having blood draws performed by 
certified phlebotomists.  Risks will be evaluated at each study visit through observation of the 
subject and by eliciting a verbal description of the subject’s comfort level.  The local research 
team meets every day when possible (at minimum, on a monthly basis) and all aspects of the 
studies are discussed, including adverse events, recruitment, and subject retention.  There are no 
alternative procedures not already utilized in managing the subject with multifetal gestation. 
These subjects are at substantially increased risk of preterm birth and there is no therapy that is 
recognized as beneficial in such cases.  No attempt will be made to alter or mandate clinical 
management of the subjects.  The principal investigator will terminate the involvement of a 
given subject in the research study if said subject develops a condition that precludes her from 
having a blood draw.  This ancillary study will be terminated if the risk-to-benefit ratio changes, 
i.e., risk outweighing benefits. 
All records pertaining to the subject’s involvement in this research study will be stored in 
a locked file cabinet in the office of the research staff.  A case number will indicate the subject’s 
identity on these records.  This information will be accessible to the investigators and their 
research study staff listed on the first page of this document.  Individuals from the agencies 
funding this research may review the subject’s records as part of their ongoing audit of this 
project.  Any information about the subject or the subject’s hospital treatment will be handled in 
a confidential (private) manner consistent with other hospital medical records.  The subject will 
not be specifically identified in any publication or research results.  However, in unusual cases, 
the subject’s research records may be inspected by appropriate government agencies, such as the 
US Food and Drug Administration and the Office for Human Research Protections or be released 
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in response to an order from a court of law.  All research records will be kept for a minimum of 
seven years following closure of this study. 
 
Data and Safety Monitoring Plan 
The multicenter Data and Safety Monitoring Committee (DSMC), a group of individuals not 
affiliated with any of the participating institutions was established by the NICHD.  Before the 
trial can begin, the protocol must be approved by the committee.  During the conduct of the 
study, the committee is charged with monitoring the emerging results for efficacy and safety, in 
addition to center performance and protocol adherence.  Recommendations by the committee can 
include protocol modification, early termination for efficacy, or for unexpected safety problems.  
Recommendations are made to the NICHD and disseminated to the Steering Committee.  Any 
changes in the risk level ascertained by the DSMC would be recommended for change 
immediately. Such changes would be reported to the IRB in a timely fashion.  Local study staff 
will be responsible for reporting any adverse events to the IRB and sponsor.  A summary of 
DSMC findings will be provided to the IRB upon receipt, but no later than at the time of annual 
renewal. 
7. Evaluation of Risk/Benefit Ratio: There is minimal risk to subjects participating in this study.  
The subject may not benefit directly from participation in this study.  The privacy of all subject 
information will be maintained as per HIPAA requirements by de-identification of subject 
information.  A unique code, consisting of a computer-generated network number, check digit, 
and the first digit of the subject’s first name, will be used in lieu of any personal identifiers.  The 
code letter/number combination assigned by the BCC is the only link to the subject information 
and may not be identified, other than to MWH research staff.  All data that is sent to the BCC is 
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backed up on tape prior to transmission. Edits, audits and queries are performed weekly as per 
the data sent.   
8. Costs and payments:  Neither the subject nor the subject’s insurance company will be charged 
for any tests, procedures, or study visits performed in this research study.  The cost of the blood 
draws and study visits performed in this research study will be covered by the study budget.  The 
subject will receive $30 for food/inconvenience and/or bus/cab fare for completion of the first 8 
scheduled blood draws (a total of $240).  If the subject misses any one of the first 8 scheduled 
blood draws, she will be removed from the study.  The subject will receive an additional $30 for 
food/inconvenience and/or bus/cab fare for completion of each of the last two scheduled blood 
draws (between 24-28 weeks and 32-35 weeks, for a total of $60).  The subject will receive an 
additional $100 for completing all scheduled blood draws.  If the subject misses one of the last 
two scheduled blood draws, she will not collect the additional $100.  Hence, the subject will be 
compensated a total of $400 if all scheduled blood draws are completed.  The subject also will 
receive free parking at Magee-Womens Hospital for all study visits.  If the subject delivers prior 
to completion of the scheduled study visits, she will be compensated as though she had 
completed all study visits and blood draws.      
 
I.  Justification for Utilization of GCRC Resources:  All subjects for this trial will be seen 
in the outpatient clinic of the GCRC to allow them to have a centralized area to which to report 
for visits.  
 
J. Study Size and GCRC Resources:  1) Number of Research Subjects = 20; 2) Total 
Number of Inpatient Days = 0; 3) Total Number of Outpatient Days: (10 subjects per year) x (10 
 205 
visits per subject) = 100 outpatient visits per year; 4) Estimated GCRC Inpatient Ancillary Cost 
of the Study = No requested ancillary funding; 5) Estimated GCRC Outpatient Ancillary Cost of 
the Study = No ancillary costs for outpatient visits; 6) No other GCRC resources requested other 
than those described in section I. 
 
K.  Research Needs to be Provided by Investigators’ Laboratory or Outside 
Laboratory: None 
 
L.  Funding Support: National Institutes of Health Grant #HD21410-17  
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N.  Qualification of Investigators: 
 
Steve N. Caritis, MD, Professor, OB/GYN/RS, has been a contributing member of the Maternal 
Fetal Medicine Units Network at Magee-Womens Hospital for the past 19 years.  He is the MFM 
Division Director and has been conducting research at the University of Pittsburgh since 1975. 
 
Drs. Simhan, Daftary, Watt-Morse, and Jeyabalan are faculty members who conduct their own 
research studies and are well acquainted with MFMU Network trials. All have completed 
Masters programs in either Public Health or in Clinical Research.  
 
Raman Venkataramanan, PhD, Professor of Pharmaceutical Sciences, University of Pittsburgh, 
has served as the kineticist on several projects with Dr. Caritis.  He was a subcontractor for the 
Drug Metabolism in Pregnancy Study, an MFMU Network trial.   He has completed extensive 
post-doctoral work in pharmacokinetics and has a total of 176 publications to date.  
 
Dr. Parviainen is a fellow who has presented projects at the MFMU Network and is working on 
her own research projects.   
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 Margaret Cotroneo, RN, CCRC, has been the Clinical Research Coordinator for the Maternal 
Fetal Medicine Units Network at Magee-Womens Hospital since 1988.  She has served on 
several subcommittees for the Network and is certified to perform all study-related tasks for all 
of the trials. 
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